id	sid	tid	token	lemma	pos
dpc-5570	1	1	dermatology	dermatology	NOUN
dpc-5570	1	2	:	:	PUNCT
dpc-5570	1	3	practical	practical	ADJ
dpc-5570	1	4	and	and	CCONJ
dpc-5570	1	5	conceptual	conceptual	ADJ
dpc-5570	1	6	original	original	ADJ
dpc-5570	1	7	article	article	NOUN
dpc-5570	1	8	|	|	ADV
dpc-5570	1	9	dermatol	dermatol	ADJ
dpc-5570	1	10	pract	pract	NOUN
dpc-5570	1	11	concept	concept	NOUN
dpc-5570	1	12	.	.	PUNCT
dpc-5570	2	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	2	2	1	1	NUM
dpc-5570	2	3	tildrakizumab	tildrakizumab	NOUN
dpc-5570	2	4	as	as	ADP
dpc-5570	2	5	a	a	DET
dpc-5570	2	6	potential	potential	ADJ
dpc-5570	2	7	option	option	NOUN
dpc-5570	2	8	for	for	ADP
dpc-5570	2	9	early	early	ADJ
dpc-5570	2	10	psoriatic	psoriatic	ADJ
dpc-5570	2	11	arthritis	arthritis	NOUN
dpc-5570	2	12	in	in	ADP
dpc-5570	2	13	patients	patient	NOUN
dpc-5570	2	14	with	with	ADP
dpc-5570	2	15	metabolic	metabolic	NOUN
dpc-5570	2	16	comorbidities	comorbiditie	NOUN
dpc-5570	2	17	and	and	CCONJ
dpc-5570	2	18	psoriasis	psoriasis	NOUN
dpc-5570	2	19	:	:	PUNCT
dpc-5570	2	20	a	a	DET
dpc-5570	2	21	case	case	NOUN
dpc-5570	2	22	series	series	NOUN
dpc-5570	2	23	fabio	fabio	PROPN
dpc-5570	2	24	artosi1	artosi1	PROPN
dpc-5570	2	25	,	,	PUNCT
dpc-5570	2	26	caterina	caterina	PROPN
dpc-5570	2	27	lanna1	lanna1	PROPN
dpc-5570	2	28	,	,	PUNCT
dpc-5570	2	29	ruslana	ruslana	PROPN
dpc-5570	2	30	gaeta	gaeta	PROPN
dpc-5570	2	31	shumak1	shumak1	PROPN
dpc-5570	2	32	,	,	PUNCT
dpc-5570	2	33	cristiana	cristiana	PROPN
dpc-5570	2	34	borselli1	borselli1	PROPN
dpc-5570	2	35	,	,	PUNCT
dpc-5570	2	36	gaetana	gaetana	NOUN
dpc-5570	2	37	costanza2	costanza2	PROPN
dpc-5570	2	38	,	,	PUNCT
dpc-5570	2	39	antonia	antonia	PROPN
dpc-5570	2	40	rivieccio1	rivieccio1	PROPN
dpc-5570	2	41	,	,	PUNCT
dpc-5570	2	42	diego	diego	PROPN
dpc-5570	2	43	orsini3	orsini3	PROPN
dpc-5570	2	44	,	,	PUNCT
dpc-5570	2	45	sara	sara	PROPN
dpc-5570	2	46	lambiase1	lambiase1	PROPN
dpc-5570	2	47	,	,	PUNCT
dpc-5570	2	48	laura	laura	PROPN
dpc-5570	2	49	diluvio1	diluvio1	PROPN
dpc-5570	2	50	,	,	PUNCT
dpc-5570	2	51	luca	luca	PROPN
dpc-5570	2	52	bianchi1	bianchi1	PROPN
dpc-5570	2	53	and	and	CCONJ
dpc-5570	2	54	elena	elena	PROPN
dpc-5570	2	55	campione1	campione1	PROPN
dpc-5570	2	56	1	1	NUM
dpc-5570	2	57	unit	unit	NOUN
dpc-5570	2	58	of	of	ADP
dpc-5570	2	59	dermatology	dermatology	NOUN
dpc-5570	2	60	,	,	PUNCT
dpc-5570	2	61	department	department	NOUN
dpc-5570	2	62	of	of	ADP
dpc-5570	2	63	systems	system	NOUN
dpc-5570	2	64	medicine	medicine	NOUN
dpc-5570	2	65	,	,	PUNCT
dpc-5570	2	66	university	university	NOUN
dpc-5570	2	67	of	of	ADP
dpc-5570	2	68	rome	rome	PROPN
dpc-5570	2	69	tor	tor	PROPN
dpc-5570	2	70	vergata	vergata	PROPN
dpc-5570	2	71	,	,	PUNCT
dpc-5570	2	72	rome	rome	PROPN
dpc-5570	2	73	2	2	NUM
dpc-5570	2	74	unit	unit	NOUN
dpc-5570	2	75	of	of	ADP
dpc-5570	2	76	virology	virology	NOUN
dpc-5570	2	77	,	,	PUNCT
dpc-5570	2	78	department	department	NOUN
dpc-5570	2	79	of	of	ADP
dpc-5570	2	80	experimental	experimental	ADJ
dpc-5570	2	81	medicine	medicine	NOUN
dpc-5570	2	82	,	,	PUNCT
dpc-5570	2	83	university	university	NOUN
dpc-5570	2	84	of	of	ADP
dpc-5570	2	85	rome	rome	PROPN
dpc-5570	2	86	tor	tor	PROPN
dpc-5570	2	87	vergata	vergata	PROPN
dpc-5570	2	88	,	,	PUNCT
dpc-5570	2	89	rome	rome	PROPN
dpc-5570	2	90	,	,	PUNCT
dpc-5570	2	91	italy	italy	PROPN
dpc-5570	2	92	3	3	NUM
dpc-5570	2	93	san	san	PROPN
dpc-5570	2	94	gallicano	gallicano	PROPN
dpc-5570	2	95	dermatological	dermatological	PROPN
dpc-5570	2	96	institute	institute	NOUN
dpc-5570	2	97	(	(	PUNCT
dpc-5570	2	98	ifo	ifo	NOUN
dpc-5570	2	99	-	-	PUNCT
dpc-5570	2	100	irccs	irccs	NOUN
dpc-5570	2	101	)	)	PUNCT
dpc-5570	2	102	,	,	PUNCT
dpc-5570	2	103	clinical	clinical	ADJ
dpc-5570	2	104	dermatology	dermatology	NOUN
dpc-5570	2	105	unit	unit	NOUN
dpc-5570	2	106	,	,	PUNCT
dpc-5570	2	107	rome	rome	PROPN
dpc-5570	2	108	key	key	ADJ
dpc-5570	2	109	words	word	NOUN
dpc-5570	2	110	:	:	PUNCT
dpc-5570	2	111	tildrakizumab	tildrakizumab	NOUN
dpc-5570	2	112	,	,	PUNCT
dpc-5570	2	113	psoriatic	psoriatic	ADJ
dpc-5570	2	114	arthritis	arthritis	NOUN
dpc-5570	2	115	,	,	PUNCT
dpc-5570	2	116	metabolic	metabolic	NOUN
dpc-5570	2	117	syndrome	syndrome	NOUN
dpc-5570	2	118	,	,	PUNCT
dpc-5570	2	119	psoriasis	psoriasis	NOUN
dpc-5570	2	120	,	,	PUNCT
dpc-5570	2	121	nail	nail	NOUN
dpc-5570	2	122	psoriasis	psoriasis	NOUN
dpc-5570	2	123	citation	citation	NOUN
dpc-5570	2	124	:	:	PUNCT
dpc-5570	2	125	artosi	artosi	PROPN
dpc-5570	2	126	f	f	PROPN
dpc-5570	2	127	,	,	PUNCT
dpc-5570	2	128	lanna	lanna	PROPN
dpc-5570	2	129	c	c	PROPN
dpc-5570	2	130	,	,	PUNCT
dpc-5570	2	131	gaeta	gaeta	PROPN
dpc-5570	2	132	shumak	shumak	PROPN
dpc-5570	2	133	r.	r.	PROPN
dpc-5570	2	134	tildrakizumab	tildrakizumab	PROPN
dpc-5570	2	135	as	as	ADP
dpc-5570	2	136	a	a	DET
dpc-5570	2	137	potential	potential	ADJ
dpc-5570	2	138	option	option	NOUN
dpc-5570	2	139	for	for	ADP
dpc-5570	2	140	early	early	ADJ
dpc-5570	2	141	psoriatic	psoriatic	ADJ
dpc-5570	2	142	arthritis	arthritis	NOUN
dpc-5570	2	143	in	in	ADP
dpc-5570	2	144	patients	patient	NOUN
dpc-5570	2	145	with	with	ADP
dpc-5570	2	146	metabolic	metabolic	NOUN
dpc-5570	2	147	comorbidities	comorbiditie	NOUN
dpc-5570	2	148	and	and	CCONJ
dpc-5570	2	149	psoriasis	psoriasis	NOUN
dpc-5570	2	150	:	:	PUNCT
dpc-5570	2	151	a	a	DET
dpc-5570	2	152	case	case	NOUN
dpc-5570	2	153	series	series	NOUN
dpc-5570	2	154	.	.	PUNCT
dpc-5570	3	1	dermatol	dermatol	NOUN
dpc-5570	3	2	pract	pract	PROPN
dpc-5570	3	3	concept	concept	NOUN
dpc-5570	3	4	.	.	PUNCT
dpc-5570	4	1	2025;15(4):5570	2025;15(4):5570	X
dpc-5570	4	2	.	.	PUNCT
dpc-5570	5	1	doi	doi	NOUN
dpc-5570	5	2	:	:	PUNCT
dpc-5570	5	3	https://doi.org/10.5826/dpc.1504a5570	https://doi.org/10.5826/dpc.1504a5570	NOUN
dpc-5570	5	4	accepted	accept	VERB
dpc-5570	5	5	:	:	PUNCT
dpc-5570	5	6	june	june	PROPN
dpc-5570	5	7	12	12	NUM
dpc-5570	5	8	,	,	PUNCT
dpc-5570	5	9	2025	2025	NUM
dpc-5570	5	10	;	;	PUNCT
dpc-5570	5	11	published	publish	VERB
dpc-5570	5	12	:	:	PUNCT
dpc-5570	6	1	october	october	PROPN
dpc-5570	6	2	2025	2025	NUM
dpc-5570	6	3	copyright	copyright	NOUN
dpc-5570	6	4	:	:	PUNCT
dpc-5570	6	5	©	©	PROPN
dpc-5570	6	6	2025	2025	NUM
dpc-5570	6	7	artosi	artosi	NOUN
dpc-5570	6	8	et	et	PROPN
dpc-5570	6	9	al	al	PROPN
dpc-5570	6	10	.	.	PUNCT
dpc-5570	7	1	this	this	PRON
dpc-5570	7	2	is	be	AUX
dpc-5570	7	3	an	an	DET
dpc-5570	7	4	open	open	ADJ
dpc-5570	7	5	-	-	PUNCT
dpc-5570	7	6	access	access	NOUN
dpc-5570	7	7	article	article	NOUN
dpc-5570	7	8	distributed	distribute	VERB
dpc-5570	7	9	under	under	ADP
dpc-5570	7	10	the	the	DET
dpc-5570	7	11	terms	term	NOUN
dpc-5570	7	12	of	of	ADP
dpc-5570	7	13	the	the	DET
dpc-5570	7	14	creative	creative	ADJ
dpc-5570	7	15	commons	common	NOUN
dpc-5570	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5570	7	17	license	license	NOUN
dpc-5570	7	18	(	(	PUNCT
dpc-5570	7	19	by	by	ADP
dpc-5570	7	20	-	-	PUNCT
dpc-5570	7	21	nc-4.0	nc-4.0	NOUN
dpc-5570	7	22	)	)	PUNCT
dpc-5570	7	23	,	,	PUNCT
dpc-5570	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5570	7	25	,	,	PUNCT
dpc-5570	7	26	which	which	PRON
dpc-5570	7	27	permits	permit	VERB
dpc-5570	7	28	unrestricted	unrestricted	ADJ
dpc-5570	7	29	noncommercial	noncommercial	ADJ
dpc-5570	7	30	use	use	NOUN
dpc-5570	7	31	,	,	PUNCT
dpc-5570	7	32	distribution	distribution	NOUN
dpc-5570	7	33	,	,	PUNCT
dpc-5570	7	34	and	and	CCONJ
dpc-5570	7	35	reproduction	reproduction	NOUN
dpc-5570	7	36	in	in	ADP
dpc-5570	7	37	any	any	DET
dpc-5570	7	38	medium	medium	NOUN
dpc-5570	7	39	,	,	PUNCT
dpc-5570	7	40	provided	provide	VERB
dpc-5570	7	41	the	the	DET
dpc-5570	7	42	original	original	ADJ
dpc-5570	7	43	authors	author	NOUN
dpc-5570	7	44	and	and	CCONJ
dpc-5570	7	45	source	source	NOUN
dpc-5570	7	46	are	be	AUX
dpc-5570	7	47	credited	credit	VERB
dpc-5570	7	48	.	.	PUNCT
dpc-5570	8	1	funding	funding	NOUN
dpc-5570	8	2	:	:	PUNCT
dpc-5570	8	3	none	none	NOUN
dpc-5570	8	4	.	.	PUNCT
dpc-5570	9	1	competing	compete	VERB
dpc-5570	9	2	interests	interest	NOUN
dpc-5570	9	3	:	:	PUNCT
dpc-5570	9	4	none	none	NOUN
dpc-5570	9	5	.	.	PUNCT
dpc-5570	10	1	authorship	authorship	NOUN
dpc-5570	10	2	:	:	PUNCT
dpc-5570	10	3	all	all	DET
dpc-5570	10	4	authors	author	NOUN
dpc-5570	10	5	have	have	AUX
dpc-5570	10	6	contributed	contribute	VERB
dpc-5570	10	7	significantly	significantly	ADV
dpc-5570	10	8	to	to	ADP
dpc-5570	10	9	this	this	DET
dpc-5570	10	10	publication	publication	NOUN
dpc-5570	10	11	.	.	PUNCT
dpc-5570	11	1	corresponding	correspond	VERB
dpc-5570	11	2	author	author	NOUN
dpc-5570	11	3	:	:	PUNCT
dpc-5570	11	4	fabio	fabio	PROPN
dpc-5570	11	5	artosi	artosi	PROPN
dpc-5570	11	6	md	md	PROPN
dpc-5570	11	7	,	,	PUNCT
dpc-5570	11	8	dermatology	dermatology	NOUN
dpc-5570	11	9	unit	unit	NOUN
dpc-5570	11	10	,	,	PUNCT
dpc-5570	11	11	department	department	NOUN
dpc-5570	11	12	of	of	ADP
dpc-5570	11	13	systems	system	NOUN
dpc-5570	11	14	medicine	medicine	NOUN
dpc-5570	11	15	,	,	PUNCT
dpc-5570	11	16	university	university	NOUN
dpc-5570	11	17	of	of	ADP
dpc-5570	11	18	rome	rome	PROPN
dpc-5570	11	19	tor	tor	PROPN
dpc-5570	11	20	vergata	vergata	NOUN
dpc-5570	11	21	,	,	PUNCT
dpc-5570	11	22	via	via	ADP
dpc-5570	11	23	montpellier	montpellier	NOUN
dpc-5570	11	24	1	1	NUM
dpc-5570	11	25	,	,	PUNCT
dpc-5570	11	26	rome	rome	PROPN
dpc-5570	11	27	,	,	PUNCT
dpc-5570	11	28	italy	italy	PROPN
dpc-5570	11	29	.	.	PUNCT
dpc-5570	12	1	e	e	X
dpc-5570	12	2	-	-	NOUN
dpc-5570	12	3	mail	mail	NOUN
dpc-5570	12	4	:	:	PUNCT
dpc-5570	12	5	fabio.artosi994@gmail.com	fabio.artosi994@gmail.com	X
dpc-5570	12	6	introduction	introduction	NOUN
dpc-5570	12	7	:	:	PUNCT
dpc-5570	12	8	psoriasis	psoriasis	NOUN
dpc-5570	12	9	is	be	AUX
dpc-5570	12	10	a	a	DET
dpc-5570	12	11	chronic	chronic	NOUN
dpc-5570	12	12	relapsing	relapse	VERB
dpc-5570	12	13	inflammatory	inflammatory	ADJ
dpc-5570	12	14	disease	disease	NOUN
dpc-5570	12	15	.	.	PUNCT
dpc-5570	13	1	and	and	CCONJ
dpc-5570	13	2	approximately	approximately	ADV
dpc-5570	13	3	20	20	NUM
dpc-5570	13	4	%	%	NOUN
dpc-5570	13	5	of	of	ADP
dpc-5570	13	6	psoriasis	psoriasis	NOUN
dpc-5570	13	7	patients	patient	NOUN
dpc-5570	13	8	also	also	ADV
dpc-5570	13	9	develop	develop	VERB
dpc-5570	13	10	psoriatic	psoriatic	ADJ
dpc-5570	13	11	arthritis	arthritis	NOUN
dpc-5570	13	12	(	(	PUNCT
dpc-5570	13	13	psa	psa	NOUN
dpc-5570	13	14	)	)	PUNCT
dpc-5570	13	15	..	..	PUNCT
dpc-5570	14	1	interleukin	interleukin	NOUN
dpc-5570	14	2	23	23	NUM
dpc-5570	14	3	(	(	PUNCT
dpc-5570	14	4	il-23	il-23	NOUN
dpc-5570	14	5	)	)	PUNCT
dpc-5570	14	6	plays	play	VERB
dpc-5570	14	7	a	a	DET
dpc-5570	14	8	crucial	crucial	ADJ
dpc-5570	14	9	role	role	NOUN
dpc-5570	14	10	in	in	ADP
dpc-5570	14	11	maintaining	maintain	VERB
dpc-5570	14	12	the	the	DET
dpc-5570	14	13	t	t	NOUN
dpc-5570	14	14	-	-	PUNCT
dpc-5570	14	15	helper	helper	NOUN
dpc-5570	14	16	(	(	PUNCT
dpc-5570	14	17	th	th	NOUN
dpc-5570	14	18	)	)	PUNCT
dpc-5570	14	19	17	17	NUM
dpc-5570	14	20	cell	cell	NOUN
dpc-5570	14	21	population	population	NOUN
dpc-5570	14	22	derived	derive	VERB
dpc-5570	14	23	from	from	ADP
dpc-5570	14	24	naïve	naïve	ADJ
dpc-5570	14	25	th1	th1	NOUN
dpc-5570	14	26	cells	cell	NOUN
dpc-5570	14	27	as	as	ADV
dpc-5570	14	28	well	well	ADV
dpc-5570	14	29	as	as	ADP
dpc-5570	14	30	in	in	ADP
dpc-5570	14	31	sustaining	sustain	VERB
dpc-5570	14	32	inflammation	inflammation	NOUN
dpc-5570	14	33	at	at	ADP
dpc-5570	14	34	the	the	DET
dpc-5570	14	35	enthesis	enthesis	NOUN
dpc-5570	14	36	and	and	CCONJ
dpc-5570	14	37	joints	joint	NOUN
dpc-5570	14	38	,	,	PUNCT
dpc-5570	14	39	acting	act	VERB
dpc-5570	14	40	as	as	ADP
dpc-5570	14	41	a	a	DET
dpc-5570	14	42	pathogenic	pathogenic	ADJ
dpc-5570	14	43	effector	effector	NOUN
dpc-5570	14	44	in	in	ADP
dpc-5570	14	45	psa	psa	NOUN
dpc-5570	14	46	.	.	PUNCT
dpc-5570	15	1	among	among	ADP
dpc-5570	15	2	anti	anti	ADJ
dpc-5570	15	3	-	-	ADJ
dpc-5570	15	4	il-23	il-23	ADJ
dpc-5570	15	5	monoclonal	monoclonal	NOUN
dpc-5570	15	6	antibodies	antibody	NOUN
dpc-5570	15	7	,	,	PUNCT
dpc-5570	15	8	ustekinumab	ustekinumab	NOUN
dpc-5570	15	9	,	,	PUNCT
dpc-5570	15	10	guselkumab	guselkumab	NOUN
dpc-5570	15	11	,	,	PUNCT
dpc-5570	15	12	and	and	CCONJ
dpc-5570	15	13	risankizumab	risankizumab	NOUN
dpc-5570	15	14	are	be	AUX
dpc-5570	15	15	approved	approve	VERB
dpc-5570	15	16	in	in	ADP
dpc-5570	15	17	europe	europe	PROPN
dpc-5570	15	18	for	for	ADP
dpc-5570	15	19	both	both	DET
dpc-5570	15	20	psoriasis	psoriasis	NOUN
dpc-5570	15	21	and	and	CCONJ
dpc-5570	15	22	psa	psa	VERB
dpc-5570	15	23	for	for	ADP
dpc-5570	15	24	psoriasis	psoriasis	NOUN
dpc-5570	15	25	and	and	CCONJ
dpc-5570	15	26	psa	psa	VERB
dpc-5570	15	27	treatment	treatment	NOUN
dpc-5570	15	28	.	.	PUNCT
dpc-5570	16	1	tildrakizumab	tildrakizumab	NOUN
dpc-5570	16	2	,	,	PUNCT
dpc-5570	16	3	another	another	DET
dpc-5570	16	4	il-23p19	il-23p19	PROPN
dpc-5570	16	5	inhibitor	inhibitor	NOUN
dpc-5570	16	6	,	,	PUNCT
dpc-5570	16	7	is	be	AUX
dpc-5570	16	8	currently	currently	ADV
dpc-5570	16	9	approved	approve	VERB
dpc-5570	16	10	only	only	ADV
dpc-5570	16	11	for	for	ADP
dpc-5570	16	12	plaque	plaque	NOUN
dpc-5570	16	13	psoriasis	psoriasis	NOUN
dpc-5570	16	14	but	but	CCONJ
dpc-5570	16	15	has	have	AUX
dpc-5570	16	16	shown	show	VERB
dpc-5570	16	17	favorable	favorable	ADJ
dpc-5570	16	18	safety	safety	NOUN
dpc-5570	16	19	in	in	ADP
dpc-5570	16	20	patients	patient	NOUN
dpc-5570	16	21	with	with	ADP
dpc-5570	16	22	metabolic	metabolic	NOUN
dpc-5570	16	23	comorbidities	comorbiditie	NOUN
dpc-5570	16	24	and	and	CCONJ
dpc-5570	16	25	potential	potential	ADJ
dpc-5570	16	26	efficacy	efficacy	NOUN
dpc-5570	16	27	in	in	ADP
dpc-5570	16	28	psa	psa	PROPN
dpc-5570	16	29	.	.	PUNCT
dpc-5570	17	1	objectives	objective	NOUN
dpc-5570	17	2	:	:	PUNCT
dpc-5570	17	3	to	to	PART
dpc-5570	17	4	retrospectively	retrospectively	ADV
dpc-5570	17	5	assess	assess	VERB
dpc-5570	17	6	the	the	DET
dpc-5570	17	7	efficacy	efficacy	NOUN
dpc-5570	17	8	of	of	ADP
dpc-5570	17	9	tildrakizumab	tildrakizumab	NOUN
dpc-5570	17	10	on	on	ADP
dpc-5570	17	11	psoriatic	psoriatic	ADJ
dpc-5570	17	12	arthritis	arthritis	NOUN
dpc-5570	17	13	manifestations	manifestation	NOUN
dpc-5570	17	14	in	in	ADP
dpc-5570	17	15	patients	patient	NOUN
dpc-5570	17	16	treated	treat	VERB
dpc-5570	17	17	according	accord	VERB
dpc-5570	17	18	to	to	ADP
dpc-5570	17	19	real	real	ADJ
dpc-5570	17	20	-	-	PUNCT
dpc-5570	17	21	world	world	NOUN
dpc-5570	17	22	clinical	clinical	ADJ
dpc-5570	17	23	practice	practice	NOUN
dpc-5570	17	24	.	.	PUNCT
dpc-5570	18	1	methods	method	NOUN
dpc-5570	18	2	:	:	PUNCT
dpc-5570	18	3	we	we	PRON
dpc-5570	18	4	conducted	conduct	VERB
dpc-5570	18	5	a	a	DET
dpc-5570	18	6	retrospective	retrospective	ADJ
dpc-5570	18	7	analysis	analysis	NOUN
dpc-5570	18	8	of	of	ADP
dpc-5570	18	9	eight	eight	NUM
dpc-5570	18	10	patients	patient	NOUN
dpc-5570	18	11	affected	affect	VERB
dpc-5570	18	12	by	by	ADP
dpc-5570	18	13	psoriasis	psoriasis	NOUN
dpc-5570	18	14	,	,	PUNCT
dpc-5570	18	15	early	early	ADJ
dpc-5570	18	16	psa	psa	NOUN
dpc-5570	18	17	,	,	PUNCT
dpc-5570	18	18	and	and	CCONJ
dpc-5570	18	19	metabolic	metabolic	NOUN
dpc-5570	18	20	comorbidities	comorbiditie	NOUN
dpc-5570	18	21	,	,	PUNCT
dpc-5570	18	22	treated	treat	VERB
dpc-5570	18	23	with	with	ADP
dpc-5570	18	24	tildrakizumab	tildrakizumab	NOUN
dpc-5570	18	25	100	100	NUM
dpc-5570	18	26	mg	mg	NOUN
dpc-5570	18	27	every	every	DET
dpc-5570	18	28	12	12	NUM
dpc-5570	18	29	weeks	week	NOUN
dpc-5570	18	30	after	after	ADP
dpc-5570	18	31	induction	induction	NOUN
dpc-5570	18	32	.	.	PUNCT
dpc-5570	19	1	descriptive	descriptive	ADJ
dpc-5570	19	2	and	and	CCONJ
dpc-5570	19	3	inferential	inferential	ADJ
dpc-5570	19	4	statistical	statistical	ADJ
dpc-5570	19	5	analyses	analysis	NOUN
dpc-5570	19	6	were	be	AUX
dpc-5570	19	7	performed	perform	VERB
dpc-5570	19	8	.	.	PUNCT
dpc-5570	20	1	efficacy	efficacy	NOUN
dpc-5570	20	2	and	and	CCONJ
dpc-5570	20	3	safety	safety	NOUN
dpc-5570	20	4	were	be	AUX
dpc-5570	20	5	evaluated	evaluate	VERB
dpc-5570	20	6	using	use	VERB
dpc-5570	20	7	standard	standard	ADJ
dpc-5570	20	8	clinimetric	clinimetric	ADJ
dpc-5570	20	9	indices	index	NOUN
dpc-5570	20	10	over	over	ADP
dpc-5570	20	11	a	a	DET
dpc-5570	20	12	28	28	NUM
dpc-5570	20	13	-	-	PUNCT
dpc-5570	20	14	week	week	NOUN
dpc-5570	20	15	follow	follow	NOUN
dpc-5570	20	16	-	-	PUNCT
dpc-5570	20	17	up	up	NOUN
dpc-5570	20	18	period	period	NOUN
dpc-5570	20	19	.	.	PUNCT
dpc-5570	21	1	results	result	NOUN
dpc-5570	21	2	:	:	PUNCT
dpc-5570	21	3	after	after	ADP
dpc-5570	21	4	28	28	NUM
dpc-5570	21	5	weeks	week	NOUN
dpc-5570	21	6	,	,	PUNCT
dpc-5570	21	7	a	a	DET
dpc-5570	21	8	significant	significant	ADJ
dpc-5570	21	9	mean	mean	NOUN
dpc-5570	21	10	reduction	reduction	NOUN
dpc-5570	21	11	was	be	AUX
dpc-5570	21	12	observed	observe	VERB
dpc-5570	21	13	in	in	ADP
dpc-5570	21	14	psoriasis	psoriasis	NOUN
dpc-5570	21	15	area	area	NOUN
dpc-5570	21	16	and	and	CCONJ
dpc-5570	21	17	severity	severity	NOUN
dpc-5570	21	18	index	index	NOUN
dpc-5570	21	19	(	(	PUNCT
dpc-5570	21	20	-81.3	-81.3	NUM
dpc-5570	21	21	%	%	INTJ
dpc-5570	21	22	,	,	PUNCT
dpc-5570	21	23	p<0.001	p<0.001	PROPN
dpc-5570	21	24	)	)	PUNCT
dpc-5570	21	25	,	,	PUNCT
dpc-5570	21	26	pain	pain	NOUN
dpc-5570	21	27	visual	visual	ADJ
dpc-5570	21	28	analogue	analogue	NOUN
dpc-5570	21	29	scale	scale	NOUN
dpc-5570	21	30	(	(	PUNCT
dpc-5570	21	31	-85	-85	PROPN
dpc-5570	21	32	%	%	INTJ
dpc-5570	21	33	,	,	PUNCT
dpc-5570	21	34	p<0.002	p<0.002	NOUN
dpc-5570	21	35	)	)	PUNCT
dpc-5570	21	36	,	,	PUNCT
dpc-5570	21	37	nail	nail	NOUN
dpc-5570	21	38	psoriasis	psoriasis	NOUN
dpc-5570	21	39	severity	severity	NOUN
dpc-5570	21	40	index	index	NOUN
dpc-5570	21	41	abstract	abstract	ADJ
dpc-5570	21	42	2	2	NUM
dpc-5570	21	43	original	original	ADJ
dpc-5570	21	44	article	article	NOUN
dpc-5570	21	45	|	|	ADV
dpc-5570	21	46	dermatol	dermatol	ADJ
dpc-5570	21	47	pract	pract	NOUN
dpc-5570	21	48	concept	concept	NOUN
dpc-5570	21	49	.	.	PUNCT
dpc-5570	22	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	22	2	introduction	introduction	NOUN
dpc-5570	22	3	psoriasis	psoriasis	NOUN
dpc-5570	22	4	is	be	AUX
dpc-5570	22	5	a	a	DET
dpc-5570	22	6	chronic	chronic	NOUN
dpc-5570	22	7	relapsing	relapse	VERB
dpc-5570	22	8	inflammatory	inflammatory	ADJ
dpc-5570	22	9	disease	disease	NOUN
dpc-5570	22	10	mainly	mainly	ADV
dpc-5570	22	11	involving	involve	VERB
dpc-5570	22	12	the	the	DET
dpc-5570	22	13	skin	skin	NOUN
dpc-5570	22	14	.	.	PUNCT
dpc-5570	23	1	the	the	DET
dpc-5570	23	2	pathogenesis	pathogenesis	NOUN
dpc-5570	23	3	has	have	AUX
dpc-5570	23	4	not	not	PART
dpc-5570	23	5	yet	yet	ADV
dpc-5570	23	6	been	be	AUX
dpc-5570	23	7	fully	fully	ADV
dpc-5570	23	8	understood	understand	VERB
dpc-5570	23	9	and	and	CCONJ
dpc-5570	23	10	includes	include	VERB
dpc-5570	23	11	both	both	DET
dpc-5570	23	12	immunological	immunological	ADJ
dpc-5570	23	13	cells	cell	NOUN
dpc-5570	23	14	such	such	ADJ
dpc-5570	23	15	as	as	ADP
dpc-5570	23	16	t	t	PROPN
dpc-5570	23	17	lymphocytes	lymphocyte	NOUN
dpc-5570	23	18	but	but	CCONJ
dpc-5570	23	19	also	also	ADV
dpc-5570	23	20	epithelial	epithelial	ADJ
dpc-5570	23	21	cells	cell	NOUN
dpc-5570	23	22	such	such	ADJ
dpc-5570	23	23	keratinocytes	keratinocyte	NOUN
dpc-5570	24	1	[	[	X
dpc-5570	24	2	1	1	NUM
dpc-5570	24	3	]	]	PUNCT
dpc-5570	24	4	.	.	PUNCT
dpc-5570	25	1	physical	physical	ADJ
dpc-5570	25	2	,	,	PUNCT
dpc-5570	25	3	immunological	immunological	ADJ
dpc-5570	25	4	,	,	PUNCT
dpc-5570	25	5	and	and	CCONJ
dpc-5570	25	6	infectious	infectious	ADJ
dpc-5570	25	7	factors	factor	NOUN
dpc-5570	25	8	activate	activate	VERB
dpc-5570	25	9	keratinocytes	keratinocyte	NOUN
dpc-5570	25	10	,	,	PUNCT
dpc-5570	25	11	favoring	favor	VERB
dpc-5570	25	12	the	the	DET
dpc-5570	25	13	release	release	NOUN
dpc-5570	25	14	of	of	ADP
dpc-5570	25	15	antimicrobial	antimicrobial	ADJ
dpc-5570	25	16	peptides	peptide	NOUN
dpc-5570	25	17	,	,	PUNCT
dpc-5570	25	18	dna	dna	NOUN
dpc-5570	25	19	,	,	PUNCT
dpc-5570	25	20	and	and	CCONJ
dpc-5570	25	21	rna	rna	NOUN
dpc-5570	25	22	self	self	NOUN
dpc-5570	25	23	recruiting	recruiting	NOUN
dpc-5570	25	24	plasmacytoid	plasmacytoid	NOUN
dpc-5570	25	25	dendritic	dendritic	ADJ
dpc-5570	25	26	cells	cell	NOUN
dpc-5570	25	27	in	in	ADP
dpc-5570	25	28	the	the	DET
dpc-5570	25	29	affected	affected	ADJ
dpc-5570	25	30	skin	skin	NOUN
dpc-5570	25	31	.	.	PUNCT
dpc-5570	26	1	after	after	ADP
dpc-5570	26	2	the	the	DET
dpc-5570	26	3	release	release	NOUN
dpc-5570	26	4	of	of	ADP
dpc-5570	26	5	the	the	DET
dpc-5570	26	6	interferon	interferon	NOUN
dpc-5570	26	7	-	-	PUNCT
dpc-5570	26	8	α	α	NOUN
dpc-5570	26	9	(	(	PUNCT
dpc-5570	26	10	infa	infa	NOUN
dpc-5570	26	11	)	)	PUNCT
dpc-5570	26	12	by	by	ADP
dpc-5570	26	13	the	the	DET
dpc-5570	26	14	plasmacytoid	plasmacytoid	NOUN
dpc-5570	26	15	dendritic	dendritic	ADJ
dpc-5570	26	16	cells	cell	NOUN
dpc-5570	26	17	(	(	PUNCT
dpc-5570	26	18	pdc	pdc	PROPN
dpc-5570	26	19	)	)	PUNCT
dpc-5570	26	20	and	and	CCONJ
dpc-5570	26	21	the	the	DET
dpc-5570	26	22	subsequent	subsequent	ADJ
dpc-5570	26	23	activation	activation	NOUN
dpc-5570	26	24	of	of	ADP
dpc-5570	26	25	the	the	DET
dpc-5570	26	26	dermal	dermal	ADJ
dpc-5570	26	27	dendritic	dendritic	ADJ
dpc-5570	26	28	cells	cell	NOUN
dpc-5570	26	29	(	(	PUNCT
dpc-5570	26	30	ddcs	ddcs	PROPN
dpc-5570	26	31	)	)	PUNCT
dpc-5570	26	32	,	,	PUNCT
dpc-5570	26	33	the	the	DET
dpc-5570	26	34	acquired	acquire	VERB
dpc-5570	26	35	immunity	immunity	NOUN
dpc-5570	26	36	is	be	AUX
dpc-5570	26	37	activated	activate	VERB
dpc-5570	26	38	through	through	ADP
dpc-5570	26	39	il-12	il-12	NOUN
dpc-5570	26	40	and	and	CCONJ
dpc-5570	26	41	il-23	il-23	NOUN
dpc-5570	26	42	.	.	PUNCT
dpc-5570	27	1	the	the	DET
dpc-5570	27	2	subsequent	subsequent	ADJ
dpc-5570	27	3	differentiation	differentiation	NOUN
dpc-5570	27	4	of	of	ADP
dpc-5570	27	5	the	the	DET
dpc-5570	27	6	t	t	PROPN
dpc-5570	27	7	-	-	PUNCT
dpc-5570	27	8	helper	helper	NOUN
dpc-5570	27	9	(	(	PUNCT
dpc-5570	27	10	th)-naive	th)-naive	ADJ
dpc-5570	27	11	into	into	ADP
dpc-5570	27	12	th1	th1	PROPN
dpc-5570	27	13	,	,	PUNCT
dpc-5570	27	14	th17	th17	PROPN
dpc-5570	27	15	,	,	PUNCT
dpc-5570	27	16	and	and	CCONJ
dpc-5570	27	17	th22	th22	PROPN
dpc-5570	27	18	sets	set	VERB
dpc-5570	27	19	the	the	DET
dpc-5570	27	20	groundwork	groundwork	NOUN
dpc-5570	27	21	of	of	ADP
dpc-5570	27	22	psoriatic	psoriatic	ADJ
dpc-5570	27	23	plaque	plaque	NOUN
dpc-5570	27	24	[	[	X
dpc-5570	27	25	1–3	1–3	NOUN
dpc-5570	27	26	]	]	X
dpc-5570	27	27	.	.	PUNCT
dpc-5570	28	1	keratinocytes	keratinocyte	NOUN
dpc-5570	28	2	contribute	contribute	VERB
dpc-5570	28	3	to	to	ADP
dpc-5570	28	4	maintaining	maintain	VERB
dpc-5570	28	5	the	the	DET
dpc-5570	28	6	inflammatory	inflammatory	ADJ
dpc-5570	28	7	process	process	NOUN
dpc-5570	28	8	over	over	ADP
dpc-5570	28	9	time	time	NOUN
dpc-5570	28	10	by	by	ADP
dpc-5570	28	11	promoting	promote	VERB
dpc-5570	28	12	angiogenesis	angiogenesis	NOUN
dpc-5570	28	13	and	and	CCONJ
dpc-5570	28	14	releasing	release	VERB
dpc-5570	28	15	cytokines	cytokine	NOUN
dpc-5570	28	16	and	and	CCONJ
dpc-5570	28	17	chemokines	chemokine	NOUN
dpc-5570	28	18	for	for	ADP
dpc-5570	28	19	recruitment	recruitment	NOUN
dpc-5570	28	20	of	of	ADP
dpc-5570	28	21	macrophages	macrophage	NOUN
dpc-5570	28	22	,	,	PUNCT
dpc-5570	28	23	neutrophils	neutrophil	NOUN
dpc-5570	28	24	,	,	PUNCT
dpc-5570	28	25	and	and	CCONJ
dpc-5570	28	26	th17	th17	PROPN
dpc-5570	28	27	lymphocytes[1	lymphocytes[1	NUM
dpc-5570	28	28	]	]	PUNCT
dpc-5570	28	29	.	.	PUNCT
dpc-5570	29	1	interleukin-23	interleukin-23	PROPN
dpc-5570	29	2	(	(	PUNCT
dpc-5570	29	3	il-23	il-23	NOUN
dpc-5570	29	4	)	)	PUNCT
dpc-5570	29	5	plays	play	VERB
dpc-5570	29	6	a	a	DET
dpc-5570	29	7	crucial	crucial	ADJ
dpc-5570	29	8	role	role	NOUN
dpc-5570	29	9	in	in	ADP
dpc-5570	29	10	psoriasis	psoriasis	NOUN
dpc-5570	29	11	;	;	PUNCT
dpc-5570	29	12	produced	produce	VERB
dpc-5570	29	13	by	by	ADP
dpc-5570	29	14	both	both	DET
dpc-5570	29	15	keratinocytes	keratinocyte	NOUN
dpc-5570	29	16	and	and	CCONJ
dpc-5570	29	17	dendritic	dendritic	ADJ
dpc-5570	29	18	cells	cell	NOUN
dpc-5570	29	19	,	,	PUNCT
dpc-5570	29	20	it	it	PRON
dpc-5570	29	21	guarantees	guarantee	VERB
dpc-5570	29	22	the	the	DET
dpc-5570	29	23	maintenance	maintenance	NOUN
dpc-5570	29	24	,	,	PUNCT
dpc-5570	29	25	expansion	expansion	NOUN
dpc-5570	29	26	,	,	PUNCT
dpc-5570	29	27	and	and	CCONJ
dpc-5570	29	28	activation	activation	NOUN
dpc-5570	29	29	of	of	ADP
dpc-5570	29	30	th-17	th-17	NOUN
dpc-5570	29	31	lymphocytes	lymphocyte	NOUN
dpc-5570	29	32	,	,	PUNCT
dpc-5570	29	33	promotes	promote	VERB
dpc-5570	29	34	epidermal	epidermal	ADJ
dpc-5570	29	35	hyperplasia	hyperplasia	NOUN
dpc-5570	29	36	,	,	PUNCT
dpc-5570	29	37	inhibits	inhibit	VERB
dpc-5570	29	38	the	the	DET
dpc-5570	29	39	function	function	NOUN
dpc-5570	29	40	of	of	ADP
dpc-5570	29	41	regulatory	regulatory	ADJ
dpc-5570	29	42	t	t	NOUN
dpc-5570	29	43	cells	cell	NOUN
dpc-5570	29	44	,	,	PUNCT
dpc-5570	29	45	and	and	CCONJ
dpc-5570	29	46	recalls	recall	VERB
dpc-5570	29	47	neutrophils	neutrophil	NOUN
dpc-5570	29	48	in	in	ADP
dpc-5570	29	49	psoriatic	psoriatic	ADJ
dpc-5570	29	50	lesional	lesional	ADJ
dpc-5570	29	51	skin	skin	NOUN
dpc-5570	29	52	with	with	ADP
dpc-5570	29	53	il-17[2,4	il-17[2,4	PROPN
dpc-5570	29	54	]	]	PUNCT
dpc-5570	29	55	.	.	PUNCT
dpc-5570	30	1	it	it	PRON
dpc-5570	30	2	is	be	AUX
dpc-5570	30	3	estimated	estimate	VERB
dpc-5570	30	4	that	that	SCONJ
dpc-5570	30	5	about	about	ADV
dpc-5570	30	6	20	20	NUM
dpc-5570	30	7	%	%	NOUN
dpc-5570	30	8	of	of	ADP
dpc-5570	30	9	patients	patient	NOUN
dpc-5570	30	10	with	with	ADP
dpc-5570	30	11	psoriasis	psoriasis	NOUN
dpc-5570	30	12	are	be	AUX
dpc-5570	30	13	also	also	ADV
dpc-5570	30	14	affected	affect	VERB
dpc-5570	30	15	by	by	ADP
dpc-5570	30	16	psoriatic	psoriatic	ADJ
dpc-5570	30	17	arthritis	arthritis	NOUN
dpc-5570	30	18	(	(	PUNCT
dpc-5570	30	19	psa	psa	NOUN
dpc-5570	30	20	)	)	PUNCT
dpc-5570	30	21	,	,	PUNCT
dpc-5570	30	22	with	with	ADP
dpc-5570	30	23	an	an	DET
dpc-5570	30	24	annual	annual	ADJ
dpc-5570	30	25	incidence	incidence	NOUN
dpc-5570	30	26	of	of	ADP
dpc-5570	30	27	about	about	ADV
dpc-5570	30	28	2	2	NUM
dpc-5570	30	29	%	%	NOUN
dpc-5570	30	30	per	per	ADP
dpc-5570	30	31	year[2	year[2	NOUN
dpc-5570	30	32	]	]	PUNCT
dpc-5570	30	33	.	.	PUNCT
dpc-5570	31	1	differently	differently	ADV
dpc-5570	31	2	from	from	ADP
dpc-5570	31	3	rheumatoid	rheumatoid	NOUN
dpc-5570	31	4	arthritis	arthritis	NOUN
dpc-5570	31	5	(	(	PUNCT
dpc-5570	31	6	ra	ra	NOUN
dpc-5570	31	7	)	)	PUNCT
dpc-5570	31	8	,	,	PUNCT
dpc-5570	31	9	there	there	PRON
dpc-5570	31	10	is	be	VERB
dpc-5570	31	11	no	no	DET
dpc-5570	31	12	evidence	evidence	NOUN
dpc-5570	31	13	that	that	SCONJ
dpc-5570	31	14	il-23	il-23	NOUN
dpc-5570	31	15	is	be	AUX
dpc-5570	31	16	increased	increase	VERB
dpc-5570	31	17	in	in	ADP
dpc-5570	31	18	the	the	DET
dpc-5570	31	19	synovial	synovial	ADJ
dpc-5570	31	20	fluid	fluid	NOUN
dpc-5570	31	21	in	in	ADP
dpc-5570	31	22	psa	psa	NOUN
dpc-5570	31	23	[	[	X
dpc-5570	31	24	5	5	NUM
dpc-5570	31	25	]	]	PUNCT
dpc-5570	31	26	.	.	PUNCT
dpc-5570	32	1	histological	histological	ADJ
dpc-5570	32	2	and	and	CCONJ
dpc-5570	32	3	molecular	molecular	ADJ
dpc-5570	32	4	studies	study	NOUN
dpc-5570	32	5	have	have	AUX
dpc-5570	32	6	shown	show	VERB
dpc-5570	32	7	that	that	SCONJ
dpc-5570	32	8	il-23	il-23	NOUN
dpc-5570	32	9	is	be	AUX
dpc-5570	32	10	expressed	express	VERB
dpc-5570	32	11	within	within	ADP
dpc-5570	32	12	the	the	DET
dpc-5570	32	13	ra	ra	PROPN
dpc-5570	32	14	synovium	synovium	NOUN
dpc-5570	32	15	and	and	CCONJ
dpc-5570	32	16	plays	play	VERB
dpc-5570	32	17	a	a	DET
dpc-5570	32	18	pro	pro	ADJ
dpc-5570	32	19	-	-	ADJ
dpc-5570	32	20	inflammatory	inflammatory	ADJ
dpc-5570	32	21	role	role	NOUN
dpc-5570	32	22	,	,	PUNCT
dpc-5570	32	23	inducing	induce	VERB
dpc-5570	32	24	both	both	CCONJ
dpc-5570	32	25	joint	joint	ADJ
dpc-5570	32	26	inflammation	inflammation	NOUN
dpc-5570	32	27	and	and	CCONJ
dpc-5570	32	28	bone	bone	NOUN
dpc-5570	32	29	destruction	destruction	NOUN
dpc-5570	32	30	.	.	PUNCT
dpc-5570	33	1	however	however	ADV
dpc-5570	33	2	,	,	PUNCT
dpc-5570	33	3	its	its	PRON
dpc-5570	33	4	expression	expression	NOUN
dpc-5570	33	5	seems	seem	VERB
dpc-5570	33	6	to	to	PART
dpc-5570	33	7	be	be	AUX
dpc-5570	33	8	restricted	restrict	VERB
dpc-5570	33	9	to	to	ADP
dpc-5570	33	10	highly	highly	ADV
dpc-5570	33	11	-	-	PUNCT
dpc-5570	33	12	inflamed	inflame	VERB
dpc-5570	33	13	synovial	synovial	ADJ
dpc-5570	33	14	tissue	tissue	NOUN
dpc-5570	33	15	rich	rich	ADJ
dpc-5570	33	16	in	in	ADP
dpc-5570	33	17	lymphoid	lymphoid	NOUN
dpc-5570	33	18	aggregates[6	aggregates[6	ADV
dpc-5570	33	19	]	]	PUNCT
dpc-5570	33	20	.	.	PUNCT
dpc-5570	34	1	on	on	ADP
dpc-5570	34	2	the	the	DET
dpc-5570	34	3	other	other	ADJ
dpc-5570	34	4	hand	hand	NOUN
dpc-5570	34	5	,	,	PUNCT
dpc-5570	34	6	as	as	ADP
dpc-5570	34	7	for	for	ADP
dpc-5570	34	8	il-17	il-17	NUM
dpc-5570	34	9	,	,	PUNCT
dpc-5570	34	10	a	a	DET
dpc-5570	34	11	higher	high	ADJ
dpc-5570	34	12	concentration	concentration	NOUN
dpc-5570	34	13	in	in	ADP
dpc-5570	34	14	the	the	DET
dpc-5570	34	15	synovial	synovial	ADJ
dpc-5570	34	16	fluid	fluid	NOUN
dpc-5570	34	17	was	be	AUX
dpc-5570	34	18	found	find	VERB
dpc-5570	34	19	mainly	mainly	ADV
dpc-5570	34	20	in	in	ADP
dpc-5570	34	21	patients	patient	NOUN
dpc-5570	34	22	suffering	suffer	VERB
dpc-5570	34	23	from	from	ADP
dpc-5570	34	24	psa	psa	NOUN
dpc-5570	34	25	[	[	X
dpc-5570	34	26	7	7	NUM
dpc-5570	34	27	]	]	PUNCT
dpc-5570	34	28	.	.	PUNCT
dpc-5570	35	1	anti	anti	ADJ
dpc-5570	35	2	-	-	ADJ
dpc-5570	35	3	il-17	il-17	ADJ
dpc-5570	35	4	antibodies	antibody	NOUN
dpc-5570	35	5	in	in	ADP
dpc-5570	35	6	psa	psa	NOUN
dpc-5570	35	7	therapy	therapy	NOUN
dpc-5570	35	8	play	play	VERB
dpc-5570	35	9	a	a	DET
dpc-5570	35	10	key	key	ADJ
dpc-5570	35	11	role	role	NOUN
dpc-5570	35	12	but	but	CCONJ
dpc-5570	35	13	have	have	VERB
dpc-5570	35	14	a	a	DET
dpc-5570	35	15	different	different	ADJ
dpc-5570	35	16	safety	safety	NOUN
dpc-5570	35	17	profile	profile	NOUN
dpc-5570	35	18	compared	compare	VERB
dpc-5570	35	19	to	to	ADP
dpc-5570	35	20	anti	anti	ADJ
dpc-5570	35	21	-	-	ADJ
dpc-5570	35	22	il-23	il-23	ADJ
dpc-5570	35	23	antibodies	antibody	NOUN
dpc-5570	35	24	[	[	X
dpc-5570	35	25	8,9	8,9	NUM
dpc-5570	35	26	]	]	PUNCT
dpc-5570	35	27	.	.	PUNCT
dpc-5570	36	1	in	in	ADP
dpc-5570	36	2	order	order	NOUN
dpc-5570	36	3	to	to	PART
dpc-5570	36	4	explain	explain	VERB
dpc-5570	36	5	the	the	DET
dpc-5570	36	6	effectiveness	effectiveness	NOUN
dpc-5570	36	7	of	of	ADP
dpc-5570	36	8	anti	anti	ADJ
dpc-5570	36	9	-	-	ADJ
dpc-5570	36	10	il-23	il-23	ADJ
dpc-5570	36	11	drugs	drug	NOUN
dpc-5570	36	12	on	on	ADP
dpc-5570	36	13	the	the	DET
dpc-5570	36	14	arthritic	arthritic	ADJ
dpc-5570	36	15	process	process	NOUN
dpc-5570	36	16	,	,	PUNCT
dpc-5570	36	17	some	some	DET
dpc-5570	36	18	authors	author	NOUN
dpc-5570	36	19	have	have	AUX
dpc-5570	36	20	suggested	suggest	VERB
dpc-5570	36	21	that	that	SCONJ
dpc-5570	36	22	elevated	elevated	ADJ
dpc-5570	36	23	levels	level	NOUN
dpc-5570	36	24	of	of	ADP
dpc-5570	36	25	il-23	il-23	NOUN
dpc-5570	36	26	in	in	ADP
dpc-5570	36	27	the	the	DET
dpc-5570	36	28	synovial	synovial	ADJ
dpc-5570	36	29	fluid	fluid	NOUN
dpc-5570	36	30	of	of	ADP
dpc-5570	36	31	psa	psa	NOUN
dpc-5570	36	32	patients	patient	NOUN
dpc-5570	36	33	may	may	AUX
dpc-5570	36	34	play	play	VERB
dpc-5570	36	35	a	a	DET
dpc-5570	36	36	key	key	ADJ
dpc-5570	36	37	role	role	NOUN
dpc-5570	36	38	in	in	ADP
dpc-5570	36	39	the	the	DET
dpc-5570	36	40	pathogenesis[2	pathogenesis[2	PROPN
dpc-5570	36	41	,	,	PUNCT
dpc-5570	36	42	9–11	9–11	NOUN
dpc-5570	36	43	]	]	PUNCT
dpc-5570	36	44	.	.	PUNCT
dpc-5570	37	1	currently	currently	ADV
dpc-5570	37	2	available	available	ADJ
dpc-5570	37	3	data	datum	NOUN
dpc-5570	37	4	support	support	VERB
dpc-5570	37	5	a	a	DET
dpc-5570	37	6	clear	clear	ADJ
dpc-5570	37	7	association	association	NOUN
dpc-5570	37	8	between	between	ADP
dpc-5570	37	9	nail	nail	NOUN
dpc-5570	37	10	psoriasis	psoriasis	NOUN
dpc-5570	37	11	and	and	CCONJ
dpc-5570	37	12	psa	psa	VERB
dpc-5570	37	13	,	,	PUNCT
dpc-5570	37	14	with	with	ADP
dpc-5570	37	15	further	further	ADJ
dpc-5570	37	16	evidence	evidence	NOUN
dpc-5570	37	17	suggesting	suggest	VERB
dpc-5570	37	18	that	that	PRON
dpc-5570	37	19	improvement	improvement	NOUN
dpc-5570	37	20	in	in	ADP
dpc-5570	37	21	nail	nail	NOUN
dpc-5570	37	22	disease	disease	NOUN
dpc-5570	37	23	correlates	correlate	VERB
dpc-5570	37	24	with	with	ADP
dpc-5570	37	25	improvement	improvement	NOUN
dpc-5570	37	26	in	in	ADP
dpc-5570	37	27	joint	joint	ADJ
dpc-5570	37	28	involvement[13	involvement[13	NOUN
dpc-5570	37	29	]	]	X
dpc-5570	37	30	.	.	PUNCT
dpc-5570	38	1	there	there	PRON
dpc-5570	38	2	is	be	VERB
dpc-5570	38	3	evidence	evidence	NOUN
dpc-5570	38	4	that	that	SCONJ
dpc-5570	38	5	there	there	PRON
dpc-5570	38	6	is	be	VERB
dpc-5570	38	7	an	an	DET
dpc-5570	38	8	anatomical	anatomical	ADJ
dpc-5570	38	9	continuity	continuity	NOUN
dpc-5570	38	10	between	between	ADP
dpc-5570	38	11	the	the	DET
dpc-5570	38	12	nail	nail	NOUN
dpc-5570	38	13	matrix	matrix	NOUN
dpc-5570	38	14	and	and	CCONJ
dpc-5570	38	15	the	the	DET
dpc-5570	38	16	entheses	enthese	NOUN
dpc-5570	38	17	of	of	ADP
dpc-5570	38	18	the	the	DET
dpc-5570	38	19	distal	distal	ADJ
dpc-5570	38	20	interphalangeal	interphalangeal	ADJ
dpc-5570	38	21	joints	joint	NOUN
dpc-5570	38	22	extensors	extensor	NOUN
dpc-5570	38	23	,	,	PUNCT
dpc-5570	38	24	i.e.	i.e.	X
dpc-5570	38	25	,	,	PUNCT
dpc-5570	38	26	the	the	DET
dpc-5570	38	27	most	most	ADV
dpc-5570	38	28	frequently	frequently	ADV
dpc-5570	38	29	affected	affect	VERB
dpc-5570	38	30	site	site	NOUN
dpc-5570	38	31	by	by	ADP
dpc-5570	38	32	psa	psa	NOUN
dpc-5570	38	33	,	,	PUNCT
dpc-5570	38	34	confirming	confirm	VERB
dpc-5570	38	35	that	that	SCONJ
dpc-5570	38	36	both	both	DET
dpc-5570	38	37	nail	nail	NOUN
dpc-5570	38	38	psoriasis	psoriasis	NOUN
dpc-5570	38	39	and	and	CCONJ
dpc-5570	38	40	psa	psa	NOUN
dpc-5570	38	41	could	could	AUX
dpc-5570	38	42	be	be	AUX
dpc-5570	38	43	considered	consider	VERB
dpc-5570	38	44	two	two	NUM
dpc-5570	38	45	different	different	ADJ
dpc-5570	38	46	aspects	aspect	NOUN
dpc-5570	38	47	of	of	ADP
dpc-5570	38	48	the	the	DET
dpc-5570	38	49	same	same	ADJ
dpc-5570	38	50	pathogenetic	pathogenetic	ADJ
dpc-5570	38	51	process	process	NOUN
dpc-5570	38	52	[	[	X
dpc-5570	38	53	14–16	14–16	NUM
dpc-5570	38	54	]	]	X
dpc-5570	38	55	.	.	PUNCT
dpc-5570	39	1	currently	currently	ADV
dpc-5570	39	2	,	,	PUNCT
dpc-5570	39	3	three	three	NUM
dpc-5570	39	4	monoclonal	monoclonal	NOUN
dpc-5570	39	5	antibodies	antibody	NOUN
dpc-5570	39	6	directed	direct	VERB
dpc-5570	39	7	against	against	ADP
dpc-5570	39	8	il-23	il-23	NOUN
dpc-5570	39	9	(	(	PUNCT
dpc-5570	39	10	or	or	CCONJ
dpc-5570	39	11	il-12	il-12	NOUN
dpc-5570	39	12	and	and	CCONJ
dpc-5570	39	13	il-23	il-23	NOUN
dpc-5570	39	14	)	)	PUNCT
dpc-5570	39	15	have	have	AUX
dpc-5570	39	16	been	be	AUX
dpc-5570	39	17	approved	approve	VERB
dpc-5570	39	18	for	for	ADP
dpc-5570	39	19	the	the	DET
dpc-5570	39	20	treatment	treatment	NOUN
dpc-5570	39	21	of	of	ADP
dpc-5570	39	22	both	both	DET
dpc-5570	39	23	psoriasis	psoriasis	NOUN
dpc-5570	39	24	and	and	CCONJ
dpc-5570	39	25	psa	psa	NOUN
dpc-5570	39	26	,	,	PUNCT
dpc-5570	39	27	including	include	VERB
dpc-5570	39	28	guselkumab	guselkumab	NOUN
dpc-5570	39	29	,	,	PUNCT
dpc-5570	39	30	ustekinumab	ustekinumab	NOUN
dpc-5570	39	31	,	,	PUNCT
dpc-5570	39	32	and	and	CCONJ
dpc-5570	39	33	risankizumab[17	risankizumab[17	VERB
dpc-5570	39	34	]	]	PUNCT
dpc-5570	39	35	.	.	PUNCT
dpc-5570	40	1	tildrakizumab	tildrakizumab	NOUN
dpc-5570	40	2	,	,	PUNCT
dpc-5570	40	3	another	another	DET
dpc-5570	40	4	il23	il23	PROPN
dpc-5570	40	5	inhibitor	inhibitor	NOUN
dpc-5570	40	6	,	,	PUNCT
dpc-5570	40	7	approved	approve	VERB
dpc-5570	40	8	for	for	ADP
dpc-5570	40	9	plaque	plaque	NOUN
dpc-5570	40	10	psoriasis	psoriasis	NOUN
dpc-5570	40	11	treatment	treatment	NOUN
dpc-5570	40	12	,	,	PUNCT
dpc-5570	40	13	is	be	AUX
dpc-5570	40	14	awaiting	await	VERB
dpc-5570	40	15	final	final	ADJ
dpc-5570	40	16	approval	approval	NOUN
dpc-5570	40	17	for	for	ADP
dpc-5570	40	18	psa	psa	NOUN
dpc-5570	40	19	.	.	PUNCT
dpc-5570	41	1	indeed	indeed	ADV
dpc-5570	41	2	,	,	PUNCT
dpc-5570	41	3	phase	phase	NOUN
dpc-5570	41	4	2	2	NUM
dpc-5570	41	5	randomized	randomize	VERB
dpc-5570	41	6	clinical	clinical	ADJ
dpc-5570	41	7	trials	trial	NOUN
dpc-5570	41	8	highlight	highlight	VERB
dpc-5570	41	9	,	,	PUNCT
dpc-5570	41	10	in	in	ADP
dpc-5570	41	11	patients	patient	NOUN
dpc-5570	41	12	suffering	suffer	VERB
dpc-5570	41	13	from	from	ADP
dpc-5570	41	14	psa	psa	NOUN
dpc-5570	41	15	,	,	PUNCT
dpc-5570	41	16	a	a	DET
dpc-5570	41	17	significant	significant	ADJ
dpc-5570	41	18	improvement	improvement	NOUN
dpc-5570	41	19	in	in	ADP
dpc-5570	41	20	joint	joint	ADJ
dpc-5570	41	21	involvement	involvement	NOUN
dpc-5570	41	22	except	except	SCONJ
dpc-5570	41	23	for	for	ADP
dpc-5570	41	24	dactylitis	dactylitis	NOUN
dpc-5570	41	25	and	and	CCONJ
dpc-5570	41	26	enthesitis	enthesitis	NOUN
dpc-5570	41	27	despite	despite	SCONJ
dpc-5570	41	28	the	the	DET
dpc-5570	41	29	mean	mean	ADJ
dpc-5570	41	30	duration	duration	NOUN
dpc-5570	41	31	of	of	ADP
dpc-5570	41	32	psa	psa	NOUN
dpc-5570	41	33	was	be	AUX
dpc-5570	41	34	more	more	ADJ
dpc-5570	41	35	than	than	ADP
dpc-5570	41	36	6	6	NUM
dpc-5570	41	37	years	year	NOUN
dpc-5570	42	1	[	[	X
dpc-5570	42	2	18	18	NUM
dpc-5570	42	3	]	]	PUNCT
dpc-5570	42	4	.	.	PUNCT
dpc-5570	43	1	psoriasis	psoriasis	NOUN
dpc-5570	43	2	,	,	PUNCT
dpc-5570	43	3	as	as	ADP
dpc-5570	43	4	a	a	DET
dpc-5570	43	5	systemic	systemic	ADJ
dpc-5570	43	6	inflammatory	inflammatory	ADJ
dpc-5570	43	7	disease	disease	NOUN
dpc-5570	43	8	,	,	PUNCT
dpc-5570	43	9	is	be	AUX
dpc-5570	43	10	closely	closely	ADV
dpc-5570	43	11	intertwined	intertwine	VERB
dpc-5570	43	12	with	with	ADP
dpc-5570	43	13	several	several	ADJ
dpc-5570	43	14	comorbidities	comorbiditie	NOUN
dpc-5570	43	15	characterized	characterize	VERB
dpc-5570	43	16	by	by	ADP
dpc-5570	43	17	dysregulated	dysregulate	VERB
dpc-5570	43	18	systemic	systemic	ADJ
dpc-5570	43	19	inflammation	inflammation	NOUN
dpc-5570	43	20	,	,	PUNCT
dpc-5570	43	21	with	with	ADP
dpc-5570	43	22	reciprocal	reciprocal	ADJ
dpc-5570	43	23	influences	influence	NOUN
dpc-5570	43	24	that	that	PRON
dpc-5570	43	25	contribute	contribute	VERB
dpc-5570	43	26	to	to	ADP
dpc-5570	43	27	a	a	DET
dpc-5570	43	28	vicious	vicious	ADJ
dpc-5570	43	29	cycle	cycle	NOUN
dpc-5570	43	30	whose	whose	DET
dpc-5570	43	31	management	management	NOUN
dpc-5570	43	32	remains	remain	VERB
dpc-5570	43	33	challenging[19	challenging[19	NOUN
dpc-5570	43	34	]	]	PUNCT
dpc-5570	43	35	.	.	PUNCT
dpc-5570	44	1	in	in	ADP
dpc-5570	44	2	this	this	DET
dpc-5570	44	3	context	context	NOUN
dpc-5570	44	4	,	,	PUNCT
dpc-5570	44	5	it	it	PRON
dpc-5570	44	6	should	should	AUX
dpc-5570	44	7	be	be	AUX
dpc-5570	44	8	emphasized	emphasize	VERB
dpc-5570	44	9	that	that	SCONJ
dpc-5570	44	10	psoriasis	psoriasis	NOUN
dpc-5570	44	11	is	be	AUX
dpc-5570	44	12	associated	associate	VERB
dpc-5570	44	13	with	with	ADP
dpc-5570	44	14	diabetes	diabetes	NOUN
dpc-5570	44	15	mellitus	mellitus	NOUN
dpc-5570	44	16	,	,	PUNCT
dpc-5570	44	17	high	high	ADJ
dpc-5570	44	18	abdominal	abdominal	ADJ
dpc-5570	44	19	circumference	circumference	NOUN
dpc-5570	44	20	,	,	PUNCT
dpc-5570	44	21	obesity	obesity	NOUN
dpc-5570	44	22	,	,	PUNCT
dpc-5570	44	23	hypertension	hypertension	NOUN
dpc-5570	44	24	,	,	PUNCT
dpc-5570	44	25	and	and	CCONJ
dpc-5570	44	26	insulin	insulin	NOUN
dpc-5570	44	27	resistance	resistance	NOUN
dpc-5570	44	28	favoring	favor	VERB
dpc-5570	44	29	progression	progression	NOUN
dpc-5570	44	30	of	of	ADP
dpc-5570	44	31	metabolic	metabolic	NOUN
dpc-5570	44	32	syndrome	syndrome	NOUN
dpc-5570	45	1	[	[	X
dpc-5570	45	2	19–21	19–21	NUM
dpc-5570	45	3	]	]	PUNCT
dpc-5570	45	4	.	.	PUNCT
dpc-5570	46	1	the	the	DET
dpc-5570	46	2	therapeutic	therapeutic	ADJ
dpc-5570	46	3	management	management	NOUN
dpc-5570	46	4	of	of	ADP
dpc-5570	46	5	patients	patient	NOUN
dpc-5570	46	6	with	with	ADP
dpc-5570	46	7	metabolic	metabolic	NOUN
dpc-5570	46	8	syndrome	syndrome	NOUN
dpc-5570	46	9	requires	require	VERB
dpc-5570	46	10	drugs	drug	NOUN
dpc-5570	46	11	with	with	ADP
dpc-5570	46	12	high	high	ADJ
dpc-5570	46	13	safety	safety	NOUN
dpc-5570	46	14	profile	profile	NOUN
dpc-5570	46	15	in	in	ADP
dpc-5570	46	16	terms	term	NOUN
dpc-5570	46	17	of	of	ADP
dpc-5570	46	18	blood	blood	NOUN
dpc-5570	46	19	chemistry	chemistry	NOUN
dpc-5570	46	20	parameters	parameter	NOUN
dpc-5570	46	21	and	and	CCONJ
dpc-5570	46	22	the	the	DET
dpc-5570	46	23	other	other	ADJ
dpc-5570	46	24	co	co	NOUN
dpc-5570	46	25	-	-	NOUN
dpc-5570	46	26	medications	medication	NOUN
dpc-5570	46	27	allowed	allow	VERB
dpc-5570	46	28	in	in	ADP
dpc-5570	46	29	this	this	DET
dpc-5570	46	30	class	class	NOUN
dpc-5570	46	31	of	of	ADP
dpc-5570	46	32	patients	patient	NOUN
dpc-5570	46	33	[	[	X
dpc-5570	46	34	22,23	22,23	NOUN
dpc-5570	46	35	]	]	X
dpc-5570	46	36	.	.	PUNCT
dpc-5570	47	1	as	as	SCONJ
dpc-5570	47	2	documented	document	VERB
dpc-5570	47	3	in	in	ADP
dpc-5570	47	4	rcts	rct	NOUN
dpc-5570	47	5	,	,	PUNCT
dpc-5570	47	6	il-23	il-23	PUNCT
dpc-5570	47	7	inhibitors	inhibitor	NOUN
dpc-5570	47	8	are	be	AUX
dpc-5570	47	9	a	a	DET
dpc-5570	47	10	preferred	preferred	ADJ
dpc-5570	47	11	option	option	NOUN
dpc-5570	47	12	due	due	ADP
dpc-5570	47	13	to	to	ADP
dpc-5570	47	14	their	their	PRON
dpc-5570	47	15	renowned	renowned	ADJ
dpc-5570	47	16	higher	high	ADJ
dpc-5570	47	17	efficacy	efficacy	NOUN
dpc-5570	47	18	and	and	CCONJ
dpc-5570	47	19	better	well	ADJ
dpc-5570	47	20	safety	safety	NOUN
dpc-5570	47	21	profile	profile	NOUN
dpc-5570	47	22	for	for	ADP
dpc-5570	47	23	psoriatic	psoriatic	ADJ
dpc-5570	47	24	patients	patient	NOUN
dpc-5570	47	25	suffering	suffer	VERB
dpc-5570	47	26	from	from	ADP
dpc-5570	47	27	metabolic	metabolic	NOUN
dpc-5570	47	28	syndrome	syndrome	NOUN
dpc-5570	47	29	[	[	X
dpc-5570	47	30	19,21,23,24	19,21,23,24	NUM
dpc-5570	47	31	]	]	PUNCT
dpc-5570	47	32	.	.	PUNCT
dpc-5570	48	1	in	in	ADP
dpc-5570	48	2	a	a	DET
dpc-5570	48	3	post	post	X
dpc-5570	48	4	hoc	hoc	X
dpc-5570	48	5	analysis	analysis	NOUN
dpc-5570	48	6	of	of	ADP
dpc-5570	48	7	the	the	DET
dpc-5570	48	8	resurface	resurface	NOUN
dpc-5570	48	9	1	1	NUM
dpc-5570	48	10	and	and	CCONJ
dpc-5570	48	11	resurface	resurface	PROPN
dpc-5570	48	12	2	2	NUM
dpc-5570	48	13	randomized	randomized	ADJ
dpc-5570	48	14	trials	trial	NOUN
dpc-5570	48	15	,	,	PUNCT
dpc-5570	48	16	among	among	ADP
dpc-5570	48	17	patients	patient	NOUN
dpc-5570	48	18	with	with	ADP
dpc-5570	48	19	metabolic	metabolic	NOUN
dpc-5570	48	20	syndrome	syndrome	NOUN
dpc-5570	48	21	treated	treat	VERB
dpc-5570	48	22	with	with	ADP
dpc-5570	48	23	tildrakizumab	tildrakizumab	NOUN
dpc-5570	48	24	100	100	NUM
dpc-5570	48	25	mg	mg	NOUN
dpc-5570	48	26	,	,	PUNCT
dpc-5570	48	27	mean	mean	VERB
dpc-5570	48	28	reductions	reduction	NOUN
dpc-5570	48	29	were	be	AUX
dpc-5570	48	30	observed	observe	VERB
dpc-5570	48	31	in	in	ADP
dpc-5570	48	32	fasting	fast	VERB
dpc-5570	48	33	glucose	glucose	NOUN
dpc-5570	48	34	,	,	PUNCT
dpc-5570	48	35	triglyceride	triglyceride	ADJ
dpc-5570	48	36	levels	level	NOUN
dpc-5570	48	37	,	,	PUNCT
dpc-5570	48	38	and	and	CCONJ
dpc-5570	48	39	systolic	systolic	ADJ
dpc-5570	48	40	blood	blood	NOUN
dpc-5570	48	41	pressure	pressure	NOUN
dpc-5570	48	42	compared	compare	VERB
dpc-5570	48	43	to	to	ADP
dpc-5570	48	44	patients	patient	NOUN
dpc-5570	48	45	without	without	ADP
dpc-5570	48	46	metabolic	metabolic	NOUN
dpc-5570	48	47	syndrome	syndrome	NOUN
dpc-5570	48	48	.	.	PUNCT
dpc-5570	49	1	similarly	similarly	ADV
dpc-5570	49	2	,	,	PUNCT
dpc-5570	49	3	those	those	PRON
dpc-5570	49	4	receiving	receive	VERB
dpc-5570	49	5	the	the	DET
dpc-5570	49	6	200	200	NUM
dpc-5570	49	7	mg	mg	NOUN
dpc-5570	49	8	dose	dose	NOUN
dpc-5570	49	9	experienced	experience	VERB
dpc-5570	49	10	numerical	numerical	ADJ
dpc-5570	49	11	decreases	decrease	NOUN
dpc-5570	49	12	in	in	ADP
dpc-5570	49	13	both	both	CCONJ
dpc-5570	49	14	systolic	systolic	ADJ
dpc-5570	49	15	and	and	CCONJ
dpc-5570	49	16	diastolic	diastolic	ADJ
dpc-5570	49	17	blood	blood	NOUN
dpc-5570	49	18	pressure	pressure	NOUN
dpc-5570	49	19	compared	compare	VERB
dpc-5570	49	20	to	to	ADP
dpc-5570	49	21	patients	patient	NOUN
dpc-5570	49	22	(	(	PUNCT
dpc-5570	49	23	-78	-78	NUM
dpc-5570	49	24	%	%	NOUN
dpc-5570	49	25	,	,	PUNCT
dpc-5570	49	26	p<0.002	p<0.002	NOUN
dpc-5570	49	27	)	)	PUNCT
dpc-5570	49	28	,	,	PUNCT
dpc-5570	49	29	dermatology	dermatology	NOUN
dpc-5570	49	30	life	life	NOUN
dpc-5570	49	31	quality	quality	NOUN
dpc-5570	49	32	index	index	NOUN
dpc-5570	49	33	(	(	PUNCT
dpc-5570	49	34	-86	-86	PROPN
dpc-5570	49	35	%	%	INTJ
dpc-5570	49	36	,	,	PUNCT
dpc-5570	49	37	p<0.001	p<0.001	PROPN
dpc-5570	49	38	)	)	PUNCT
dpc-5570	49	39	,	,	PUNCT
dpc-5570	49	40	physician	physician	NOUN
dpc-5570	49	41	global	global	ADJ
dpc-5570	49	42	assessment	assessment	NOUN
dpc-5570	49	43	(	(	PUNCT
dpc-5570	49	44	-73	-73	PROPN
dpc-5570	49	45	%	%	INTJ
dpc-5570	49	46	,	,	PUNCT
dpc-5570	49	47	p<0.0003	p<0.0003	NOUN
dpc-5570	49	48	)	)	PUNCT
dpc-5570	49	49	,	,	PUNCT
dpc-5570	49	50	and	and	CCONJ
dpc-5570	49	51	disease	disease	NOUN
dpc-5570	49	52	activity	activity	NOUN
dpc-5570	49	53	index	index	NOUN
dpc-5570	49	54	for	for	ADP
dpc-5570	49	55	psa	psa	PROPN
dpc-5570	49	56	(	(	PUNCT
dpc-5570	49	57	-82	-82	PROPN
dpc-5570	49	58	%	%	NOUN
dpc-5570	49	59	,	,	PUNCT
dpc-5570	49	60	p<0.000023	p<0.000023	NUM
dpc-5570	49	61	)	)	PUNCT
dpc-5570	49	62	.	.	PUNCT
dpc-5570	50	1	no	no	DET
dpc-5570	50	2	adverse	adverse	ADJ
dpc-5570	50	3	events	event	NOUN
dpc-5570	50	4	were	be	AUX
dpc-5570	50	5	reported	report	VERB
dpc-5570	50	6	.	.	PUNCT
dpc-5570	51	1	conclusions	conclusion	NOUN
dpc-5570	51	2	:	:	PUNCT
dpc-5570	51	3	tildrakizumab	tildrakizumab	NOUN
dpc-5570	51	4	confirmed	confirm	VERB
dpc-5570	51	5	its	its	PRON
dpc-5570	51	6	efficacy	efficacy	NOUN
dpc-5570	51	7	in	in	ADP
dpc-5570	51	8	reducing	reduce	VERB
dpc-5570	51	9	signs	sign	NOUN
dpc-5570	51	10	and	and	CCONJ
dpc-5570	51	11	symptoms	symptom	NOUN
dpc-5570	51	12	of	of	ADP
dpc-5570	51	13	early	early	ADJ
dpc-5570	51	14	psa	psa	NOUN
dpc-5570	51	15	,	,	PUNCT
dpc-5570	51	16	with	with	ADP
dpc-5570	51	17	high	high	ADJ
dpc-5570	51	18	safety	safety	NOUN
dpc-5570	51	19	profile	profile	NOUN
dpc-5570	51	20	in	in	ADP
dpc-5570	51	21	our	our	PRON
dpc-5570	51	22	psoriasis	psoriasis	NOUN
dpc-5570	51	23	patients	patient	NOUN
dpc-5570	51	24	also	also	ADV
dpc-5570	51	25	affected	affect	VERB
dpc-5570	51	26	by	by	ADP
dpc-5570	51	27	multiple	multiple	ADJ
dpc-5570	51	28	metabolic	metabolic	NOUN
dpc-5570	51	29	comorbidities	comorbiditie	NOUN
dpc-5570	51	30	.	.	PUNCT
dpc-5570	52	1	original	original	ADJ
dpc-5570	52	2	article	article	NOUN
dpc-5570	52	3	|	|	ADV
dpc-5570	52	4	dermatol	dermatol	ADJ
dpc-5570	52	5	pract	pract	NOUN
dpc-5570	52	6	concept	concept	NOUN
dpc-5570	52	7	.	.	PUNCT
dpc-5570	53	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	53	2	3	3	NUM
dpc-5570	53	3	without	without	ADP
dpc-5570	53	4	metabolic	metabolic	NOUN
dpc-5570	53	5	syndrome	syndrome	NOUN
dpc-5570	53	6	.	.	PUNCT
dpc-5570	54	1	notably	notably	ADV
dpc-5570	54	2	,	,	PUNCT
dpc-5570	54	3	patients	patient	NOUN
dpc-5570	54	4	without	without	ADP
dpc-5570	54	5	metabolic	metabolic	NOUN
dpc-5570	54	6	syndrome	syndrome	NOUN
dpc-5570	54	7	did	do	AUX
dpc-5570	54	8	not	not	PART
dpc-5570	54	9	exhibit	exhibit	VERB
dpc-5570	54	10	any	any	DET
dpc-5570	54	11	increase	increase	NOUN
dpc-5570	54	12	in	in	ADP
dpc-5570	54	13	metabolic	metabolic	NOUN
dpc-5570	54	14	risk	risk	NOUN
dpc-5570	54	15	factors	factor	NOUN
dpc-5570	54	16	over	over	ADP
dpc-5570	54	17	the	the	DET
dpc-5570	54	18	course	course	NOUN
dpc-5570	54	19	of	of	ADP
dpc-5570	54	20	the	the	DET
dpc-5570	54	21	study[23	study[23	NOUN
dpc-5570	54	22	]	]	PUNCT
dpc-5570	54	23	.	.	PUNCT
dpc-5570	55	1	according	accord	VERB
dpc-5570	55	2	to	to	ADP
dpc-5570	55	3	european	european	ADJ
dpc-5570	55	4	guidelines	guideline	NOUN
dpc-5570	55	5	,	,	PUNCT
dpc-5570	55	6	il-23	il-23	NOUN
dpc-5570	55	7	or	or	CCONJ
dpc-5570	55	8	il-17	il-17	NUM
dpc-5570	55	9	inhibitors	inhibitor	NOUN
dpc-5570	55	10	should	should	AUX
dpc-5570	55	11	be	be	AUX
dpc-5570	55	12	preferred	prefer	VERB
dpc-5570	55	13	in	in	ADP
dpc-5570	55	14	all	all	DET
dpc-5570	55	15	psoriatic	psoriatic	ADJ
dpc-5570	55	16	patients	patient	NOUN
dpc-5570	55	17	without	without	ADP
dpc-5570	55	18	contraindications	contraindication	NOUN
dpc-5570	55	19	to	to	ADP
dpc-5570	55	20	systemic	systemic	ADJ
dpc-5570	55	21	agents	agent	NOUN
dpc-5570	55	22	or	or	CCONJ
dpc-5570	55	23	when	when	SCONJ
dpc-5570	55	24	they	they	PRON
dpc-5570	55	25	are	be	AUX
dpc-5570	55	26	ineffective	ineffective	ADJ
dpc-5570	55	27	[	[	X
dpc-5570	55	28	24	24	NUM
dpc-5570	55	29	]	]	PUNCT
dpc-5570	55	30	.	.	PUNCT
dpc-5570	56	1	apremilast	apremilast	PROPN
dpc-5570	56	2	is	be	AUX
dpc-5570	56	3	considered	consider	VERB
dpc-5570	56	4	a	a	DET
dpc-5570	56	5	second	second	ADJ
dpc-5570	56	6	-	-	PUNCT
dpc-5570	56	7	line	line	NOUN
dpc-5570	56	8	treatment	treatment	NOUN
dpc-5570	56	9	when	when	SCONJ
dpc-5570	56	10	biological	biological	ADJ
dpc-5570	56	11	therapies	therapy	NOUN
dpc-5570	56	12	are	be	AUX
dpc-5570	56	13	contraindicated	contraindicate	VERB
dpc-5570	56	14	,	,	PUNCT
dpc-5570	56	15	and	and	CCONJ
dpc-5570	56	16	in	in	ADP
dpc-5570	56	17	this	this	DET
dpc-5570	56	18	context	context	NOUN
dpc-5570	56	19	,	,	PUNCT
dpc-5570	56	20	it	it	PRON
dpc-5570	56	21	should	should	AUX
dpc-5570	56	22	be	be	AUX
dpc-5570	56	23	favored	favor	VERB
dpc-5570	56	24	over	over	ADP
dpc-5570	56	25	other	other	ADJ
dpc-5570	56	26	agents	agent	NOUN
dpc-5570	56	27	in	in	ADP
dpc-5570	56	28	patients	patient	NOUN
dpc-5570	56	29	with	with	ADP
dpc-5570	56	30	metabolic	metabolic	NOUN
dpc-5570	56	31	comorbidities	comorbiditie	NOUN
dpc-5570	56	32	as	as	SCONJ
dpc-5570	56	33	it	it	PRON
dpc-5570	56	34	has	have	AUX
dpc-5570	56	35	demonstrated	demonstrate	VERB
dpc-5570	56	36	significant	significant	ADJ
dpc-5570	56	37	benefits	benefit	NOUN
dpc-5570	56	38	in	in	ADP
dpc-5570	56	39	this	this	DET
dpc-5570	56	40	population	population	NOUN
dpc-5570	57	1	[	[	X
dpc-5570	57	2	22,24,25	22,24,25	NUM
dpc-5570	57	3	]	]	X
dpc-5570	57	4	.	.	PUNCT
dpc-5570	58	1	a	a	DET
dpc-5570	58	2	case	case	NOUN
dpc-5570	58	3	series	series	NOUN
dpc-5570	58	4	of	of	ADP
dpc-5570	58	5	patients	patient	NOUN
dpc-5570	58	6	affected	affect	VERB
dpc-5570	58	7	by	by	ADP
dpc-5570	58	8	moderate	moderate	ADJ
dpc-5570	58	9	-	-	PUNCT
dpc-5570	58	10	to	to	ADP
dpc-5570	58	11	-	-	PUNCT
dpc-5570	58	12	severe	severe	ADJ
dpc-5570	58	13	psoriasis	psoriasis	NOUN
dpc-5570	58	14	,	,	PUNCT
dpc-5570	58	15	early	early	ADJ
dpc-5570	58	16	psa	psa	NOUN
dpc-5570	58	17	,	,	PUNCT
dpc-5570	58	18	and	and	CCONJ
dpc-5570	58	19	metabolic	metabolic	NOUN
dpc-5570	58	20	disorders	disorder	NOUN
dpc-5570	58	21	treated	treat	VERB
dpc-5570	58	22	with	with	ADP
dpc-5570	58	23	tildrakizumab	tildrakizumab	NOUN
dpc-5570	58	24	was	be	AUX
dpc-5570	58	25	carried	carry	VERB
dpc-5570	58	26	out	out	ADP
dpc-5570	58	27	.	.	PUNCT
dpc-5570	59	1	after	after	ADP
dpc-5570	59	2	28	28	NUM
dpc-5570	59	3	weeks	week	NOUN
dpc-5570	59	4	of	of	ADP
dpc-5570	59	5	treatment	treatment	NOUN
dpc-5570	59	6	,	,	PUNCT
dpc-5570	59	7	patients	patient	NOUN
dpc-5570	59	8	achieved	achieve	VERB
dpc-5570	59	9	complete	complete	ADJ
dpc-5570	59	10	or	or	CCONJ
dpc-5570	59	11	partial	partial	ADJ
dpc-5570	59	12	resolution	resolution	NOUN
dpc-5570	59	13	of	of	ADP
dpc-5570	59	14	both	both	DET
dpc-5570	59	15	psoriasis	psoriasis	NOUN
dpc-5570	59	16	and	and	CCONJ
dpc-5570	59	17	articular	articular	ADJ
dpc-5570	59	18	disease	disease	NOUN
dpc-5570	59	19	.	.	PUNCT
dpc-5570	60	1	methods	method	NOUN
dpc-5570	60	2	we	we	PRON
dpc-5570	60	3	enrolled	enrol	VERB
dpc-5570	60	4	eight	eight	NUM
dpc-5570	60	5	patients	patient	NOUN
dpc-5570	60	6	with	with	ADP
dpc-5570	60	7	moderate	moderate	ADJ
dpc-5570	60	8	-	-	PUNCT
dpc-5570	60	9	to	to	ADP
dpc-5570	60	10	-	-	PUNCT
dpc-5570	60	11	severe	severe	ADJ
dpc-5570	60	12	psoriasis	psoriasis	NOUN
dpc-5570	60	13	and	and	CCONJ
dpc-5570	60	14	early	early	ADJ
dpc-5570	60	15	psa	psa	NOUN
dpc-5570	60	16	who	who	PRON
dpc-5570	60	17	were	be	AUX
dpc-5570	60	18	treated	treat	VERB
dpc-5570	60	19	at	at	ADP
dpc-5570	60	20	the	the	DET
dpc-5570	60	21	dermatology	dermatology	NOUN
dpc-5570	60	22	unit	unit	NOUN
dpc-5570	60	23	of	of	ADP
dpc-5570	60	24	tor	tor	PROPN
dpc-5570	60	25	vergata	vergata	PROPN
dpc-5570	60	26	university	university	NOUN
dpc-5570	60	27	hospital	hospital	NOUN
dpc-5570	60	28	with	with	ADP
dpc-5570	60	29	tildrakizumab	tildrakizumab	NOUN
dpc-5570	60	30	100	100	NUM
dpc-5570	60	31	mg	mg	NOUN
dpc-5570	60	32	at	at	ADP
dpc-5570	60	33	baseline	baseline	PROPN
dpc-5570	60	34	(	(	PUNCT
dpc-5570	60	35	t0	t0	NOUN
dpc-5570	60	36	)	)	PUNCT
dpc-5570	60	37	,	,	PUNCT
dpc-5570	60	38	after	after	ADP
dpc-5570	60	39	four	four	NUM
dpc-5570	60	40	weeks	week	NOUN
dpc-5570	60	41	,	,	PUNCT
dpc-5570	60	42	and	and	CCONJ
dpc-5570	60	43	with	with	ADP
dpc-5570	60	44	a	a	DET
dpc-5570	60	45	maintenance	maintenance	NOUN
dpc-5570	60	46	dose	dose	NOUN
dpc-5570	60	47	of	of	ADP
dpc-5570	60	48	100	100	NUM
dpc-5570	60	49	mg	mg	NOUN
dpc-5570	60	50	every	every	DET
dpc-5570	60	51	12	12	NUM
dpc-5570	60	52	weeks	week	NOUN
dpc-5570	60	53	.	.	PUNCT
dpc-5570	61	1	all	all	DET
dpc-5570	61	2	patients	patient	NOUN
dpc-5570	61	3	signed	sign	VERB
dpc-5570	61	4	the	the	DET
dpc-5570	61	5	informed	informed	ADJ
dpc-5570	61	6	consent	consent	NOUN
dpc-5570	61	7	for	for	ADP
dpc-5570	61	8	clinical	clinical	ADJ
dpc-5570	61	9	data	datum	NOUN
dpc-5570	61	10	collection	collection	NOUN
dpc-5570	61	11	.	.	PUNCT
dpc-5570	62	1	exclusion	exclusion	NOUN
dpc-5570	62	2	criteria	criterion	NOUN
dpc-5570	62	3	were	be	AUX
dpc-5570	62	4	patients	patient	NOUN
dpc-5570	62	5	 	 	SPACE
dpc-5570	62	6	<	<	X
dpc-5570	62	7	18	18	NUM
dpc-5570	62	8	years	year	NOUN
dpc-5570	62	9	old	old	ADJ
dpc-5570	62	10	and	and	CCONJ
dpc-5570	62	11	those	those	PRON
dpc-5570	62	12	who	who	PRON
dpc-5570	62	13	refused	refuse	VERB
dpc-5570	62	14	to	to	PART
dpc-5570	62	15	sign	sign	VERB
dpc-5570	62	16	the	the	DET
dpc-5570	62	17	informed	informed	ADJ
dpc-5570	62	18	consent	consent	NOUN
dpc-5570	62	19	for	for	ADP
dpc-5570	62	20	the	the	DET
dpc-5570	62	21	collection	collection	NOUN
dpc-5570	62	22	of	of	ADP
dpc-5570	62	23	clinical	clinical	ADJ
dpc-5570	62	24	data	datum	NOUN
dpc-5570	62	25	.	.	PUNCT
dpc-5570	63	1	the	the	DET
dpc-5570	63	2	following	follow	VERB
dpc-5570	63	3	data	datum	NOUN
dpc-5570	63	4	were	be	AUX
dpc-5570	63	5	collected	collect	VERB
dpc-5570	63	6	for	for	ADP
dpc-5570	63	7	each	each	DET
dpc-5570	63	8	patient	patient	NOUN
dpc-5570	63	9	at	at	ADP
dpc-5570	63	10	baseline	baseline	NOUN
dpc-5570	63	11	and	and	CCONJ
dpc-5570	63	12	after	after	ADP
dpc-5570	63	13	28	28	NUM
dpc-5570	63	14	weeks	week	NOUN
dpc-5570	63	15	of	of	ADP
dpc-5570	63	16	follow	follow	NOUN
dpc-5570	63	17	-	-	PUNCT
dpc-5570	63	18	up	up	NOUN
dpc-5570	63	19	:	:	PUNCT
dpc-5570	63	20	demographic	demographic	ADJ
dpc-5570	63	21	data	datum	NOUN
dpc-5570	63	22	,	,	PUNCT
dpc-5570	63	23	psoriasis	psoriasis	NOUN
dpc-5570	63	24	area	area	NOUN
dpc-5570	63	25	and	and	CCONJ
dpc-5570	63	26	severity	severity	NOUN
dpc-5570	63	27	index	index	NOUN
dpc-5570	63	28	(	(	PUNCT
dpc-5570	63	29	pasi	pasi	NOUN
dpc-5570	63	30	)	)	PUNCT
dpc-5570	63	31	,	,	PUNCT
dpc-5570	63	32	pain	pain	NOUN
dpc-5570	63	33	visual	visual	ADJ
dpc-5570	63	34	analogue	analogue	NOUN
dpc-5570	63	35	scale	scale	NOUN
dpc-5570	63	36	(	(	PUNCT
dpc-5570	63	37	pain	pain	NOUN
dpc-5570	63	38	vas	vas	NOUN
dpc-5570	63	39	)	)	PUNCT
dpc-5570	63	40	score	score	NOUN
dpc-5570	63	41	,	,	PUNCT
dpc-5570	63	42	nail	nail	NOUN
dpc-5570	63	43	psoriasis	psoriasis	NOUN
dpc-5570	63	44	severity	severity	NOUN
dpc-5570	63	45	index	index	NOUN
dpc-5570	63	46	(	(	PUNCT
dpc-5570	63	47	napsi	napsi	NOUN
dpc-5570	63	48	)	)	PUNCT
dpc-5570	63	49	,	,	PUNCT
dpc-5570	63	50	the	the	DET
dpc-5570	63	51	patient	patient	ADJ
dpc-5570	63	52	global	global	ADJ
dpc-5570	63	53	assessment	assessment	NOUN
dpc-5570	63	54	(	(	PUNCT
dpc-5570	63	55	pga	pga	PROPN
dpc-5570	63	56	)	)	PUNCT
dpc-5570	63	57	,	,	PUNCT
dpc-5570	63	58	the	the	DET
dpc-5570	63	59	disease	disease	NOUN
dpc-5570	63	60	activity	activity	NOUN
dpc-5570	63	61	in	in	ADP
dpc-5570	63	62	psoriatic	psoriatic	ADJ
dpc-5570	63	63	arthritis	arthritis	NOUN
dpc-5570	63	64	(	(	PUNCT
dpc-5570	63	65	dapsa	dapsa	NOUN
dpc-5570	63	66	)	)	PUNCT
dpc-5570	64	1	[	[	X
dpc-5570	64	2	26	26	NUM
dpc-5570	64	3	]	]	PUNCT
dpc-5570	64	4	,	,	PUNCT
dpc-5570	64	5	and	and	CCONJ
dpc-5570	64	6	the	the	DET
dpc-5570	64	7	dermatology	dermatology	NOUN
dpc-5570	64	8	life	life	NOUN
dpc-5570	64	9	quality	quality	NOUN
dpc-5570	64	10	index	index	NOUN
dpc-5570	64	11	(	(	PUNCT
dpc-5570	64	12	dlqi	dlqi	PROPN
dpc-5570	64	13	)	)	PUNCT
dpc-5570	65	1	[	[	X
dpc-5570	65	2	27	27	NUM
dpc-5570	65	3	]	]	PUNCT
dpc-5570	65	4	.	.	PUNCT
dpc-5570	66	1	data	datum	NOUN
dpc-5570	66	2	on	on	ADP
dpc-5570	66	3	previous	previous	ADJ
dpc-5570	66	4	treatments	treatment	NOUN
dpc-5570	66	5	for	for	ADP
dpc-5570	66	6	psoriatic	psoriatic	ADJ
dpc-5570	66	7	and/or	and/or	CCONJ
dpc-5570	66	8	arthritic	arthritic	ADJ
dpc-5570	66	9	disease	disease	NOUN
dpc-5570	66	10	,	,	PUNCT
dpc-5570	66	11	comorbidities	comorbiditie	NOUN
dpc-5570	66	12	,	,	PUNCT
dpc-5570	66	13	and	and	CCONJ
dpc-5570	66	14	related	related	ADJ
dpc-5570	66	15	drugs	drug	NOUN
dpc-5570	66	16	were	be	AUX
dpc-5570	66	17	also	also	ADV
dpc-5570	66	18	collected	collect	VERB
dpc-5570	66	19	.	.	PUNCT
dpc-5570	67	1	the	the	DET
dpc-5570	67	2	diagnosis	diagnosis	NOUN
dpc-5570	67	3	of	of	ADP
dpc-5570	67	4	psa	psa	NOUN
dpc-5570	67	5	followed	follow	VERB
dpc-5570	67	6	the	the	DET
dpc-5570	67	7	caspar	caspar	NOUN
dpc-5570	67	8	classification	classification	NOUN
dpc-5570	67	9	criteria	criterion	NOUN
dpc-5570	67	10	for	for	ADP
dpc-5570	67	11	psa	psa	NOUN
dpc-5570	67	12	[	[	X
dpc-5570	67	13	28,29	28,29	NUM
dpc-5570	67	14	]	]	X
dpc-5570	67	15	.	.	PUNCT
dpc-5570	68	1	the	the	DET
dpc-5570	68	2	presence	presence	NOUN
dpc-5570	68	3	of	of	ADP
dpc-5570	68	4	psa	psa	NOUN
dpc-5570	68	5	was	be	AUX
dpc-5570	68	6	suspected	suspect	VERB
dpc-5570	68	7	in	in	ADP
dpc-5570	68	8	each	each	DET
dpc-5570	68	9	patient	patient	NOUN
dpc-5570	68	10	with	with	ADP
dpc-5570	68	11	a	a	DET
dpc-5570	68	12	positive	positive	ADJ
dpc-5570	68	13	anamnesis	anamnesis	NOUN
dpc-5570	68	14	of	of	ADP
dpc-5570	68	15	specific	specific	ADJ
dpc-5570	68	16	signs	sign	NOUN
dpc-5570	68	17	and	and	CCONJ
dpc-5570	68	18	symptoms	symptom	NOUN
dpc-5570	68	19	such	such	ADJ
dpc-5570	68	20	as	as	ADP
dpc-5570	68	21	morning	morning	NOUN
dpc-5570	68	22	stiffness	stiffness	NOUN
dpc-5570	68	23	lasting	last	VERB
dpc-5570	68	24	more	more	ADJ
dpc-5570	68	25	than	than	ADP
dpc-5570	68	26	30	30	NUM
dpc-5570	68	27	minutes	minute	NOUN
dpc-5570	68	28	,	,	PUNCT
dpc-5570	68	29	joint	joint	ADJ
dpc-5570	68	30	tenderness	tenderness	NOUN
dpc-5570	68	31	,	,	PUNCT
dpc-5570	68	32	pain	pain	NOUN
dpc-5570	68	33	worse	bad	ADJ
dpc-5570	68	34	after	after	ADP
dpc-5570	68	35	rest	rest	NOUN
dpc-5570	68	36	and	and	CCONJ
dpc-5570	68	37	relieved	relieve	VERB
dpc-5570	68	38	by	by	ADP
dpc-5570	68	39	exercise	exercise	NOUN
dpc-5570	68	40	,	,	PUNCT
dpc-5570	68	41	current	current	ADJ
dpc-5570	68	42	or	or	CCONJ
dpc-5570	68	43	reported	report	VERB
dpc-5570	68	44	presence	presence	NOUN
dpc-5570	68	45	of	of	ADP
dpc-5570	68	46	swelling	swell	VERB
dpc-5570	68	47	joint	joint	NOUN
dpc-5570	68	48	,	,	PUNCT
dpc-5570	68	49	dactylitis	dactylitis	NOUN
dpc-5570	68	50	,	,	PUNCT
dpc-5570	68	51	limited	limited	ADJ
dpc-5570	68	52	joint	joint	ADJ
dpc-5570	68	53	mobility	mobility	NOUN
dpc-5570	68	54	,	,	PUNCT
dpc-5570	68	55	and	and	CCONJ
dpc-5570	68	56	joint	joint	ADJ
dpc-5570	68	57	deformity	deformity	NOUN
dpc-5570	68	58	[	[	X
dpc-5570	68	59	17,21	17,21	NUM
dpc-5570	68	60	]	]	PUNCT
dpc-5570	68	61	.	.	PUNCT
dpc-5570	69	1	all	all	DET
dpc-5570	69	2	patients	patient	NOUN
dpc-5570	69	3	had	have	VERB
dpc-5570	69	4	a	a	DET
dpc-5570	69	5	confirmatory	confirmatory	NOUN
dpc-5570	69	6	color	color	NOUN
dpc-5570	69	7	doppler	doppler	NOUN
dpc-5570	69	8	ultrasound	ultrasound	NOUN
dpc-5570	69	9	and/or	and/or	CCONJ
dpc-5570	69	10	magnetic	magnetic	ADJ
dpc-5570	69	11	resonance	resonance	NOUN
dpc-5570	69	12	imaging	imaging	NOUN
dpc-5570	69	13	of	of	ADP
dpc-5570	69	14	the	the	DET
dpc-5570	69	15	hands	hand	NOUN
dpc-5570	69	16	and/or	and/or	CCONJ
dpc-5570	69	17	feet	foot	NOUN
dpc-5570	69	18	to	to	PART
dpc-5570	69	19	evaluate	evaluate	VERB
dpc-5570	69	20	the	the	DET
dpc-5570	69	21	presence	presence	NOUN
dpc-5570	69	22	of	of	ADP
dpc-5570	69	23	synovitis	synovitis	PROPN
dpc-5570	69	24	,	,	PUNCT
dpc-5570	69	25	dactylitis	dactylitis	NOUN
dpc-5570	69	26	,	,	PUNCT
dpc-5570	69	27	tenosynovitis	tenosynovitis	ADJ
dpc-5570	69	28	,	,	PUNCT
dpc-5570	69	29	erosions	erosion	NOUN
dpc-5570	69	30	,	,	PUNCT
dpc-5570	69	31	bone	bone	NOUN
dpc-5570	69	32	edema	edema	NOUN
dpc-5570	69	33	,	,	PUNCT
dpc-5570	69	34	and/or	and/or	CCONJ
dpc-5570	69	35	enthesitis	enthesitis	NOUN
dpc-5570	69	36	[	[	X
dpc-5570	69	37	29	29	NUM
dpc-5570	69	38	]	]	PUNCT
dpc-5570	69	39	.	.	PUNCT
dpc-5570	70	1	all	all	DET
dpc-5570	70	2	patients	patient	NOUN
dpc-5570	70	3	received	receive	VERB
dpc-5570	70	4	tildrakizumab	tildrakizumab	NOUN
dpc-5570	70	5	therapy	therapy	NOUN
dpc-5570	70	6	administered	administer	VERB
dpc-5570	70	7	with	with	ADP
dpc-5570	70	8	100	100	NUM
dpc-5570	70	9	mg	mg	ADJ
dpc-5570	70	10	subcutaneous	subcutaneous	ADJ
dpc-5570	70	11	injections	injection	NOUN
dpc-5570	70	12	,	,	PUNCT
dpc-5570	70	13	with	with	ADP
dpc-5570	70	14	a	a	DET
dpc-5570	70	15	dosage	dosage	NOUN
dpc-5570	70	16	established	establish	VERB
dpc-5570	70	17	according	accord	VERB
dpc-5570	70	18	to	to	ADP
dpc-5570	70	19	the	the	DET
dpc-5570	70	20	technical	technical	ADJ
dpc-5570	70	21	data	data	PROPN
dpc-5570	70	22	sheet	sheet	NOUN
dpc-5570	70	23	(	(	PUNCT
dpc-5570	70	24	induction	induction	NOUN
dpc-5570	70	25	and	and	CCONJ
dpc-5570	70	26	maintenance	maintenance	NOUN
dpc-5570	70	27	)	)	PUNCT
dpc-5570	70	28	for	for	ADP
dpc-5570	70	29	at	at	ADV
dpc-5570	70	30	least	least	ADV
dpc-5570	70	31	28	28	NUM
dpc-5570	70	32	weeks	week	NOUN
dpc-5570	70	33	[	[	X
dpc-5570	70	34	23	23	NUM
dpc-5570	70	35	]	]	PUNCT
dpc-5570	70	36	.	.	PUNCT
dpc-5570	71	1	statistical	statistical	ADJ
dpc-5570	71	2	analysis	analysis	NOUN
dpc-5570	71	3	descriptive	descriptive	ADJ
dpc-5570	71	4	and	and	CCONJ
dpc-5570	71	5	inferential	inferential	ADJ
dpc-5570	71	6	analyses	analysis	NOUN
dpc-5570	71	7	were	be	AUX
dpc-5570	71	8	performed	perform	VERB
dpc-5570	71	9	.	.	PUNCT
dpc-5570	72	1	the	the	DET
dpc-5570	72	2	results	result	NOUN
dpc-5570	72	3	are	be	AUX
dpc-5570	72	4	expressed	express	VERB
dpc-5570	72	5	as	as	ADP
dpc-5570	72	6	means	mean	NOUN
dpc-5570	72	7	or	or	CCONJ
dpc-5570	72	8	 	 	SPACE
dpc-5570	72	9	percentages	percentage	NOUN
dpc-5570	72	10	,	,	PUNCT
dpc-5570	72	11	considering	consider	VERB
dpc-5570	72	12	the	the	DET
dpc-5570	72	13	type	type	NOUN
dpc-5570	72	14	of	of	ADP
dpc-5570	72	15	each	each	DET
dpc-5570	72	16	analyzed	analyze	VERB
dpc-5570	72	17	variable	variable	NOUN
dpc-5570	72	18	.	.	PUNCT
dpc-5570	73	1	to	to	PART
dpc-5570	73	2	 	 	SPACE
dpc-5570	73	3	analyze	analyze	VERB
dpc-5570	73	4	the	the	DET
dpc-5570	73	5	differences	difference	NOUN
dpc-5570	73	6	in	in	ADP
dpc-5570	73	7	terms	term	NOUN
dpc-5570	73	8	of	of	ADP
dpc-5570	73	9	pasi	pasi	NOUN
dpc-5570	73	10	,	,	PUNCT
dpc-5570	73	11	dlqi	dlqi	ADJ
dpc-5570	73	12	,	,	PUNCT
dpc-5570	73	13	and	and	CCONJ
dpc-5570	73	14	other	other	ADJ
dpc-5570	73	15	indexes	index	NOUN
dpc-5570	73	16	or	or	CCONJ
dpc-5570	73	17	  	  	SPACE
dpc-5570	73	18	parameters	parameter	NOUN
dpc-5570	73	19	of	of	ADP
dpc-5570	73	20	interest	interest	NOUN
dpc-5570	73	21	before	before	ADP
dpc-5570	73	22	and	and	CCONJ
dpc-5570	73	23	after	after	ADP
dpc-5570	73	24	treatment	treatment	NOUN
dpc-5570	73	25	at	at	ADP
dpc-5570	73	26	different	different	ADJ
dpc-5570	73	27	timepoints	timepoint	NOUN
dpc-5570	73	28	(	(	PUNCT
dpc-5570	73	29	weeks	week	NOUN
dpc-5570	73	30	)	)	PUNCT
dpc-5570	73	31	,	,	PUNCT
dpc-5570	73	32	the	the	DET
dpc-5570	73	33	t	t	NOUN
dpc-5570	73	34	-	-	PUNCT
dpc-5570	73	35	test	test	NOUN
dpc-5570	73	36	or	or	CCONJ
dpc-5570	73	37	anova	anova	PROPN
dpc-5570	73	38	was	be	AUX
dpc-5570	73	39	used	use	VERB
dpc-5570	73	40	,	,	PUNCT
dpc-5570	73	41	followed	follow	VERB
dpc-5570	73	42	by	by	ADP
dpc-5570	73	43	the	the	DET
dpc-5570	73	44	bonferroni	bonferroni	NOUN
dpc-5570	73	45	correction	correction	NOUN
dpc-5570	73	46	ad	ad	X
dpc-5570	73	47	hoc	hoc	X
dpc-5570	73	48	test	test	NOUN
dpc-5570	73	49	.	.	PUNCT
dpc-5570	74	1	differences	difference	NOUN
dpc-5570	74	2	of	of	ADP
dpc-5570	74	3	p<0.05	p<0.05	NOUN
dpc-5570	74	4	were	be	AUX
dpc-5570	74	5	 	 	SPACE
dpc-5570	74	6	considered	consider	VERB
dpc-5570	74	7	statistically	statistically	ADV
dpc-5570	74	8	significant	significant	ADJ
dpc-5570	74	9	.	.	PUNCT
dpc-5570	75	1	all	all	DET
dpc-5570	75	2	statistical	statistical	ADJ
dpc-5570	75	3	analyses	analysis	NOUN
dpc-5570	75	4	were	be	AUX
dpc-5570	75	5	  	  	SPACE
dpc-5570	75	6	performed	perform	VERB
dpc-5570	75	7	using	use	VERB
dpc-5570	75	8	the	the	DET
dpc-5570	75	9	spss	spss	PROPN
dpc-5570	75	10	20.0	20.0	NUM
dpc-5570	75	11	statistical	statistical	ADJ
dpc-5570	75	12	package	package	NOUN
dpc-5570	75	13	(	(	PUNCT
dpc-5570	75	14	spss	spss	PROPN
dpc-5570	75	15	incorporated	incorporate	VERB
dpc-5570	75	16	,	,	PUNCT
dpc-5570	75	17	chicago)[21	chicago)[21	NOUN
dpc-5570	75	18	]	]	PUNCT
dpc-5570	75	19	.	.	PUNCT
dpc-5570	76	1	results	result	VERB
dpc-5570	76	2	eight	eight	NUM
dpc-5570	76	3	patients	patient	NOUN
dpc-5570	76	4	affected	affect	VERB
dpc-5570	76	5	by	by	ADP
dpc-5570	76	6	psoriasis	psoriasis	NOUN
dpc-5570	76	7	and	and	CCONJ
dpc-5570	76	8	early	early	ADJ
dpc-5570	76	9	psa	psa	NOUN
dpc-5570	76	10	were	be	AUX
dpc-5570	76	11	enrolled	enrol	VERB
dpc-5570	76	12	to	to	PART
dpc-5570	76	13	start	start	VERB
dpc-5570	76	14	tildrakizumab	tildrakizumab	NOUN
dpc-5570	76	15	100	100	NUM
dpc-5570	76	16	mg	mg	ADJ
dpc-5570	76	17	treatment	treatment	NOUN
dpc-5570	76	18	in	in	ADP
dpc-5570	76	19	the	the	DET
dpc-5570	76	20	period	period	NOUN
dpc-5570	76	21	between	between	ADP
dpc-5570	76	22	march	march	PROPN
dpc-5570	76	23	2022	2022	NUM
dpc-5570	76	24	and	and	CCONJ
dpc-5570	76	25	december	december	PROPN
dpc-5570	76	26	2023	2023	NUM
dpc-5570	76	27	.	.	PUNCT
dpc-5570	77	1	the	the	DET
dpc-5570	77	2	patients	patient	NOUN
dpc-5570	77	3	’	'	PUNCT
dpc-5570	77	4	demographics	demographic	NOUN
dpc-5570	77	5	and	and	CCONJ
dpc-5570	77	6	clinical	clinical	ADJ
dpc-5570	77	7	data	datum	NOUN
dpc-5570	77	8	are	be	AUX
dpc-5570	77	9	reported	report	VERB
dpc-5570	77	10	in	in	ADP
dpc-5570	77	11	table	table	NOUN
dpc-5570	77	12	1	1	NUM
dpc-5570	77	13	.	.	PUNCT
dpc-5570	78	1	the	the	DET
dpc-5570	78	2	mean	mean	ADJ
dpc-5570	78	3	duration	duration	NOUN
dpc-5570	78	4	of	of	ADP
dpc-5570	78	5	psa	psa	NOUN
dpc-5570	78	6	at	at	ADP
dpc-5570	78	7	baseline	baseline	PROPN
dpc-5570	78	8	was	be	AUX
dpc-5570	78	9	less	less	ADJ
dpc-5570	78	10	than	than	ADP
dpc-5570	78	11	one	one	NUM
dpc-5570	78	12	year	year	NOUN
dpc-5570	78	13	.	.	PUNCT
dpc-5570	79	1	no	no	DET
dpc-5570	79	2	patient	patient	NOUN
dpc-5570	79	3	had	have	AUX
dpc-5570	79	4	psa	psa	VERB
dpc-5570	79	5	with	with	ADP
dpc-5570	79	6	axial	axial	ADJ
dpc-5570	79	7	involvement	involvement	NOUN
dpc-5570	79	8	.	.	PUNCT
dpc-5570	80	1	five	five	NUM
dpc-5570	80	2	patients	patient	NOUN
dpc-5570	80	3	(	(	PUNCT
dpc-5570	80	4	62.5	62.5	NUM
dpc-5570	80	5	%	%	NOUN
dpc-5570	80	6	)	)	PUNCT
dpc-5570	80	7	were	be	AUX
dpc-5570	80	8	male	male	ADJ
dpc-5570	80	9	,	,	PUNCT
dpc-5570	80	10	and	and	CCONJ
dpc-5570	80	11	the	the	DET
dpc-5570	80	12	mean	mean	ADJ
dpc-5570	80	13	age	age	NOUN
dpc-5570	80	14	was	be	AUX
dpc-5570	80	15	56	56	NUM
dpc-5570	80	16	years	year	NOUN
dpc-5570	80	17	.	.	PUNCT
dpc-5570	81	1	the	the	DET
dpc-5570	81	2	mean	mean	ADJ
dpc-5570	81	3	pasi	pasi	NOUN
dpc-5570	81	4	at	at	ADP
dpc-5570	81	5	t0	t0	PROPN
dpc-5570	81	6	was	be	AUX
dpc-5570	81	7	14.13	14.13	NUM
dpc-5570	81	8	.	.	PUNCT
dpc-5570	82	1	in	in	ADP
dpc-5570	82	2	six	six	NUM
dpc-5570	82	3	patients	patient	NOUN
dpc-5570	82	4	crp	crp	NOUN
dpc-5570	82	5	values	value	NOUN
dpc-5570	82	6	were	be	AUX
dpc-5570	82	7	found	find	VERB
dpc-5570	82	8	to	to	PART
dpc-5570	82	9	be	be	AUX
dpc-5570	82	10	beyond	beyond	ADP
dpc-5570	82	11	the	the	DET
dpc-5570	82	12	normal	normal	ADJ
dpc-5570	82	13	upper	upper	ADJ
dpc-5570	82	14	limit	limit	NOUN
dpc-5570	82	15	for	for	ADP
dpc-5570	82	16	the	the	DET
dpc-5570	82	17	laboratory	laboratory	NOUN
dpc-5570	82	18	cutoff	cutoff	NOUN
dpc-5570	82	19	(	(	PUNCT
dpc-5570	82	20	1	1	NUM
dpc-5570	82	21	mg	mg	PROPN
dpc-5570	82	22	/	/	SYM
dpc-5570	82	23	dl	dl	NOUN
dpc-5570	82	24	)	)	PUNCT
dpc-5570	82	25	.	.	PUNCT
dpc-5570	83	1	the	the	DET
dpc-5570	83	2	mean	mean	ADJ
dpc-5570	83	3	baseline	baseline	PROPN
dpc-5570	83	4	pain	pain	PROPN
dpc-5570	83	5	vas	vas	PROPN
dpc-5570	83	6	was	be	AUX
dpc-5570	83	7	≃50	≃50	VERB
dpc-5570	83	8	.	.	PUNCT
dpc-5570	84	1	five	five	NUM
dpc-5570	84	2	(	(	PUNCT
dpc-5570	84	3	62.5	62.5	NUM
dpc-5570	84	4	%	%	NOUN
dpc-5570	84	5	)	)	PUNCT
dpc-5570	84	6	patients	patient	NOUN
dpc-5570	84	7	had	have	VERB
dpc-5570	84	8	nail	nail	NOUN
dpc-5570	84	9	involvement	involvement	NOUN
dpc-5570	84	10	,	,	PUNCT
dpc-5570	84	11	with	with	ADP
dpc-5570	84	12	a	a	DET
dpc-5570	84	13	mean	mean	ADJ
dpc-5570	84	14	hand	hand	NOUN
dpc-5570	84	15	napsi	napsi	NOUN
dpc-5570	84	16	score	score	NOUN
dpc-5570	84	17	of	of	ADP
dpc-5570	84	18	30/80	30/80	NUM
dpc-5570	84	19	.	.	PUNCT
dpc-5570	85	1	mean	mean	VERB
dpc-5570	85	2	dlqi	dlqi	ADJ
dpc-5570	85	3	value	value	NOUN
dpc-5570	85	4	at	at	ADP
dpc-5570	85	5	t0	t0	PROPN
dpc-5570	85	6	was	be	AUX
dpc-5570	85	7	16.4	16.4	NUM
dpc-5570	85	8	.	.	PUNCT
dpc-5570	86	1	patients	patient	NOUN
dpc-5570	86	2	n.	n.	VERB
dpc-5570	86	3	2	2	PROPN
dpc-5570	86	4	and	and	CCONJ
dpc-5570	86	5	n.	n.	NOUN
dpc-5570	86	6	3	3	NUM
dpc-5570	86	7	interrupted	interrupt	VERB
dpc-5570	86	8	their	their	PRON
dpc-5570	86	9	previous	previous	ADJ
dpc-5570	86	10	treatment	treatment	NOUN
dpc-5570	86	11	with	with	ADP
dpc-5570	86	12	biological	biological	ADJ
dpc-5570	86	13	drugs	drug	NOUN
dpc-5570	86	14	due	due	ADJ
dpc-5570	86	15	to	to	ADP
dpc-5570	86	16	secondary	secondary	ADJ
dpc-5570	86	17	therapeutic	therapeutic	ADJ
dpc-5570	86	18	ineffectiveness	ineffectiveness	NOUN
dpc-5570	86	19	.	.	PUNCT
dpc-5570	87	1	patient	patient	ADJ
dpc-5570	87	2	n.	n.	PROPN
dpc-5570	87	3	5	5	NUM
dpc-5570	87	4	interrupted	interrupt	VERB
dpc-5570	87	5	the	the	DET
dpc-5570	87	6	treatment	treatment	NOUN
dpc-5570	87	7	with	with	ADP
dpc-5570	87	8	dimethyl	dimethyl	NOUN
dpc-5570	87	9	fumarate	fumarate	NOUN
dpc-5570	87	10	due	due	ADP
dpc-5570	87	11	to	to	ADP
dpc-5570	87	12	the	the	DET
dpc-5570	87	13	onset	onset	NOUN
dpc-5570	87	14	of	of	ADP
dpc-5570	87	15	daytime	daytime	NOUN
dpc-5570	87	16	flushing	flushing	NOUN
dpc-5570	87	17	and	and	CCONJ
dpc-5570	87	18	diarrhea	diarrhea	NOUN
dpc-5570	87	19	.	.	PUNCT
dpc-5570	88	1	patients	patient	NOUN
dpc-5570	88	2	n.	n.	VERB
dpc-5570	88	3	1	1	NUM
dpc-5570	88	4	and	and	CCONJ
dpc-5570	88	5	n.	n.	PROPN
dpc-5570	88	6	7	7	NUM
dpc-5570	88	7	interrupted	interrupt	VERB
dpc-5570	88	8	the	the	DET
dpc-5570	88	9	cyclosporine	cyclosporine	NOUN
dpc-5570	88	10	due	due	ADP
dpc-5570	88	11	to	to	ADP
dpc-5570	88	12	an	an	DET
dpc-5570	88	13	increase	increase	NOUN
dpc-5570	88	14	in	in	ADP
dpc-5570	88	15	mean	mean	ADJ
dpc-5570	88	16	blood	blood	NOUN
dpc-5570	88	17	pressure	pressure	NOUN
dpc-5570	88	18	.	.	PUNCT
dpc-5570	89	1	in	in	ADP
dpc-5570	89	2	all	all	DET
dpc-5570	89	3	other	other	ADJ
dpc-5570	89	4	cases	case	NOUN
dpc-5570	89	5	,	,	PUNCT
dpc-5570	89	6	the	the	DET
dpc-5570	89	7	previous	previous	ADJ
dpc-5570	89	8	treatments	treatment	NOUN
dpc-5570	89	9	were	be	AUX
dpc-5570	89	10	suspended	suspend	VERB
dpc-5570	89	11	due	due	ADP
dpc-5570	89	12	to	to	ADP
dpc-5570	89	13	primary	primary	ADJ
dpc-5570	89	14	or	or	CCONJ
dpc-5570	89	15	secondary	secondary	ADJ
dpc-5570	89	16	therapeutic	therapeutic	ADJ
dpc-5570	89	17	ineffectiveness	ineffectiveness	NOUN
dpc-5570	89	18	.	.	PUNCT
dpc-5570	90	1	all	all	DET
dpc-5570	90	2	patients	patient	NOUN
dpc-5570	90	3	were	be	AUX
dpc-5570	90	4	affected	affect	VERB
dpc-5570	90	5	by	by	ADP
dpc-5570	90	6	oligoarticular	oligoarticular	ADJ
dpc-5570	90	7	  	  	SPACE
dpc-5570	90	8	psa	psa	NOUN
dpc-5570	90	9	,	,	PUNCT
dpc-5570	90	10	with	with	ADP
dpc-5570	90	11	a	a	DET
dpc-5570	90	12	prevalent	prevalent	ADJ
dpc-5570	90	13	involvement	involvement	NOUN
dpc-5570	90	14	of	of	ADP
dpc-5570	90	15	the	the	DET
dpc-5570	90	16	distal	distal	ADJ
dpc-5570	90	17	interphalangeal	interphalangeal	ADJ
dpc-5570	90	18	joints	joint	NOUN
dpc-5570	90	19	.	.	PUNCT
dpc-5570	91	1	the	the	DET
dpc-5570	91	2	mean	mean	ADJ
dpc-5570	91	3	patient	patient	ADJ
dpc-5570	91	4	pga	pga	NOUN
dpc-5570	91	5	value	value	NOUN
dpc-5570	91	6	at	at	ADP
dpc-5570	91	7	baseline	baseline	NOUN
dpc-5570	91	8	of	of	ADP
dpc-5570	91	9	treatment	treatment	NOUN
dpc-5570	91	10	with	with	ADP
dpc-5570	91	11	tildrakizumab	tildrakizumab	NOUN
dpc-5570	91	12	was	be	AUX
dpc-5570	91	13	6.5	6.5	NUM
dpc-5570	91	14	;	;	PUNCT
dpc-5570	91	15	mean	mean	VERB
dpc-5570	91	16	dapsa	dapsa	ADJ
dpc-5570	91	17	value	value	NOUN
dpc-5570	91	18	at	at	ADP
dpc-5570	91	19	t0	t0	PROPN
dpc-5570	91	20	was	be	AUX
dpc-5570	91	21	20.75	20.75	NUM
dpc-5570	91	22	.	.	PUNCT
dpc-5570	92	1	although	although	SCONJ
dpc-5570	92	2	just	just	ADV
dpc-5570	92	3	patient	patient	ADJ
dpc-5570	92	4	n.	n.	NOUN
dpc-5570	92	5	1	1	NUM
dpc-5570	92	6	and	and	CCONJ
dpc-5570	92	7	patient	patient	ADJ
dpc-5570	92	8	n.	n.	NOUN
dpc-5570	92	9	7	7	NUM
dpc-5570	92	10	had	have	VERB
dpc-5570	92	11	a	a	DET
dpc-5570	92	12	diagnosis	diagnosis	NOUN
dpc-5570	92	13	of	of	ADP
dpc-5570	92	14	metabolic	metabolic	NOUN
dpc-5570	92	15	syndrome	syndrome	NOUN
dpc-5570	92	16	,	,	PUNCT
dpc-5570	92	17	each	each	DET
dpc-5570	92	18	patient	patient	NOUN
dpc-5570	92	19	had	have	VERB
dpc-5570	92	20	at	at	ADV
dpc-5570	92	21	least	least	ADV
dpc-5570	92	22	one	one	NUM
dpc-5570	92	23	metabolic	metabolic	NOUN
dpc-5570	92	24	comorbidity	comorbidity	NOUN
dpc-5570	92	25	treated	treat	VERB
dpc-5570	92	26	with	with	ADP
dpc-5570	92	27	multiple	multiple	ADJ
dpc-5570	92	28	drugs	drug	NOUN
dpc-5570	92	29	(	(	PUNCT
dpc-5570	92	30	table	table	NOUN
dpc-5570	92	31	1	1	NUM
dpc-5570	92	32	)	)	PUNCT
dpc-5570	92	33	.	.	PUNCT
dpc-5570	93	1	one	one	NUM
dpc-5570	93	2	patient	patient	NOUN
dpc-5570	93	3	also	also	ADV
dpc-5570	93	4	had	have	VERB
dpc-5570	93	5	active	active	ADJ
dpc-5570	93	6	bowel	bowel	NOUN
dpc-5570	93	7	diverticulitis	diverticulitis	NOUN
dpc-5570	93	8	undergoing	undergo	VERB
dpc-5570	93	9	treatment	treatment	NOUN
dpc-5570	93	10	with	with	ADP
dpc-5570	93	11	antibiotics	antibiotic	NOUN
dpc-5570	93	12	,	,	PUNCT
dpc-5570	93	13	whilst	whilst	SCONJ
dpc-5570	93	14	another	another	DET
dpc-5570	93	15	patient	patient	NOUN
dpc-5570	93	16	had	have	AUX
dpc-5570	93	17	been	be	AUX
dpc-5570	93	18	diagnosed	diagnose	VERB
dpc-5570	93	19	with	with	ADP
dpc-5570	93	20	benign	benign	ADJ
dpc-5570	93	21	prostatic	prostatic	ADJ
dpc-5570	93	22	hyperplasia	hyperplasia	NOUN
dpc-5570	93	23	and	and	CCONJ
dpc-5570	93	24	had	have	AUX
dpc-5570	93	25	been	be	AUX
dpc-5570	93	26	treated	treat	VERB
dpc-5570	93	27	with	with	ADP
dpc-5570	93	28	dutasteride	dutasteride	PROPN
dpc-5570	93	29	.	.	PUNCT
dpc-5570	94	1	the	the	DET
dpc-5570	94	2	distribution	distribution	NOUN
dpc-5570	94	3	of	of	ADP
dpc-5570	94	4	comorbidities	comorbiditie	NOUN
dpc-5570	94	5	is	be	AUX
dpc-5570	94	6	reported	report	VERB
dpc-5570	94	7	in	in	ADP
dpc-5570	94	8	figure	figure	NOUN
dpc-5570	94	9	1	1	NUM
dpc-5570	94	10	.	.	PUNCT
dpc-5570	94	11	table	table	NOUN
dpc-5570	94	12	2	2	NUM
dpc-5570	94	13	shows	show	VERB
dpc-5570	94	14	patient	patient	NOUN
dpc-5570	94	15	’s	’s	PART
dpc-5570	94	16	clinimetric	clinimetric	ADJ
dpc-5570	94	17	score	score	NOUN
dpc-5570	94	18	after	after	ADP
dpc-5570	94	19	28	28	NUM
dpc-5570	94	20	weeks	week	NOUN
dpc-5570	94	21	of	of	ADP
dpc-5570	94	22	treatment	treatment	NOUN
dpc-5570	94	23	with	with	ADP
dpc-5570	94	24	tildrakizumab	tildrakizumab	NOUN
dpc-5570	94	25	100	100	NUM
dpc-5570	94	26	mg	mg	NOUN
dpc-5570	94	27	.	.	PUNCT
dpc-5570	95	1	pasi	pasi	NOUN
dpc-5570	95	2	at	at	ADP
dpc-5570	95	3	t28	t28	NUM
dpc-5570	95	4	was	be	AUX
dpc-5570	95	5	4	4	NUM
dpc-5570	95	6	original	original	ADJ
dpc-5570	95	7	article	article	NOUN
dpc-5570	95	8	|	|	ADV
dpc-5570	95	9	dermatol	dermatol	ADJ
dpc-5570	95	10	pract	pract	NOUN
dpc-5570	95	11	concept	concept	NOUN
dpc-5570	95	12	.	.	PUNCT
dpc-5570	96	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	96	2	t	t	PROPN
dpc-5570	96	3	ab	ab	X
dpc-5570	96	4	le	le	PROPN
dpc-5570	96	5	1	1	NUM
dpc-5570	96	6	.	.	PUNCT
dpc-5570	97	1	c	c	NOUN
dpc-5570	98	1	ha	ha	INTJ
dpc-5570	98	2	ra	ra	INTJ
dpc-5570	99	1	ct	ct	INTJ
dpc-5570	99	2	er	er	INTJ
dpc-5570	99	3	is	be	AUX
dpc-5570	99	4	ti	ti	X
dpc-5570	99	5	cs	cs	ADJ
dpc-5570	99	6	o	o	NOUN
dpc-5570	99	7	f	f	PROPN
dpc-5570	99	8	e	e	X
dpc-5570	99	9	nr	nr	PROPN
dpc-5570	99	10	ol	ol	PROPN
dpc-5570	99	11	le	le	PROPN
dpc-5570	99	12	d	d	X
dpc-5570	99	13	pa	pa	PROPN
dpc-5570	99	14	ti	ti	PROPN
dpc-5570	99	15	en	en	X
dpc-5570	99	16	ts	ts	X
dpc-5570	99	17	.	.	PUNCT
dpc-5570	100	1	pa	pa	PROPN
dpc-5570	100	2	t	t	PROPN
dpc-5570	100	3	ie	ie	X
dpc-5570	100	4	n	n	PROPN
dpc-5570	100	5	t	t	NOUN
dpc-5570	100	6	s	s	PART
dpc-5570	100	7	c	c	NOUN
dpc-5570	100	8	om	om	NOUN
dpc-5570	100	9	or	or	CCONJ
dpc-5570	100	10	bi	bi	NOUN
dpc-5570	100	11	di	di	NOUN
dpc-5570	100	12	ti	ti	PROPN
dpc-5570	100	13	es	es	NOUN
dpc-5570	100	14	/t	/t	PUNCT
dpc-5570	101	1	he	he	PRON
dpc-5570	101	2	ra	ra	INTJ
dpc-5570	102	1	pi	pi	NOUN
dpc-5570	102	2	es	es	X
dpc-5570	102	3	pr	pr	NOUN
dpc-5570	102	4	ev	ev	INTJ
dpc-5570	102	5	io	io	X
dpc-5570	102	6	us	us	PROPN
dpc-5570	102	7	t	t	PROPN
dpc-5570	102	8	re	re	NOUN
dpc-5570	102	9	at	at	ADP
dpc-5570	102	10	m	m	PROPN
dpc-5570	102	11	en	en	ADP
dpc-5570	102	12	ts	ts	ADP
dpc-5570	102	13	fo	fo	ADP
dpc-5570	102	14	r	r	NOUN
dpc-5570	102	15	ps	ps	NOUN
dpc-5570	102	16	or	or	CCONJ
dpc-5570	102	17	ia	ia	PROPN
dpc-5570	102	18	si	si	X
dpc-5570	102	19	s/	s/	VERB
dpc-5570	102	20	ps	ps	PROPN
dpc-5570	102	21	or	or	CCONJ
dpc-5570	102	22	ia	ia	PROPN
dpc-5570	102	23	ti	ti	PROPN
dpc-5570	102	24	c	c	PROPN
dpc-5570	102	25	ar	ar	PROPN
dpc-5570	102	26	th	th	X
dpc-5570	102	27	ri	ri	PROPN
dpc-5570	103	1	ti	ti	PROPN
dpc-5570	103	2	s	s	PROPN
dpc-5570	103	3	t	t	NOUN
dpc-5570	103	4	0	0	PUNCT
dpc-5570	104	1	pa	pa	PROPN
dpc-5570	104	2	si	si	PROPN
dpc-5570	104	3	t	t	PROPN
dpc-5570	104	4	0	0	PUNCT
dpc-5570	104	5	c	c	NOUN
dpc-5570	104	6	r	r	NOUN
dpc-5570	104	7	p	p	NOUN
dpc-5570	104	8	(	(	PUNCT
dpc-5570	104	9	m	m	PROPN
dpc-5570	104	10	g/	g/	NOUN
dpc-5570	104	11	dl	dl	PROPN
dpc-5570	104	12	)	)	PUNCT
dpc-5570	104	13	t	t	NOUN
dpc-5570	104	14	0	0	NUM
dpc-5570	105	1	pa	pa	PROPN
dpc-5570	105	2	in	in	ADP
dpc-5570	105	3	v	v	NUM
dpc-5570	105	4	a	a	DET
dpc-5570	105	5	s	s	NOUN
dpc-5570	105	6	t	t	NOUN
dpc-5570	105	7	0	0	NUM
dpc-5570	105	8	h	h	NOUN
dpc-5570	106	1	an	an	DET
dpc-5570	106	2	d	d	PROPN
dpc-5570	106	3	n	n	CCONJ
dpc-5570	106	4	a	a	DET
dpc-5570	106	5	ps	ps	NOUN
dpc-5570	107	1	i	i	PRON
dpc-5570	107	2	t	t	NOUN
dpc-5570	107	3	0	0	PUNCT
dpc-5570	108	1	d	d	NOUN
dpc-5570	108	2	l	l	NOUN
dpc-5570	109	1	q	q	X
dpc-5570	110	1	i	i	PRON
dpc-5570	110	2	t	t	NOUN
dpc-5570	110	3	0	0	PUNCT
dpc-5570	111	1	pa	pa	PROPN
dpc-5570	111	2	ti	ti	PROPN
dpc-5570	111	3	en	en	PROPN
dpc-5570	111	4	t	t	PROPN
dpc-5570	111	5	pg	pg	PROPN
dpc-5570	111	6	a	a	DET
dpc-5570	111	7	d	d	NOUN
dpc-5570	111	8	a	a	DET
dpc-5570	111	9	ps	ps	NOUN
dpc-5570	111	10	a	a	DET
dpc-5570	111	11	n	n	NOUN
dpc-5570	111	12	.	.	PUNCT
dpc-5570	112	1	1	1	NUM
dpc-5570	112	2	m	m	NOUN
dpc-5570	112	3	al	al	PROPN
dpc-5570	112	4	e	e	PROPN
dpc-5570	112	5	,	,	PUNCT
dpc-5570	112	6	52	52	NUM
dpc-5570	112	7	y	y	NOUN
dpc-5570	112	8	ea	ea	NOUN
dpc-5570	112	9	rs	rs	INTJ
dpc-5570	113	1	o	o	INTJ
dpc-5570	113	2	ld	ld	PROPN
dpc-5570	113	3	h	h	NOUN
dpc-5570	113	4	yp	yp	PROPN
dpc-5570	114	1	er	er	INTJ
dpc-5570	114	2	te	te	INTJ
dpc-5570	114	3	ns	ns	PROPN
dpc-5570	114	4	io	io	PROPN
dpc-5570	114	5	n	n	X
dpc-5570	114	6	,	,	PUNCT
dpc-5570	114	7	d	d	PROPN
dpc-5570	114	8	ia	ia	PROPN
dpc-5570	114	9	be	be	AUX
dpc-5570	114	10	te	te	PROPN
dpc-5570	114	11	s	s	PROPN
dpc-5570	114	12	,	,	PUNCT
dpc-5570	114	13	hy	hy	PROPN
dpc-5570	114	14	pe	pe	PROPN
dpc-5570	114	15	rc	rc	PROPN
dpc-5570	114	16	ho	ho	PROPN
dpc-5570	114	17	le	le	PROPN
dpc-5570	114	18	st	st	PROPN
dpc-5570	115	1	er	er	INTJ
dpc-5570	115	2	ol	ol	PROPN
dpc-5570	115	3	em	em	PROPN
dpc-5570	115	4	ia	ia	PROPN
dpc-5570	115	5	/o	/o	PUNCT
dpc-5570	115	6	lm	lm	INTJ
dpc-5570	115	7	es	es	ADP
dpc-5570	115	8	ar	ar	PROPN
dpc-5570	115	9	ta	ta	PROPN
dpc-5570	115	10	n	n	CCONJ
dpc-5570	115	11	,	,	PUNCT
dpc-5570	115	12	m	m	VERB
dpc-5570	115	13	et	et	NOUN
dpc-5570	115	14	fo	fo	ADP
dpc-5570	115	15	rm	rm	PROPN
dpc-5570	115	16	in	in	ADV
dpc-5570	115	17	,	,	PUNCT
dpc-5570	115	18	r	r	NOUN
dpc-5570	115	19	os	os	NOUN
dpc-5570	115	20	uv	uv	NOUN
dpc-5570	115	21	as	as	ADP
dpc-5570	115	22	ta	ta	X
dpc-5570	115	23	ti	ti	PROPN
dpc-5570	115	24	n	n	PART
dpc-5570	115	25	to	to	ADP
dpc-5570	115	26	pi	pi	NOUN
dpc-5570	115	27	ca	can	AUX
dpc-5570	115	28	ls	ls	INTJ
dpc-5570	115	29	,	,	PUNCT
dpc-5570	115	30	m	m	VERB
dpc-5570	115	31	et	et	NOUN
dpc-5570	115	32	ho	ho	PROPN
dpc-5570	115	33	tr	tr	VERB
dpc-5570	115	34	ex	ex	X
dpc-5570	115	35	at	at	ADP
dpc-5570	115	36	e	e	NOUN
dpc-5570	115	37	,	,	PUNCT
dpc-5570	115	38	cy	cy	PROPN
dpc-5570	115	39	cl	cl	NOUN
dpc-5570	115	40	os	os	INTJ
dpc-5570	115	41	po	po	PROPN
dpc-5570	115	42	ri	ri	PROPN
dpc-5570	115	43	n	n	CCONJ
dpc-5570	115	44	,	,	PUNCT
dpc-5570	115	45	m	m	VERB
dpc-5570	115	46	et	et	NOUN
dpc-5570	115	47	hy	hy	NOUN
dpc-5570	115	48	lp	lp	PROPN
dpc-5570	115	49	re	re	AUX
dpc-5570	115	50	dn	dn	PROPN
dpc-5570	115	51	is	be	AUX
dpc-5570	115	52	ol	ol	ADJ
dpc-5570	115	53	on	on	ADP
dpc-5570	115	54	e	e	PROPN
dpc-5570	115	55	10	10	NUM
dpc-5570	115	56	2	2	NUM
dpc-5570	115	57	.	.	NOUN
dpc-5570	115	58	31	31	NUM
dpc-5570	115	59	60	60	NUM
dpc-5570	115	60	40	40	NUM
dpc-5570	115	61	14	14	NUM
dpc-5570	115	62	7	7	NUM
dpc-5570	115	63	31	31	NUM
dpc-5570	115	64	n	n	NOUN
dpc-5570	115	65	.	.	PUNCT
dpc-5570	116	1	2	2	NUM
dpc-5570	116	2	f	f	X
dpc-5570	116	3	em	em	PROPN
dpc-5570	116	4	al	al	PROPN
dpc-5570	116	5	e	e	PROPN
dpc-5570	116	6	,	,	PUNCT
dpc-5570	116	7	79	79	NUM
dpc-5570	116	8	y	y	NOUN
dpc-5570	116	9	ea	ea	NOUN
dpc-5570	116	10	rs	rs	INTJ
dpc-5570	117	1	o	o	INTJ
dpc-5570	117	2	ld	ld	PROPN
dpc-5570	117	3	h	h	NOUN
dpc-5570	117	4	yp	yp	PROPN
dpc-5570	118	1	er	er	INTJ
dpc-5570	118	2	te	te	INTJ
dpc-5570	118	3	ns	ns	PROPN
dpc-5570	118	4	io	io	PROPN
dpc-5570	118	5	n	n	X
dpc-5570	118	6	,	,	PUNCT
dpc-5570	119	1	h	h	NOUN
dpc-5570	119	2	yp	yp	NOUN
dpc-5570	119	3	er	er	INTJ
dpc-5570	119	4	ch	ch	NOUN
dpc-5570	119	5	ol	ol	PROPN
dpc-5570	119	6	es	es	X
dpc-5570	119	7	te	te	PROPN
dpc-5570	119	8	ro	ro	X
dpc-5570	119	9	le	le	PROPN
dpc-5570	119	10	m	m	PROPN
dpc-5570	119	11	ia	ia	PROPN
dpc-5570	119	12	/	/	SYM
dpc-5570	119	13	b	b	PROPN
dpc-5570	119	14	is	be	AUX
dpc-5570	119	15	op	op	NOUN
dpc-5570	119	16	ro	ro	X
dpc-5570	120	1	lo	lo	NOUN
dpc-5570	120	2	l	l	PROPN
dpc-5570	121	1	+	+	CCONJ
dpc-5570	121	2	f	f	AUX
dpc-5570	121	3	ur	ur	INTJ
dpc-5570	121	4	os	os	VERB
dpc-5570	121	5	em	em	PRON
dpc-5570	121	6	i	i	PROPN
dpc-5570	121	7	d	d	PROPN
dpc-5570	121	8	e	e	PROPN
dpc-5570	121	9	,	,	PUNCT
dpc-5570	121	10	lo	lo	PROPN
dpc-5570	121	11	va	va	PROPN
dpc-5570	121	12	st	st	PROPN
dpc-5570	121	13	at	at	ADP
dpc-5570	121	14	in	in	ADP
dpc-5570	121	15	to	to	ADP
dpc-5570	121	16	pi	pi	NOUN
dpc-5570	121	17	ca	can	AUX
dpc-5570	121	18	ls	ls	INTJ
dpc-5570	121	19	,	,	PUNCT
dpc-5570	121	20	a	a	DET
dpc-5570	121	21	ci	ci	NOUN
dpc-5570	121	22	tr	tr	VERB
dpc-5570	121	23	et	et	NOUN
dpc-5570	121	24	in	in	ADP
dpc-5570	121	25	,	,	PUNCT
dpc-5570	121	26	br	br	PROPN
dpc-5570	121	27	od	od	PROPN
dpc-5570	121	28	al	al	PROPN
dpc-5570	121	29	um	um	INTJ
dpc-5570	121	30	ab	ab	PROPN
dpc-5570	121	31	13	13	NUM
dpc-5570	121	32	1	1	NUM
dpc-5570	121	33	.	.	SYM
dpc-5570	121	34	2	2	NUM
dpc-5570	121	35	50	50	NUM
dpc-5570	121	36	0	0	NUM
dpc-5570	121	37	11	11	NUM
dpc-5570	121	38	6	6	NUM
dpc-5570	121	39	19	19	NUM
dpc-5570	121	40	n	n	NOUN
dpc-5570	121	41	.	.	PUNCT
dpc-5570	122	1	3	3	NUM
dpc-5570	122	2	m	m	NOUN
dpc-5570	122	3	al	al	PROPN
dpc-5570	122	4	e	e	PROPN
dpc-5570	122	5	,	,	PUNCT
dpc-5570	122	6	63	63	NUM
dpc-5570	122	7	y	y	NOUN
dpc-5570	122	8	ea	ea	NOUN
dpc-5570	122	9	rs	rs	INTJ
dpc-5570	123	1	o	o	INTJ
dpc-5570	123	2	ld	ld	PROPN
dpc-5570	123	3	h	h	NOUN
dpc-5570	123	4	yp	yp	PROPN
dpc-5570	124	1	er	er	INTJ
dpc-5570	124	2	ch	ch	NOUN
dpc-5570	124	3	ol	ol	PROPN
dpc-5570	124	4	es	es	X
dpc-5570	124	5	te	te	PROPN
dpc-5570	124	6	ro	ro	X
dpc-5570	124	7	le	le	PROPN
dpc-5570	124	8	m	m	PROPN
dpc-5570	124	9	ia	ia	PROPN
dpc-5570	124	10	/r	/r	INTJ
dpc-5570	124	11	os	os	INTJ
dpc-5570	124	12	uv	uv	INTJ
dpc-5570	124	13	as	as	ADP
dpc-5570	124	14	ta	ta	X
dpc-5570	124	15	ti	ti	PROPN
dpc-5570	124	16	n	n	PROPN
dpc-5570	124	17	+	+	CCONJ
dpc-5570	124	18	ez	ez	X
dpc-5570	124	19	et	et	NOUN
dpc-5570	124	20	i	i	NOUN
dpc-5570	124	21	m	m	VERB
dpc-5570	124	22	ib	ib	NOUN
dpc-5570	124	23	e	e	NOUN
dpc-5570	124	24	to	to	ADP
dpc-5570	124	25	pi	pi	PROPN
dpc-5570	124	26	ca	can	AUX
dpc-5570	124	27	ls	ls	INTJ
dpc-5570	124	28	,	,	PUNCT
dpc-5570	124	29	c	c	X
dpc-5570	124	30	er	er	INTJ
dpc-5570	124	31	to	to	ADP
dpc-5570	124	32	liz	liz	PROPN
dpc-5570	124	33	um	um	INTJ
dpc-5570	124	34	ab	ab	PROPN
dpc-5570	124	35	pe	pe	PROPN
dpc-5570	124	36	go	go	VERB
dpc-5570	124	37	l	l	PROPN
dpc-5570	124	38	15	15	NUM
dpc-5570	124	39	0	0	NUM
dpc-5570	124	40	.	.	PUNCT
dpc-5570	125	1	26	26	NUM
dpc-5570	125	2	50	50	NUM
dpc-5570	125	3	40	40	NUM
dpc-5570	125	4	10	10	NUM
dpc-5570	125	5	5	5	NUM
dpc-5570	125	6	14	14	NUM
dpc-5570	125	7	n	n	NOUN
dpc-5570	125	8	.	.	PUNCT
dpc-5570	126	1	4	4	NUM
dpc-5570	126	2	m	m	NOUN
dpc-5570	126	3	al	al	PROPN
dpc-5570	126	4	e	e	PROPN
dpc-5570	126	5	,	,	PUNCT
dpc-5570	126	6	49	49	NUM
dpc-5570	126	7	y	y	SYM
dpc-5570	126	8	ea	ea	NOUN
dpc-5570	126	9	rs	rs	INTJ
dpc-5570	127	1	o	o	INTJ
dpc-5570	127	2	ld	ld	PROPN
dpc-5570	127	3	h	h	NOUN
dpc-5570	127	4	yp	yp	PROPN
dpc-5570	128	1	er	er	INTJ
dpc-5570	128	2	te	te	INTJ
dpc-5570	128	3	ns	ns	PROPN
dpc-5570	128	4	io	io	PROPN
dpc-5570	128	5	n	n	X
dpc-5570	128	6	,	,	PUNCT
dpc-5570	128	7	c	c	NOUN
dpc-5570	128	8	ol	ol	ADJ
dpc-5570	129	1	on	on	ADP
dpc-5570	129	2	d	d	PROPN
dpc-5570	129	3	iv	iv	X
dpc-5570	129	4	er	er	INTJ
dpc-5570	129	5	ti	ti	X
dpc-5570	129	6	cu	cu	PROPN
dpc-5570	129	7	lit	light	VERB
dpc-5570	129	8	is	be	AUX
dpc-5570	129	9	/	/	PUNCT
dpc-5570	129	10	a	a	DET
dpc-5570	129	11	m	m	NOUN
dpc-5570	129	12	lo	lo	NOUN
dpc-5570	129	13	di	di	NOUN
dpc-5570	129	14	pi	pi	PROPN
dpc-5570	129	15	ne	ne	PROPN
dpc-5570	129	16	/r	/r	PUNCT
dpc-5570	130	1	if	if	SCONJ
dpc-5570	130	2	ax	ax	NOUN
dpc-5570	130	3	i	i	PRON
dpc-5570	130	4	m	m	VERB
dpc-5570	130	5	in	in	ADP
dpc-5570	130	6	e	e	PROPN
dpc-5570	130	7	to	to	ADP
dpc-5570	130	8	pi	pi	PROPN
dpc-5570	130	9	ca	can	AUX
dpc-5570	130	10	ls	ls	VERB
dpc-5570	130	11	20	20	NUM
dpc-5570	130	12	3	3	NUM
dpc-5570	130	13	.	.	NOUN
dpc-5570	130	14	8	8	NUM
dpc-5570	130	15	40	40	NUM
dpc-5570	130	16	33	33	NUM
dpc-5570	130	17	18	18	NUM
dpc-5570	130	18	9	9	NUM
dpc-5570	130	19	17	17	NUM
dpc-5570	130	20	n	n	NOUN
dpc-5570	130	21	.	.	PUNCT
dpc-5570	131	1	5	5	NUM
dpc-5570	131	2	m	m	NOUN
dpc-5570	131	3	al	al	PROPN
dpc-5570	131	4	e	e	PROPN
dpc-5570	131	5	,	,	PUNCT
dpc-5570	131	6	53	53	NUM
dpc-5570	131	7	y	y	SYM
dpc-5570	131	8	ea	ea	NOUN
dpc-5570	131	9	rs	rs	INTJ
dpc-5570	132	1	o	o	INTJ
dpc-5570	132	2	ld	ld	PROPN
dpc-5570	132	3	h	h	NOUN
dpc-5570	132	4	yp	yp	PROPN
dpc-5570	133	1	er	er	INTJ
dpc-5570	133	2	ch	ch	NOUN
dpc-5570	133	3	ol	ol	PROPN
dpc-5570	133	4	es	es	X
dpc-5570	133	5	te	te	PROPN
dpc-5570	133	6	ro	ro	X
dpc-5570	133	7	le	le	PROPN
dpc-5570	133	8	m	m	PROPN
dpc-5570	133	9	ia	ia	PROPN
dpc-5570	133	10	/	/	SYM
dpc-5570	133	11	l	l	NOUN
dpc-5570	133	12	ov	ov	PROPN
dpc-5570	133	13	as	as	ADP
dpc-5570	133	14	ta	ta	ADP
dpc-5570	133	15	ti	ti	PROPN
dpc-5570	133	16	n	n	PROPN
dpc-5570	133	17	d	d	PROPN
dpc-5570	133	18	i	i	PRON
dpc-5570	133	19	m	m	VERB
dpc-5570	133	20	et	et	NOUN
dpc-5570	133	21	hy	hy	NOUN
dpc-5570	133	22	l	l	PROPN
dpc-5570	133	23	f	f	X
dpc-5570	133	24	um	um	INTJ
dpc-5570	133	25	ar	ar	PROPN
dpc-5570	133	26	at	at	ADP
dpc-5570	133	27	e	e	X
dpc-5570	133	28	10	10	NUM
dpc-5570	133	29	<	<	X
dpc-5570	133	30	0	0	NUM
dpc-5570	134	1	.4	.4	NUM
dpc-5570	134	2	0	0	NUM
dpc-5570	134	3	60	60	NUM
dpc-5570	134	4	20	20	NUM
dpc-5570	134	5	10	10	NUM
dpc-5570	134	6	6	6	NUM
dpc-5570	134	7	17	17	NUM
dpc-5570	134	8	n	n	NOUN
dpc-5570	134	9	.	.	PUNCT
dpc-5570	135	1	6	6	NUM
dpc-5570	135	2	f	f	X
dpc-5570	135	3	em	em	PROPN
dpc-5570	135	4	al	al	PROPN
dpc-5570	135	5	e	e	PROPN
dpc-5570	135	6	,	,	PUNCT
dpc-5570	135	7	54	54	NUM
dpc-5570	135	8	y	y	SYM
dpc-5570	135	9	ea	ea	NOUN
dpc-5570	135	10	rs	rs	INTJ
dpc-5570	136	1	o	o	INTJ
dpc-5570	136	2	ld	ld	PROPN
dpc-5570	136	3	h	h	NOUN
dpc-5570	136	4	yp	yp	PROPN
dpc-5570	137	1	er	er	INTJ
dpc-5570	137	2	te	te	INTJ
dpc-5570	137	3	ns	ns	PROPN
dpc-5570	137	4	io	io	PROPN
dpc-5570	137	5	n	n	X
dpc-5570	137	6	,	,	PUNCT
dpc-5570	137	7	m	m	VERB
dpc-5570	137	8	ix	ix	ADV
dpc-5570	137	9	ed	ed	NOUN
dpc-5570	137	10	 	 	SPACE
dpc-5570	137	11	c	c	PROPN
dpc-5570	137	12	on	on	ADP
dpc-5570	137	13	ne	ne	PROPN
dpc-5570	137	14	ct	ct	NUM
dpc-5570	137	15	iv	iv	NUM
dpc-5570	137	16	e	e	NOUN
dpc-5570	137	17	ti	ti	NOUN
dpc-5570	137	18	ss	ss	PROPN
dpc-5570	137	19	ue	ue	PROPN
dpc-5570	137	20	di	di	PROPN
dpc-5570	137	21	se	se	PROPN
dpc-5570	137	22	as	as	ADP
dpc-5570	137	23	e/	e/	ADV
dpc-5570	137	24	r	r	NOUN
dpc-5570	137	25	am	be	AUX
dpc-5570	137	26	ip	ip	PRON
dpc-5570	137	27	ri	ri	PROPN
dpc-5570	137	28	l	l	NOUN
dpc-5570	138	1	+	+	CCONJ
dpc-5570	138	2	a	a	DET
dpc-5570	138	3	m	m	NOUN
dpc-5570	138	4	lo	lo	NOUN
dpc-5570	138	5	di	di	PROPN
dpc-5570	138	6	pi	pi	PROPN
dpc-5570	138	7	ne	ne	PROPN
dpc-5570	138	8	to	to	ADP
dpc-5570	138	9	pi	pi	PROPN
dpc-5570	138	10	ca	can	AUX
dpc-5570	138	11	ls	ls	INTJ
dpc-5570	138	12	,	,	PUNCT
dpc-5570	139	1	c	c	VERB
dpc-5570	139	2	yc	yc	NOUN
dpc-5570	139	3	lo	lo	PROPN
dpc-5570	139	4	sp	sp	ADP
dpc-5570	139	5	or	or	CCONJ
dpc-5570	139	6	in	in	ADP
dpc-5570	139	7	e	e	PROPN
dpc-5570	139	8	18	18	NUM
dpc-5570	139	9	1	1	NUM
dpc-5570	139	10	.	.	NOUN
dpc-5570	139	11	8	8	NUM
dpc-5570	139	12	70	70	NUM
dpc-5570	139	13	0	0	NUM
dpc-5570	139	14	23	23	NUM
dpc-5570	139	15	8	8	NUM
dpc-5570	139	16	32	32	NUM
dpc-5570	139	17	n	n	NOUN
dpc-5570	139	18	.	.	PUNCT
dpc-5570	140	1	7	7	NUM
dpc-5570	140	2	f	f	PROPN
dpc-5570	140	3	em	em	PROPN
dpc-5570	140	4	al	al	PROPN
dpc-5570	140	5	e	e	PROPN
dpc-5570	140	6	,	,	PUNCT
dpc-5570	140	7	62	62	NUM
dpc-5570	140	8	y	y	NOUN
dpc-5570	140	9	ea	ea	NOUN
dpc-5570	140	10	rs	rs	INTJ
dpc-5570	141	1	o	o	INTJ
dpc-5570	141	2	ld	ld	PROPN
dpc-5570	141	3	h	h	NOUN
dpc-5570	141	4	yp	yp	PROPN
dpc-5570	142	1	er	er	INTJ
dpc-5570	142	2	te	te	INTJ
dpc-5570	142	3	ns	ns	PROPN
dpc-5570	142	4	io	io	PROPN
dpc-5570	142	5	n	n	X
dpc-5570	142	6	,	,	PUNCT
dpc-5570	142	7	d	d	PROPN
dpc-5570	142	8	ia	ia	PROPN
dpc-5570	142	9	be	be	AUX
dpc-5570	142	10	te	te	ADP
dpc-5570	142	11	s	s	PROPN
dpc-5570	142	12	,	,	PUNCT
dpc-5570	142	13	o	o	INTJ
dpc-5570	142	14	be	be	AUX
dpc-5570	142	15	si	si	INTJ
dpc-5570	142	16	ty	ty	INTJ
dpc-5570	142	17	/	/	SYM
dpc-5570	142	18	m	m	VERB
dpc-5570	142	19	et	et	NOUN
dpc-5570	142	20	fo	fo	INTJ
dpc-5570	142	21	rm	rm	PROPN
dpc-5570	142	22	in	in	ADP
dpc-5570	142	23	,	,	PUNCT
dpc-5570	142	24	en	en	PROPN
dpc-5570	142	25	al	al	PROPN
dpc-5570	142	26	ap	ap	PROPN
dpc-5570	142	27	ri	ri	PROPN
dpc-5570	143	1	l	l	PROPN
dpc-5570	143	2	,	,	PUNCT
dpc-5570	143	3	ni	ni	PROPN
dpc-5570	143	4	co	co	NOUN
dpc-5570	143	5	ti	ti	PROPN
dpc-5570	143	6	na	na	NOUN
dpc-5570	143	7	m	m	PROPN
dpc-5570	143	8	i	i	NOUN
dpc-5570	143	9	d	d	PROPN
dpc-5570	143	10	e	e	PROPN
dpc-5570	143	11	to	to	ADP
dpc-5570	143	12	pi	pi	PROPN
dpc-5570	143	13	ca	can	AUX
dpc-5570	143	14	ls	ls	INTJ
dpc-5570	143	15	,	,	PUNCT
dpc-5570	144	1	d	d	PROPN
dpc-5570	144	2	i	i	PRON
dpc-5570	144	3	m	m	VERB
dpc-5570	144	4	et	et	NOUN
dpc-5570	144	5	hy	hy	PROPN
dpc-5570	144	6	l	l	PROPN
dpc-5570	144	7	fu	fu	PROPN
dpc-5570	144	8	m	m	PROPN
dpc-5570	144	9	ar	ar	NOUN
dpc-5570	144	10	at	at	ADP
dpc-5570	144	11	e	e	PROPN
dpc-5570	144	12	,	,	PUNCT
dpc-5570	145	1	c	c	PROPN
dpc-5570	145	2	yc	yc	NOUN
dpc-5570	145	3	lo	lo	PROPN
dpc-5570	145	4	sp	sp	ADP
dpc-5570	145	5	or	or	CCONJ
dpc-5570	145	6	in	in	ADP
dpc-5570	145	7	e	e	NOUN
dpc-5570	145	8	7	7	NUM
dpc-5570	145	9	2	2	NUM
dpc-5570	145	10	30	30	NUM
dpc-5570	145	11	20	20	NUM
dpc-5570	145	12	30	30	NUM
dpc-5570	145	13	4	4	NUM
dpc-5570	145	14	14	14	NUM
dpc-5570	145	15	n	n	NOUN
dpc-5570	145	16	.	.	PUNCT
dpc-5570	146	1	8	8	NUM
dpc-5570	146	2	m	m	NOUN
dpc-5570	146	3	al	al	PROPN
dpc-5570	146	4	e	e	PROPN
dpc-5570	146	5	,	,	PUNCT
dpc-5570	146	6	38	38	NUM
dpc-5570	146	7	y	y	NOUN
dpc-5570	146	8	ea	ea	NOUN
dpc-5570	146	9	rs	rs	INTJ
dpc-5570	147	1	o	o	INTJ
dpc-5570	147	2	ld	ld	PROPN
dpc-5570	147	3	h	h	NOUN
dpc-5570	147	4	yp	yp	PROPN
dpc-5570	148	1	er	er	INTJ
dpc-5570	148	2	ch	ch	NOUN
dpc-5570	148	3	ol	ol	PROPN
dpc-5570	148	4	es	es	X
dpc-5570	148	5	te	te	PROPN
dpc-5570	148	6	ro	ro	X
dpc-5570	148	7	le	le	PROPN
dpc-5570	148	8	m	m	PROPN
dpc-5570	148	9	ia	ia	PROPN
dpc-5570	148	10	,	,	PUNCT
dpc-5570	148	11	o	o	INTJ
dpc-5570	148	12	be	be	VERB
dpc-5570	148	13	si	si	INTJ
dpc-5570	148	14	ty	ty	INTJ
dpc-5570	148	15	,	,	PUNCT
dpc-5570	148	16	b	b	X
dpc-5570	148	17	en	en	ADP
dpc-5570	148	18	ig	ig	PROPN
dpc-5570	148	19	n	n	AUX
dpc-5570	148	20	pr	pr	VERB
dpc-5570	148	21	os	os	NOUN
dpc-5570	148	22	ta	ta	ADP
dpc-5570	148	23	ti	ti	PROPN
dpc-5570	148	24	c	c	PROPN
dpc-5570	148	25	hy	hy	PROPN
dpc-5570	148	26	pe	pe	PROPN
dpc-5570	148	27	rt	rt	PROPN
dpc-5570	148	28	ro	ro	X
dpc-5570	148	29	ph	ph	PROPN
dpc-5570	148	30	y/	y/	NOUN
dpc-5570	148	31	a	a	PRON
dpc-5570	148	32	to	to	ADP
dpc-5570	148	33	rv	rv	PROPN
dpc-5570	148	34	as	as	ADP
dpc-5570	148	35	ta	ta	PROPN
dpc-5570	148	36	ti	ti	PROPN
dpc-5570	148	37	n	n	CCONJ
dpc-5570	148	38	,	,	PUNCT
dpc-5570	148	39	du	du	PROPN
dpc-5570	148	40	ta	ta	PROPN
dpc-5570	148	41	st	st	PROPN
dpc-5570	148	42	er	er	INTJ
dpc-5570	148	43	i	i	PROPN
dpc-5570	148	44	d	d	PROPN
dpc-5570	148	45	e	e	PROPN
dpc-5570	148	46	to	to	ADP
dpc-5570	148	47	pi	pi	PROPN
dpc-5570	148	48	ca	can	AUX
dpc-5570	148	49	ls	ls	VERB
dpc-5570	148	50	20	20	NUM
dpc-5570	148	51	4	4	NUM
dpc-5570	148	52	.	.	SYM
dpc-5570	148	53	2	2	NUM
dpc-5570	148	54	50	50	NUM
dpc-5570	148	55	0	0	NUM
dpc-5570	148	56	15	15	NUM
dpc-5570	148	57	7	7	NUM
dpc-5570	148	58	22	22	NUM
dpc-5570	148	59	original	original	ADJ
dpc-5570	148	60	article	article	NOUN
dpc-5570	148	61	|	|	ADV
dpc-5570	148	62	dermatol	dermatol	ADJ
dpc-5570	148	63	pract	pract	NOUN
dpc-5570	148	64	concept	concept	NOUN
dpc-5570	148	65	.	.	PUNCT
dpc-5570	149	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	149	2	5	5	NUM
dpc-5570	149	3	discussion	discussion	NOUN
dpc-5570	149	4	the	the	DET
dpc-5570	149	5	role	role	NOUN
dpc-5570	149	6	of	of	ADP
dpc-5570	149	7	il-23	il-23	NOUN
dpc-5570	149	8	is	be	AUX
dpc-5570	149	9	crucial	crucial	ADJ
dpc-5570	149	10	to	to	ADP
dpc-5570	149	11	maintaining	maintain	VERB
dpc-5570	149	12	the	the	DET
dpc-5570	149	13	th17	th17	PROPN
dpc-5570	149	14	population	population	NOUN
dpc-5570	149	15	from	from	ADP
dpc-5570	149	16	th-1	th-1	DET
dpc-5570	149	17	naïve	naïve	ADJ
dpc-5570	149	18	cells	cell	NOUN
dpc-5570	149	19	being	be	AUX
dpc-5570	149	20	a	a	DET
dpc-5570	149	21	central	central	ADJ
dpc-5570	149	22	effector	effector	NOUN
dpc-5570	149	23	involved	involve	VERB
dpc-5570	149	24	in	in	ADP
dpc-5570	149	25	the	the	DET
dpc-5570	149	26	pathogenesis	pathogenesis	NOUN
dpc-5570	149	27	also	also	ADV
dpc-5570	149	28	of	of	ADP
dpc-5570	149	29	psa	psa	NOUN
dpc-5570	149	30	.	.	PUNCT
dpc-5570	150	1	therefore	therefore	ADV
dpc-5570	150	2	,	,	PUNCT
dpc-5570	150	3	it	it	PRON
dpc-5570	150	4	is	be	AUX
dpc-5570	150	5	possible	possible	ADJ
dpc-5570	150	6	to	to	PART
dpc-5570	150	7	attribute	attribute	VERB
dpc-5570	150	8	a	a	DET
dpc-5570	150	9	primary	primary	ADJ
dpc-5570	150	10	role	role	NOUN
dpc-5570	150	11	to	to	PART
dpc-5570	150	12	dermal	dermal	VERB
dpc-5570	150	13	dendritic	dendritic	ADJ
dpc-5570	150	14	cells	cell	NOUN
dpc-5570	150	15	and	and	CCONJ
dpc-5570	150	16	il-23	il-23	NOUN
dpc-5570	150	17	producing	produce	VERB
dpc-5570	150	18	keratinocytes	keratinocyte	NOUN
dpc-5570	150	19	,	,	PUNCT
dpc-5570	150	20	different	different	ADJ
dpc-5570	150	21	in	in	ADP
dpc-5570	150	22	terms	term	NOUN
dpc-5570	150	23	of	of	ADP
dpc-5570	150	24	"	"	PUNCT
dpc-5570	150	25	cytokine	cytokine	ADJ
dpc-5570	150	26	hierarchy	hierarchy	NOUN
dpc-5570	150	27	"	"	PUNCT
dpc-5570	150	28	compared	compare	VERB
dpc-5570	150	29	to	to	ADP
dpc-5570	150	30	that	that	PRON
dpc-5570	150	31	of	of	ADP
dpc-5570	150	32	th17	th17	PROPN
dpc-5570	150	33	.	.	PUNCT
dpc-5570	151	1	as	as	SCONJ
dpc-5570	151	2	the	the	DET
dpc-5570	151	3	data	datum	NOUN
dpc-5570	151	4	currently	currently	ADV
dpc-5570	151	5	available	available	ADJ
dpc-5570	151	6	show	show	VERB
dpc-5570	151	7	the	the	DET
dpc-5570	151	8	proven	prove	VERB
dpc-5570	151	9	efficacy	efficacy	NOUN
dpc-5570	151	10	of	of	ADP
dpc-5570	151	11	other	other	ADJ
dpc-5570	151	12	il-23	il-23	ADJ
dpc-5570	151	13	inhibitors	inhibitor	NOUN
dpc-5570	151	14	other	other	ADJ
dpc-5570	151	15	than	than	ADP
dpc-5570	151	16	tildrakizumab	tildrakizumab	NOUN
dpc-5570	151	17	in	in	ADP
dpc-5570	151	18	reducing	reduce	VERB
dpc-5570	151	19	the	the	DET
dpc-5570	151	20	signs	sign	NOUN
dpc-5570	151	21	,	,	PUNCT
dpc-5570	151	22	symptoms	symptom	NOUN
dpc-5570	151	23	,	,	PUNCT
dpc-5570	151	24	and	and	CCONJ
dpc-5570	151	25	progression	progression	NOUN
dpc-5570	151	26	over	over	ADP
dpc-5570	151	27	time	time	NOUN
dpc-5570	151	28	of	of	ADP
dpc-5570	151	29	psa	psa	NOUN
dpc-5570	151	30	,	,	PUNCT
dpc-5570	151	31	they	they	PRON
dpc-5570	151	32	have	have	AUX
dpc-5570	151	33	been	be	AUX
dpc-5570	151	34	approved	approve	VERB
dpc-5570	151	35	by	by	ADP
dpc-5570	151	36	both	both	CCONJ
dpc-5570	151	37	the	the	DET
dpc-5570	151	38	ema	ema	PROPN
dpc-5570	151	39	and	and	CCONJ
dpc-5570	151	40	the	the	DET
dpc-5570	151	41	fda	fda	PROPN
dpc-5570	151	42	for	for	ADP
dpc-5570	151	43	this	this	DET
dpc-5570	151	44	indication	indication	NOUN
dpc-5570	151	45	.	.	PUNCT
dpc-5570	152	1	despite	despite	SCONJ
dpc-5570	152	2	the	the	DET
dpc-5570	152	3	current	current	ADJ
dpc-5570	152	4	lack	lack	NOUN
dpc-5570	152	5	of	of	ADP
dpc-5570	152	6	a	a	DET
dpc-5570	152	7	valid	valid	ADJ
dpc-5570	152	8	pharmacodynamic	pharmacodynamic	ADJ
dpc-5570	152	9	rationale	rationale	NOUN
dpc-5570	152	10	and/or	and/or	CCONJ
dpc-5570	152	11	any	any	DET
dpc-5570	152	12	evidence	evidence	NOUN
dpc-5570	152	13	of	of	ADP
dpc-5570	152	14	ineffectiveness	ineffectiveness	NOUN
dpc-5570	152	15	,	,	PUNCT
dpc-5570	152	16	clinicians	clinician	NOUN
dpc-5570	152	17	can	can	AUX
dpc-5570	152	18	not	not	PART
dpc-5570	152	19	yet	yet	ADV
dpc-5570	152	20	prescribe	prescribe	VERB
dpc-5570	152	21	tildrakizumab	tildrakizumab	NOUN
dpc-5570	152	22	as	as	ADP
dpc-5570	152	23	an	an	DET
dpc-5570	152	24	on	on	ADP
dpc-5570	152	25	-	-	PUNCT
dpc-5570	152	26	label	label	NOUN
dpc-5570	152	27	treatment	treatment	NOUN
dpc-5570	152	28	for	for	ADP
dpc-5570	152	29	psa	psa	NOUN
dpc-5570	152	30	,	,	PUNCT
dpc-5570	152	31	unlike	unlike	ADP
dpc-5570	152	32	with	with	ADP
dpc-5570	152	33	other	other	ADJ
dpc-5570	152	34	il-23	il-23	NOUN
dpc-5570	152	35	inhibitors	inhibitor	NOUN
dpc-5570	152	36	.	.	PUNCT
dpc-5570	153	1	the	the	DET
dpc-5570	153	2	documented	document	VERB
dpc-5570	153	3	efficacy	efficacy	NOUN
dpc-5570	153	4	of	of	ADP
dpc-5570	153	5	tildrakizumab	tildrakizumab	NOUN
dpc-5570	153	6	on	on	ADP
dpc-5570	153	7	different	different	ADJ
dpc-5570	153	8	psa	psa	NOUN
dpc-5570	153	9	domains	domain	NOUN
dpc-5570	153	10	could	could	AUX
dpc-5570	153	11	allow	allow	VERB
dpc-5570	153	12	clinicians	clinician	NOUN
dpc-5570	153	13	to	to	PART
dpc-5570	153	14	promptly	promptly	ADV
dpc-5570	153	15	intervene	intervene	VERB
dpc-5570	153	16	on	on	ADP
dpc-5570	153	17	patients	patient	NOUN
dpc-5570	153	18	suffering	suffer	VERB
dpc-5570	153	19	from	from	ADP
dpc-5570	153	20	severe	severe	ADJ
dpc-5570	153	21	psoriasis	psoriasis	NOUN
dpc-5570	153	22	and	and	CCONJ
dpc-5570	153	23	metabolic	metabolic	NOUN
dpc-5570	153	24	comorbidities	comorbiditie	NOUN
dpc-5570	153	25	by	by	ADP
dpc-5570	153	26	acting	act	VERB
dpc-5570	153	27	early	early	ADV
dpc-5570	153	28	on	on	ADP
dpc-5570	153	29	co	co	VERB
dpc-5570	153	30	-	-	ADJ
dpc-5570	153	31	occurring	occurring	ADJ
dpc-5570	153	32	psa	psa	NOUN
dpc-5570	153	33	symptoms	symptom	NOUN
dpc-5570	153	34	.	.	PUNCT
dpc-5570	154	1	in	in	ADP
dpc-5570	154	2	fact	fact	NOUN
dpc-5570	154	3	,	,	PUNCT
dpc-5570	154	4	the	the	DET
dpc-5570	154	5	opportunity	opportunity	NOUN
dpc-5570	154	6	of	of	ADP
dpc-5570	154	7	early	early	ADJ
dpc-5570	154	8	psa	psa	NOUN
dpc-5570	154	9	treatment	treatment	NOUN
dpc-5570	154	10	about	about	ADV
dpc-5570	154	11	2.63	2.63	NUM
dpc-5570	154	12	,	,	PUNCT
dpc-5570	154	13	reduced	reduce	VERB
dpc-5570	154	14	by	by	ADP
dpc-5570	154	15	81.3	81.3	NUM
dpc-5570	154	16	%	%	NOUN
dpc-5570	154	17	from	from	ADP
dpc-5570	154	18	baseline	baseline	PROPN
dpc-5570	154	19	(	(	PUNCT
dpc-5570	154	20	p<0.001	p<0.001	ADJ
dpc-5570	154	21	;	;	PUNCT
dpc-5570	154	22	figure	figure	NOUN
dpc-5570	154	23	2a	2a	NUM
dpc-5570	154	24	)	)	PUNCT
dpc-5570	154	25	.	.	PUNCT
dpc-5570	155	1	c	c	X
dpc-5570	155	2	-	-	PUNCT
dpc-5570	155	3	reactive	reactive	ADJ
dpc-5570	155	4	protein	protein	NOUN
dpc-5570	155	5	at	at	ADP
dpc-5570	155	6	t28	t28	NUM
dpc-5570	155	7	remained	remain	VERB
dpc-5570	155	8	above	above	ADP
dpc-5570	155	9	the	the	DET
dpc-5570	155	10	normal	normal	ADJ
dpc-5570	155	11	limit	limit	NOUN
dpc-5570	155	12	in	in	ADP
dpc-5570	155	13	only	only	ADV
dpc-5570	155	14	one	one	NUM
dpc-5570	155	15	patient	patient	NOUN
dpc-5570	155	16	,	,	PUNCT
dpc-5570	155	17	showing	show	VERB
dpc-5570	155	18	a	a	DET
dpc-5570	155	19	statistically	statistically	ADV
dpc-5570	155	20	significant	significant	ADJ
dpc-5570	155	21	mean	mean	ADJ
dpc-5570	155	22	value	value	NOUN
dpc-5570	155	23	reduction	reduction	NOUN
dpc-5570	155	24	of	of	ADP
dpc-5570	155	25	66	66	NUM
dpc-5570	155	26	%	%	NOUN
dpc-5570	155	27	in	in	ADP
dpc-5570	155	28	all	all	DET
dpc-5570	155	29	patients	patient	NOUN
dpc-5570	155	30	(	(	PUNCT
dpc-5570	155	31	p<0.01	p<0.01	PROPN
dpc-5570	155	32	;	;	PUNCT
dpc-5570	155	33	figure	figure	NOUN
dpc-5570	155	34	2b	2b	NOUN
dpc-5570	155	35	)	)	PUNCT
dpc-5570	155	36	.	.	PUNCT
dpc-5570	156	1	after	after	ADP
dpc-5570	156	2	28	28	NUM
dpc-5570	156	3	weeks	week	NOUN
dpc-5570	156	4	only	only	ADV
dpc-5570	156	5	two	two	NUM
dpc-5570	156	6	patients	patient	NOUN
dpc-5570	156	7	reported	report	VERB
dpc-5570	156	8	still	still	ADV
dpc-5570	156	9	having	have	VERB
dpc-5570	156	10	residual	residual	ADJ
dpc-5570	156	11	arthritic	arthritic	ADJ
dpc-5570	156	12	symptoms	symptom	NOUN
dpc-5570	156	13	,	,	PUNCT
dpc-5570	156	14	though	though	SCONJ
dpc-5570	156	15	reduced	reduce	VERB
dpc-5570	156	16	in	in	ADP
dpc-5570	156	17	severity	severity	NOUN
dpc-5570	156	18	compared	compare	VERB
dpc-5570	156	19	to	to	PART
dpc-5570	156	20	baseline	baseline	VERB
dpc-5570	156	21	,	,	PUNCT
dpc-5570	156	22	with	with	ADP
dpc-5570	156	23	a	a	DET
dpc-5570	156	24	mean	mean	ADJ
dpc-5570	156	25	pain	pain	NOUN
dpc-5570	156	26	vas	vas	X
dpc-5570	156	27	among	among	ADP
dpc-5570	156	28	all	all	DET
dpc-5570	156	29	patients	patient	NOUN
dpc-5570	156	30	of	of	ADP
dpc-5570	156	31	3.75	3.75	NUM
dpc-5570	156	32	;	;	PUNCT
dpc-5570	156	33	the	the	DET
dpc-5570	156	34	pain	pain	NOUN
dpc-5570	156	35	vas	vas	X
dpc-5570	156	36	mean	mean	NOUN
dpc-5570	156	37	reduction	reduction	NOUN
dpc-5570	156	38	was	be	AUX
dpc-5570	156	39	85	85	NUM
dpc-5570	156	40	%	%	NOUN
dpc-5570	156	41	(	(	PUNCT
dpc-5570	156	42	p<0.002	p<0.002	NOUN
dpc-5570	156	43	;	;	PUNCT
dpc-5570	156	44	figure	figure	NOUN
dpc-5570	156	45	2c	2c	NUM
dpc-5570	156	46	)	)	PUNCT
dpc-5570	156	47	.	.	PUNCT
dpc-5570	157	1	four	four	NUM
dpc-5570	157	2	patients	patient	NOUN
dpc-5570	157	3	had	have	VERB
dpc-5570	157	4	residual	residual	ADJ
dpc-5570	157	5	nail	nail	NOUN
dpc-5570	157	6	involvement	involvement	NOUN
dpc-5570	157	7	,	,	PUNCT
dpc-5570	157	8	with	with	ADP
dpc-5570	157	9	a	a	DET
dpc-5570	157	10	mean	mean	ADJ
dpc-5570	157	11	napsi	napsi	NOUN
dpc-5570	157	12	of	of	ADP
dpc-5570	157	13	6.5/80	6.5/80	PROPN
dpc-5570	157	14	,	,	PUNCT
dpc-5570	157	15	showing	show	VERB
dpc-5570	157	16	a	a	DET
dpc-5570	157	17	statistically	statistically	ADV
dpc-5570	157	18	significant	significant	ADJ
dpc-5570	157	19	reduction	reduction	NOUN
dpc-5570	157	20	(	(	PUNCT
dpc-5570	157	21	p<0.001	p<0.001	ADJ
dpc-5570	157	22	;	;	PUNCT
dpc-5570	157	23	figure	figure	NOUN
dpc-5570	157	24	2d	2d	NOUN
dpc-5570	157	25	)	)	PUNCT
dpc-5570	157	26	in	in	ADP
dpc-5570	157	27	the	the	DET
dpc-5570	157	28	mean	mean	ADJ
dpc-5570	157	29	value	value	NOUN
dpc-5570	157	30	from	from	ADP
dpc-5570	157	31	t0	t0	NUM
dpc-5570	157	32	of	of	ADP
dpc-5570	157	33	≃	≃	NOUN
dpc-5570	157	34	78	78	NUM
dpc-5570	157	35	%	%	NOUN
dpc-5570	157	36	.	.	PUNCT
dpc-5570	158	1	the	the	DET
dpc-5570	158	2	dlqi	dlqi	NOUN
dpc-5570	158	3	at	at	ADP
dpc-5570	158	4	t28	t28	PROPN
dpc-5570	158	5	was	be	AUX
dpc-5570	158	6	2.25	2.25	NUM
dpc-5570	158	7	,	,	PUNCT
dpc-5570	158	8	with	with	ADP
dpc-5570	158	9	a	a	DET
dpc-5570	158	10	mean	mean	ADJ
dpc-5570	158	11	reduction	reduction	NOUN
dpc-5570	158	12	of	of	ADP
dpc-5570	158	13	86	86	NUM
dpc-5570	158	14	%	%	NOUN
dpc-5570	158	15	compared	compare	VERB
dpc-5570	158	16	to	to	ADP
dpc-5570	158	17	t0	t0	PROPN
dpc-5570	158	18	(	(	PUNCT
dpc-5570	158	19	p<0.001	p<0.001	PROPN
dpc-5570	158	20	;	;	PUNCT
dpc-5570	158	21	figure	figure	NOUN
dpc-5570	158	22	2e	2e	NUM
dpc-5570	158	23	)	)	PUNCT
dpc-5570	158	24	.	.	PUNCT
dpc-5570	159	1	the	the	DET
dpc-5570	159	2	mean	mean	ADJ
dpc-5570	159	3	patient	patient	ADJ
dpc-5570	159	4	pga	pga	NOUN
dpc-5570	159	5	at	at	ADP
dpc-5570	159	6	t28	t28	NUM
dpc-5570	159	7	was	be	AUX
dpc-5570	159	8	1.75	1.75	NUM
dpc-5570	159	9	,	,	PUNCT
dpc-5570	159	10	with	with	ADP
dpc-5570	159	11	a	a	DET
dpc-5570	159	12	statistically	statistically	ADV
dpc-5570	159	13	significant	significant	ADJ
dpc-5570	159	14	reduction	reduction	NOUN
dpc-5570	159	15	of	of	ADP
dpc-5570	159	16	73	73	NUM
dpc-5570	159	17	%	%	NOUN
dpc-5570	159	18	(	(	PUNCT
dpc-5570	159	19	p<0.001	p<0.001	ADJ
dpc-5570	159	20	;	;	PUNCT
dpc-5570	159	21	figure	figure	NOUN
dpc-5570	159	22	2f	2f	NUM
dpc-5570	159	23	)	)	PUNCT
dpc-5570	159	24	.	.	PUNCT
dpc-5570	160	1	mean	mean	VERB
dpc-5570	160	2	dapsa	dapsa	ADJ
dpc-5570	160	3	index	index	NOUN
dpc-5570	160	4	value	value	NOUN
dpc-5570	160	5	at	at	ADP
dpc-5570	160	6	t28	t28	PROPN
dpc-5570	160	7	was	be	AUX
dpc-5570	160	8	3.75	3.75	NUM
dpc-5570	160	9	,	,	PUNCT
dpc-5570	160	10	and	and	CCONJ
dpc-5570	160	11	we	we	PRON
dpc-5570	160	12	also	also	ADV
dpc-5570	160	13	highlight	highlight	VERB
dpc-5570	160	14	a	a	DET
dpc-5570	160	15	statistically	statistically	ADV
dpc-5570	160	16	significant	significant	ADJ
dpc-5570	160	17	reduction	reduction	NOUN
dpc-5570	160	18	of	of	ADP
dpc-5570	160	19	82	82	NUM
dpc-5570	160	20	%	%	NOUN
dpc-5570	160	21	index	index	NOUN
dpc-5570	160	22	between	between	ADP
dpc-5570	160	23	t0	t0	PROPN
dpc-5570	160	24	and	and	CCONJ
dpc-5570	160	25	t28	t28	PROPN
dpc-5570	160	26	(	(	PUNCT
dpc-5570	160	27	t	t	NOUN
dpc-5570	160	28	-	-	PUNCT
dpc-5570	160	29	test	test	NOUN
dpc-5570	160	30	p<0.000023	p<0.000023	NOUN
dpc-5570	160	31	;	;	PUNCT
dpc-5570	160	32	figure	figure	NOUN
dpc-5570	160	33	3	3	NUM
dpc-5570	160	34	)	)	PUNCT
dpc-5570	160	35	.	.	PUNCT
dpc-5570	161	1	the	the	DET
dpc-5570	161	2	monitoring	monitoring	NOUN
dpc-5570	161	3	of	of	ADP
dpc-5570	161	4	metabolic	metabolic	NOUN
dpc-5570	161	5	parameters	parameter	NOUN
dpc-5570	161	6	did	do	AUX
dpc-5570	161	7	not	not	PART
dpc-5570	161	8	reveal	reveal	VERB
dpc-5570	161	9	any	any	DET
dpc-5570	161	10	abnormality	abnormality	NOUN
dpc-5570	161	11	during	during	ADP
dpc-5570	161	12	study	study	NOUN
dpc-5570	161	13	protocol	protocol	NOUN
dpc-5570	161	14	in	in	ADP
dpc-5570	161	15	treated	treat	VERB
dpc-5570	161	16	patients	patient	NOUN
dpc-5570	161	17	.	.	PUNCT
dpc-5570	162	1	table	table	NOUN
dpc-5570	162	2	2	2	NUM
dpc-5570	162	3	.	.	PUNCT
dpc-5570	162	4	evaluation	evaluation	NOUN
dpc-5570	162	5	of	of	ADP
dpc-5570	162	6	clinimetric	clinimetric	ADJ
dpc-5570	162	7	scores	score	NOUN
dpc-5570	162	8	at	at	ADP
dpc-5570	162	9	baseline	baseline	NOUN
dpc-5570	162	10	and	and	CCONJ
dpc-5570	162	11	after	after	ADP
dpc-5570	162	12	28	28	NUM
dpc-5570	162	13	weeks	week	NOUN
dpc-5570	162	14	of	of	ADP
dpc-5570	162	15	treatment	treatment	NOUN
dpc-5570	162	16	.	.	PUNCT
dpc-5570	163	1	patient	patient	PROPN
dpc-5570	163	2	t28	t28	PROPN
dpc-5570	163	3	pasi	pasi	PROPN
dpc-5570	163	4	t28	t28	PROPN
dpc-5570	163	5	crp	crp	PROPN
dpc-5570	163	6	(	(	PUNCT
dpc-5570	163	7	mg	mg	PROPN
dpc-5570	163	8	/	/	SYM
dpc-5570	163	9	dl	dl	PROPN
dpc-5570	163	10	)	)	PUNCT
dpc-5570	163	11	t28	t28	PROPN
dpc-5570	163	12	pain	pain	PROPN
dpc-5570	163	13	vas	vas	X
dpc-5570	163	14	t28	t28	PROPN
dpc-5570	163	15	hand	hand	PROPN
dpc-5570	163	16	napsi	napsi	PROPN
dpc-5570	163	17	t28	t28	PROPN
dpc-5570	163	18	dlqi	dlqi	PROPN
dpc-5570	163	19	t28	t28	PROPN
dpc-5570	163	20	patient	patient	PROPN
dpc-5570	163	21	pga	pga	PROPN
dpc-5570	163	22	t28	t28	NOUN
dpc-5570	163	23	dapsa	dapsa	NOUN
dpc-5570	163	24	1	1	NUM
dpc-5570	163	25	0	0	NUM
dpc-5570	163	26	0.6	0.6	NUM
dpc-5570	163	27	0	0	NUM
dpc-5570	163	28	8	8	NUM
dpc-5570	163	29	0	0	NUM
dpc-5570	163	30	0	0	NUM
dpc-5570	163	31	2	2	NUM
dpc-5570	163	32	2	2	NUM
dpc-5570	163	33	3	3	NUM
dpc-5570	163	34	0.9	0.9	NUM
dpc-5570	163	35	0	0	NUM
dpc-5570	163	36	0	0	NUM
dpc-5570	163	37	3	3	NUM
dpc-5570	163	38	2	2	NUM
dpc-5570	163	39	2	2	NUM
dpc-5570	163	40	3	3	NUM
dpc-5570	163	41	3	3	NUM
dpc-5570	163	42	0.75	0.75	NUM
dpc-5570	163	43	0	0	NUM
dpc-5570	163	44	4	4	NUM
dpc-5570	163	45	4	4	NUM
dpc-5570	163	46	1	1	NUM
dpc-5570	163	47	1	1	NUM
dpc-5570	163	48	4	4	NUM
dpc-5570	163	49	12	12	NUM
dpc-5570	163	50	0.51	0.51	NUM
dpc-5570	163	51	0	0	NUM
dpc-5570	163	52	10	10	NUM
dpc-5570	163	53	10	10	NUM
dpc-5570	163	54	7	7	NUM
dpc-5570	163	55	1	1	NUM
dpc-5570	163	56	5	5	NUM
dpc-5570	163	57	3	3	NUM
dpc-5570	163	58	<	<	NOUN
dpc-5570	163	59	0.40	0.40	NUM
dpc-5570	163	60	20	20	NUM
dpc-5570	163	61	0	0	NUM
dpc-5570	163	62	0	0	NUM
dpc-5570	163	63	2	2	NUM
dpc-5570	163	64	9	9	NUM
dpc-5570	163	65	6	6	NUM
dpc-5570	163	66	0	0	NUM
dpc-5570	163	67	1	1	NUM
dpc-5570	163	68	0	0	NUM
dpc-5570	163	69	0	0	NUM
dpc-5570	163	70	0	0	NUM
dpc-5570	163	71	0	0	NUM
dpc-5570	163	72	2	2	NUM
dpc-5570	163	73	7	7	NUM
dpc-5570	163	74	0	0	NUM
dpc-5570	163	75	<	<	X
dpc-5570	163	76	0.40	0.40	NUM
dpc-5570	163	77	0	0	NUM
dpc-5570	163	78	4	4	NUM
dpc-5570	163	79	1	1	NUM
dpc-5570	163	80	1	1	NUM
dpc-5570	163	81	1	1	NUM
dpc-5570	163	82	8	8	NUM
dpc-5570	163	83	0	0	NUM
dpc-5570	163	84	3.1	3.1	NUM
dpc-5570	163	85	10	10	NUM
dpc-5570	163	86	0	0	NUM
dpc-5570	163	87	0	0	NUM
dpc-5570	163	88	1	1	NUM
dpc-5570	163	89	12	12	NUM
dpc-5570	163	90	hypertension	hypertension	NOUN
dpc-5570	163	91	29	29	NUM
dpc-5570	163	92	%	%	NOUN
dpc-5570	163	93	hypercholest	hypercholest	NOUN
dpc-5570	163	94	erolemia	erolemia	VERB
dpc-5570	163	95	29	29	NUM
dpc-5570	163	96	%	%	NOUN
dpc-5570	163	97	diabetes	diabetes	NOUN
dpc-5570	163	98	7	7	NUM
dpc-5570	163	99	%	%	NOUN
dpc-5570	163	100	metabolic	metabolic	NOUN
dpc-5570	163	101	syndrome	syndrome	NOUN
dpc-5570	163	102	14	14	NUM
dpc-5570	163	103	%	%	NOUN
dpc-5570	163	104	other	other	ADJ
dpc-5570	163	105	21	21	NUM
dpc-5570	163	106	%	%	NOUN
dpc-5570	163	107	hypertension	hypertension	NOUN
dpc-5570	163	108	hypercholesterolemia	hypercholesterolemia	NOUN
dpc-5570	163	109	diabetes	diabetes	NOUN
dpc-5570	163	110	metabolic	metabolic	NOUN
dpc-5570	163	111	syndrome	syndrome	PROPN
dpc-5570	163	112	other	other	ADJ
dpc-5570	163	113	figure	figure	NOUN
dpc-5570	163	114	1	1	NUM
dpc-5570	163	115	.	.	PUNCT
dpc-5570	164	1	distribution	distribution	NOUN
dpc-5570	164	2	of	of	ADP
dpc-5570	164	3	comorbidit	comorbidit	NOUN
dpc-5570	164	4	6	6	NUM
dpc-5570	164	5	original	original	ADJ
dpc-5570	164	6	article	article	NOUN
dpc-5570	164	7	|	|	ADV
dpc-5570	164	8	dermatol	dermatol	ADJ
dpc-5570	164	9	pract	pract	NOUN
dpc-5570	164	10	concept	concept	NOUN
dpc-5570	164	11	.	.	PUNCT
dpc-5570	165	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	165	2	progression	progression	NOUN
dpc-5570	165	3	of	of	ADP
dpc-5570	165	4	joint	joint	ADJ
dpc-5570	165	5	disease	disease	NOUN
dpc-5570	165	6	activity	activity	NOUN
dpc-5570	165	7	,	,	PUNCT
dpc-5570	165	8	positive	positive	ADJ
dpc-5570	165	9	in	in	ADP
dpc-5570	165	10	33–89	33–89	NUM
dpc-5570	165	11	%	%	NOUN
dpc-5570	165	12	of	of	ADP
dpc-5570	165	13	psa	psa	NOUN
dpc-5570	165	14	cases	case	NOUN
dpc-5570	165	15	,	,	PUNCT
dpc-5570	165	16	mainly	mainly	ADV
dpc-5570	165	17	in	in	ADP
dpc-5570	165	18	the	the	DET
dpc-5570	165	19	early	early	ADJ
dpc-5570	165	20	stages	stage	NOUN
dpc-5570	165	21	of	of	ADP
dpc-5570	165	22	enthesitis	enthesitis	NOUN
dpc-5570	165	23	[	[	X
dpc-5570	165	24	32	32	NUM
dpc-5570	165	25	]	]	PUNCT
dpc-5570	165	26	but	but	CCONJ
dpc-5570	165	27	not	not	PART
dpc-5570	165	28	altered	alter	VERB
dpc-5570	165	29	in	in	ADP
dpc-5570	165	30	some	some	DET
dpc-5570	165	31	active	active	ADJ
dpc-5570	165	32	psa	psa	NOUN
dpc-5570	165	33	patients[19	patients[19	NOUN
dpc-5570	165	34	]	]	PUNCT
dpc-5570	165	35	.	.	PUNCT
dpc-5570	166	1	even	even	ADV
dpc-5570	166	2	in	in	ADP
dpc-5570	166	3	our	our	PRON
dpc-5570	166	4	case	case	NOUN
dpc-5570	166	5	series	series	NOUN
dpc-5570	166	6	,	,	PUNCT
dpc-5570	166	7	25	25	NUM
dpc-5570	166	8	%	%	NOUN
dpc-5570	166	9	of	of	ADP
dpc-5570	166	10	patients	patient	NOUN
dpc-5570	166	11	with	with	ADP
dpc-5570	166	12	active	active	ADJ
dpc-5570	166	13	psa	psa	NOUN
dpc-5570	166	14	did	do	AUX
dpc-5570	166	15	not	not	PART
dpc-5570	166	16	show	show	VERB
dpc-5570	166	17	increased	increase	VERB
dpc-5570	166	18	crp	crp	NOUN
dpc-5570	166	19	values	value	NOUN
dpc-5570	166	20	at	at	ADP
dpc-5570	166	21	t0	t0	PROPN
dpc-5570	166	22	.	.	PUNCT
dpc-5570	167	1	however	however	ADV
dpc-5570	167	2	,	,	PUNCT
dpc-5570	167	3	our	our	PRON
dpc-5570	167	4	results	result	NOUN
dpc-5570	167	5	also	also	ADV
dpc-5570	167	6	show	show	VERB
dpc-5570	167	7	that	that	SCONJ
dpc-5570	167	8	only	only	ADV
dpc-5570	167	9	one	one	NUM
dpc-5570	167	10	patient	patient	NOUN
dpc-5570	167	11	exhibited	exhibit	VERB
dpc-5570	167	12	elevated	elevated	ADJ
dpc-5570	167	13	crp	crp	PROPN
dpc-5570	167	14	levels	level	NOUN
dpc-5570	167	15	at	at	ADP
dpc-5570	167	16	t28	t28	NUM
dpc-5570	167	17	,	,	PUNCT
dpc-5570	167	18	which	which	PRON
dpc-5570	167	19	remained	remain	VERB
dpc-5570	167	20	lower	low	ADJ
dpc-5570	167	21	than	than	ADP
dpc-5570	167	22	those	those	PRON
dpc-5570	167	23	recorded	record	VERB
dpc-5570	167	24	at	at	ADP
dpc-5570	167	25	t0	t0	PROPN
dpc-5570	167	26	.	.	PUNCT
dpc-5570	168	1	this	this	DET
dpc-5570	168	2	patient	patient	NOUN
dpc-5570	168	3	also	also	ADV
dpc-5570	168	4	reported	report	VERB
dpc-5570	168	5	residual	residual	ADJ
dpc-5570	168	6	,	,	PUNCT
dpc-5570	168	7	mild	mild	ADJ
dpc-5570	168	8	arthritic	arthritic	ADJ
dpc-5570	168	9	symptoms	symptom	NOUN
dpc-5570	168	10	at	at	ADP
dpc-5570	168	11	t28	t28	NUM
dpc-5570	168	12	.	.	PUNCT
dpc-5570	169	1	it	it	PRON
dpc-5570	169	2	is	be	AUX
dpc-5570	169	3	noteworthy	noteworthy	ADJ
dpc-5570	169	4	that	that	SCONJ
dpc-5570	169	5	the	the	DET
dpc-5570	169	6	mean	mean	ADJ
dpc-5570	169	7	pasi	pasi	NOUN
dpc-5570	169	8	at	at	ADP
dpc-5570	169	9	baseline	baseline	PROPN
dpc-5570	169	10	(	(	PUNCT
dpc-5570	169	11	t0	t0	NOUN
dpc-5570	169	12	)	)	PUNCT
dpc-5570	169	13	,	,	PUNCT
dpc-5570	169	14	slightly	slightly	ADV
dpc-5570	169	15	above	above	ADP
dpc-5570	169	16	14	14	NUM
dpc-5570	169	17	,	,	PUNCT
dpc-5570	169	18	did	do	AUX
dpc-5570	169	19	not	not	PART
dpc-5570	169	20	indicate	indicate	VERB
dpc-5570	169	21	severe	severe	ADJ
dpc-5570	169	22	psoriasis	psoriasis	NOUN
dpc-5570	169	23	.	.	PUNCT
dpc-5570	170	1	however	however	ADV
dpc-5570	170	2	,	,	PUNCT
dpc-5570	170	3	the	the	DET
dpc-5570	170	4	involvement	involvement	NOUN
dpc-5570	170	5	of	of	ADP
dpc-5570	170	6	special	special	ADJ
dpc-5570	170	7	sites	site	NOUN
dpc-5570	170	8	such	such	ADJ
dpc-5570	170	9	as	as	ADP
dpc-5570	170	10	the	the	DET
dpc-5570	170	11	hands	hand	NOUN
dpc-5570	170	12	,	,	PUNCT
dpc-5570	170	13	feet	foot	NOUN
dpc-5570	170	14	,	,	PUNCT
dpc-5570	170	15	nails	nail	NOUN
dpc-5570	170	16	,	,	PUNCT
dpc-5570	170	17	and	and	CCONJ
dpc-5570	170	18	genitals	genital	NOUN
dpc-5570	170	19	accounted	account	VERB
dpc-5570	170	20	for	for	ADP
dpc-5570	170	21	a	a	DET
dpc-5570	170	22	relatively	relatively	ADV
dpc-5570	170	23	high	high	ADJ
dpc-5570	170	24	mean	mean	NOUN
dpc-5570	170	25	dlqi	dlqi	NOUN
dpc-5570	170	26	at	at	ADP
dpc-5570	170	27	t0	t0	PROPN
dpc-5570	170	28	(	(	PUNCT
dpc-5570	170	29	16.4	16.4	NUM
dpc-5570	170	30	)	)	PUNCT
dpc-5570	170	31	.	.	PUNCT
dpc-5570	171	1	after	after	ADP
dpc-5570	171	2	28	28	NUM
dpc-5570	171	3	weeks	week	NOUN
dpc-5570	171	4	of	of	ADP
dpc-5570	171	5	treatment	treatment	NOUN
dpc-5570	171	6	,	,	PUNCT
dpc-5570	171	7	pasi	pasi	NOUN
dpc-5570	171	8	was	be	AUX
dpc-5570	171	9	reduced	reduce	VERB
dpc-5570	171	10	is	be	AUX
dpc-5570	171	11	now	now	ADV
dpc-5570	171	12	clear	clear	ADJ
dpc-5570	171	13	,	,	PUNCT
dpc-5570	171	14	as	as	SCONJ
dpc-5570	171	15	it	it	PRON
dpc-5570	171	16	can	can	AUX
dpc-5570	171	17	reduce	reduce	VERB
dpc-5570	171	18	its	its	PRON
dpc-5570	171	19	progression	progression	NOUN
dpc-5570	171	20	and	and	CCONJ
dpc-5570	171	21	joint	joint	ADJ
dpc-5570	171	22	damage	damage	NOUN
dpc-5570	171	23	,	,	PUNCT
dpc-5570	171	24	as	as	SCONJ
dpc-5570	171	25	has	have	AUX
dpc-5570	171	26	been	be	AUX
dpc-5570	171	27	documented	document	VERB
dpc-5570	171	28	in	in	ADP
dpc-5570	171	29	real	real	ADJ
dpc-5570	171	30	life	life	NOUN
dpc-5570	171	31	studies	study	NOUN
dpc-5570	171	32	even	even	ADV
dpc-5570	171	33	in	in	ADP
dpc-5570	171	34	bio	bio	ADJ
dpc-5570	171	35	-	-	ADJ
dpc-5570	171	36	naïve	naïve	ADJ
dpc-5570	171	37	patients	patient	NOUN
dpc-5570	172	1	[	[	X
dpc-5570	172	2	21,30	21,30	NOUN
dpc-5570	172	3	]	]	PUNCT
dpc-5570	172	4	.	.	PUNCT
dpc-5570	173	1	tildrakizumab	tildrakizumab	NOUN
dpc-5570	173	2	appears	appear	VERB
dpc-5570	173	3	to	to	PART
dpc-5570	173	4	be	be	AUX
dpc-5570	173	5	safe	safe	ADJ
dpc-5570	173	6	in	in	ADP
dpc-5570	173	7	patients	patient	NOUN
dpc-5570	173	8	with	with	ADP
dpc-5570	173	9	cardiovascular	cardiovascular	ADJ
dpc-5570	173	10	comorbidities	comorbiditie	NOUN
dpc-5570	173	11	,	,	PUNCT
dpc-5570	173	12	including	include	VERB
dpc-5570	173	13	metabolic	metabolic	NOUN
dpc-5570	173	14	syndrome	syndrome	NOUN
dpc-5570	173	15	,	,	PUNCT
dpc-5570	173	16	without	without	ADP
dpc-5570	173	17	affecting	affect	VERB
dpc-5570	173	18	metabolic	metabolic	NOUN
dpc-5570	173	19	parameters	parameter	NOUN
dpc-5570	173	20	.	.	PUNCT
dpc-5570	174	1	dermatologists	dermatologist	NOUN
dpc-5570	174	2	must	must	AUX
dpc-5570	174	3	also	also	ADV
dpc-5570	174	4	consider	consider	VERB
dpc-5570	174	5	the	the	DET
dpc-5570	174	6	issue	issue	NOUN
dpc-5570	174	7	of	of	ADP
dpc-5570	174	8	metabolic	metabolic	ADJ
dpc-5570	174	9	cardiovascular	cardiovascular	ADJ
dpc-5570	174	10	risk	risk	NOUN
dpc-5570	174	11	in	in	ADP
dpc-5570	174	12	psa	psa	NOUN
dpc-5570	174	13	patients	patient	NOUN
dpc-5570	174	14	,	,	PUNCT
dpc-5570	174	15	as	as	SCONJ
dpc-5570	174	16	shown	show	VERB
dpc-5570	174	17	by	by	ADP
dpc-5570	174	18	our	our	PRON
dpc-5570	174	19	data	datum	NOUN
dpc-5570	174	20	as	as	ADV
dpc-5570	174	21	well	well	ADV
dpc-5570	174	22	[	[	X
dpc-5570	174	23	21	21	NUM
dpc-5570	174	24	]	]	PUNCT
dpc-5570	174	25	.	.	PUNCT
dpc-5570	175	1	in	in	ADP
dpc-5570	175	2	fact	fact	NOUN
dpc-5570	175	3	,	,	PUNCT
dpc-5570	175	4	some	some	DET
dpc-5570	175	5	authors	author	NOUN
dpc-5570	175	6	have	have	AUX
dpc-5570	175	7	recognized	recognize	VERB
dpc-5570	175	8	metabolic	metabolic	NOUN
dpc-5570	175	9	comorbidities	comorbiditie	NOUN
dpc-5570	175	10	as	as	ADP
dpc-5570	175	11	a	a	DET
dpc-5570	175	12	possible	possible	ADJ
dpc-5570	175	13	pathogenetic	pathogenetic	ADJ
dpc-5570	175	14	link	link	NOUN
dpc-5570	175	15	with	with	ADP
dpc-5570	175	16	the	the	DET
dpc-5570	175	17	onset	onset	NOUN
dpc-5570	175	18	of	of	ADP
dpc-5570	175	19	psa	psa	NOUN
dpc-5570	175	20	and	and	CCONJ
dpc-5570	175	21	not	not	PART
dpc-5570	175	22	just	just	ADV
dpc-5570	175	23	as	as	ADP
dpc-5570	175	24	a	a	DET
dpc-5570	175	25	statistically	statistically	ADV
dpc-5570	175	26	associated	associate	VERB
dpc-5570	175	27	disease	disease	NOUN
dpc-5570	175	28	[	[	X
dpc-5570	175	29	31	31	NUM
dpc-5570	175	30	]	]	PUNCT
dpc-5570	175	31	.	.	PUNCT
dpc-5570	176	1	considering	consider	VERB
dpc-5570	176	2	biochemical	biochemical	ADJ
dpc-5570	176	3	parameters	parameter	NOUN
dpc-5570	176	4	,	,	PUNCT
dpc-5570	176	5	c	c	NOUN
dpc-5570	176	6	-	-	PUNCT
dpc-5570	176	7	reactive	reactive	ADJ
dpc-5570	176	8	protein	protein	NOUN
dpc-5570	176	9	is	be	AUX
dpc-5570	176	10	a	a	DET
dpc-5570	176	11	valid	valid	ADJ
dpc-5570	176	12	non	non	ADJ
dpc-5570	176	13	-	-	ADJ
dpc-5570	176	14	specific	specific	ADJ
dpc-5570	176	15	marker	marker	NOUN
dpc-5570	176	16	useful	useful	ADJ
dpc-5570	176	17	to	to	ADP
dpc-5570	176	18	monitoring	monitor	VERB
dpc-5570	176	19	the	the	DET
dpc-5570	176	20	figure	figure	NOUN
dpc-5570	176	21	2	2	NUM
dpc-5570	176	22	.	.	PUNCT
dpc-5570	176	23	a.	a.	NOUN
dpc-5570	176	24	mean	mean	PROPN
dpc-5570	176	25	pasi	pasi	NOUN
dpc-5570	176	26	values	value	NOUN
dpc-5570	176	27	at	at	ADP
dpc-5570	176	28	t0	t0	PROPN
dpc-5570	176	29	and	and	CCONJ
dpc-5570	176	30	t28	t28	NUM
dpc-5570	176	31	(	(	PUNCT
dpc-5570	176	32	14.13	14.13	NUM
dpc-5570	176	33	and	and	CCONJ
dpc-5570	176	34	2.63	2.63	NUM
dpc-5570	176	35	,	,	PUNCT
dpc-5570	176	36	respectively	respectively	ADV
dpc-5570	176	37	)	)	PUNCT
dpc-5570	176	38	.	.	PUNCT
dpc-5570	177	1	mean	mean	ADJ
dpc-5570	177	2	reduction	reduction	NOUN
dpc-5570	177	3	:	:	PUNCT
dpc-5570	177	4	81.3	81.3	NUM
dpc-5570	177	5	%	%	NOUN
dpc-5570	177	6	(	(	PUNCT
dpc-5570	177	7	pp<0.001	pp<0.001	PROPN
dpc-5570	177	8	)	)	PUNCT
dpc-5570	177	9	;	;	PUNCT
dpc-5570	177	10	b.	b.	PROPN
dpc-5570	177	11	c	c	X
dpc-5570	177	12	-	-	PUNCT
dpc-5570	177	13	reactive	reactive	ADJ
dpc-5570	177	14	protein	protein	NOUN
dpc-5570	177	15	mean	mean	NOUN
dpc-5570	177	16	levels	level	NOUN
dpc-5570	177	17	at	at	ADP
dpc-5570	177	18	t0	t0	PROPN
dpc-5570	177	19	and	and	CCONJ
dpc-5570	177	20	at	at	ADP
dpc-5570	177	21	t28	t28	NUM
dpc-5570	177	22	(	(	PUNCT
dpc-5570	177	23	1.95	1.95	NUM
dpc-5570	177	24	mg	mg	PROPN
dpc-5570	177	25	/	/	SYM
dpc-5570	177	26	dl	dl	PROPN
dpc-5570	177	27	and	and	CCONJ
dpc-5570	177	28	0.86	0.86	NUM
dpc-5570	177	29	mg	mg	PROPN
dpc-5570	177	30	/	/	SYM
dpc-5570	177	31	dl	dl	PROPN
dpc-5570	177	32	,	,	PUNCT
dpc-5570	177	33	respectively	respectively	ADV
dpc-5570	177	34	,	,	PUNCT
dpc-5570	177	35	pp<0.1	pp<0.1	PROPN
dpc-5570	177	36	)	)	PUNCT
dpc-5570	177	37	.	.	PUNCT
dpc-5570	178	1	we	we	PRON
dpc-5570	178	2	assigned	assign	VERB
dpc-5570	178	3	a	a	DET
dpc-5570	178	4	value	value	NOUN
dpc-5570	178	5	of	of	ADP
dpc-5570	178	6	“	"	PUNCT
dpc-5570	178	7	0	0	NUM
dpc-5570	178	8	”	"	PUNCT
dpc-5570	178	9	when	when	SCONJ
dpc-5570	178	10	crp	crp	NOUN
dpc-5570	178	11	value	value	NOUN
dpc-5570	178	12	was	be	AUX
dpc-5570	178	13	under	under	ADP
dpc-5570	178	14	the	the	DET
dpc-5570	178	15	lower	low	ADJ
dpc-5570	178	16	cut	cut	VERB
dpc-5570	178	17	-	-	PUNCT
dpc-5570	178	18	off	off	ADP
dpc-5570	178	19	limit	limit	NOUN
dpc-5570	178	20	.	.	PUNCT
dpc-5570	179	1	;	;	PUNCT
dpc-5570	179	2	c.	c.	PROPN
dpc-5570	179	3	mean	mean	PROPN
dpc-5570	179	4	pain	pain	PROPN
dpc-5570	179	5	vas	vas	NOUN
dpc-5570	179	6	values	value	NOUN
dpc-5570	179	7	at	at	ADP
dpc-5570	179	8	t0	t0	PROPN
dpc-5570	179	9	and	and	CCONJ
dpc-5570	179	10	t28	t28	NUM
dpc-5570	179	11	(	(	PUNCT
dpc-5570	179	12	50	50	NUM
dpc-5570	179	13	and	and	CCONJ
dpc-5570	179	14	3.75	3.75	NUM
dpc-5570	179	15	,	,	PUNCT
dpc-5570	179	16	respectively	respectively	ADV
dpc-5570	179	17	,	,	PUNCT
dpc-5570	179	18	pp	pp	ADP
dpc-5570	179	19	<	<	NOUN
dpc-5570	179	20	0.002	0.002	NUM
dpc-5570	179	21	)	)	PUNCT
dpc-5570	179	22	;	;	PUNCT
dpc-5570	179	23	d.	d.	PROPN
dpc-5570	179	24	mean	mean	VERB
dpc-5570	179	25	hand	hand	NOUN
dpc-5570	179	26	napsi	napsi	NOUN
dpc-5570	179	27	values	value	NOUN
dpc-5570	179	28	at	at	ADP
dpc-5570	179	29	t0	t0	PROPN
dpc-5570	179	30	and	and	CCONJ
dpc-5570	179	31	t28	t28	NUM
dpc-5570	179	32	(	(	PUNCT
dpc-5570	179	33	30	30	NUM
dpc-5570	179	34	and	and	CCONJ
dpc-5570	179	35	6.5	6.5	NUM
dpc-5570	179	36	,	,	PUNCT
dpc-5570	179	37	respectively	respectively	ADV
dpc-5570	179	38	)	)	PUNCT
dpc-5570	179	39	.	.	PUNCT
dpc-5570	180	1	reduction	reduction	NOUN
dpc-5570	180	2	in	in	ADP
dpc-5570	180	3	the	the	DET
dpc-5570	180	4	mean	mean	ADJ
dpc-5570	180	5	value	value	NOUN
dpc-5570	180	6	from	from	ADP
dpc-5570	180	7	t0	t0	NUM
dpc-5570	180	8	of	of	ADP
dpc-5570	180	9	≃	≃	NOUN
dpc-5570	180	10	78	78	NUM
dpc-5570	180	11	%	%	NOUN
dpc-5570	180	12	,	,	PUNCT
dpc-5570	180	13	pp<0.001	pp<0.001	PROPN
dpc-5570	180	14	.	.	PUNCT
dpc-5570	180	15	;	;	PUNCT
dpc-5570	180	16	e.	e.	PROPN
dpc-5570	180	17	mean	mean	PROPN
dpc-5570	180	18	dlqi	dlqi	PROPN
dpc-5570	180	19	values	value	NOUN
dpc-5570	180	20	at	at	ADP
dpc-5570	180	21	t0	t0	PROPN
dpc-5570	180	22	and	and	CCONJ
dpc-5570	180	23	t28	t28	NUM
dpc-5570	180	24	(	(	PUNCT
dpc-5570	180	25	16.4	16.4	NUM
dpc-5570	180	26	and	and	CCONJ
dpc-5570	180	27	2.25	2.25	NUM
dpc-5570	180	28	,	,	PUNCT
dpc-5570	180	29	respectively	respectively	ADV
dpc-5570	180	30	)	)	PUNCT
dpc-5570	180	31	,	,	PUNCT
dpc-5570	180	32	mean	mean	ADJ
dpc-5570	180	33	reduction	reduction	NOUN
dpc-5570	180	34	of	of	ADP
dpc-5570	180	35	86	86	NUM
dpc-5570	180	36	%	%	NOUN
dpc-5570	180	37	compared	compare	VERB
dpc-5570	180	38	to	to	ADP
dpc-5570	180	39	t0	t0	PROPN
dpc-5570	180	40	(	(	PUNCT
dpc-5570	180	41	pp<0.001	pp<0.001	PROPN
dpc-5570	180	42	)	)	PUNCT
dpc-5570	180	43	.	.	PUNCT
dpc-5570	181	1	;	;	PUNCT
dpc-5570	181	2	f.	f.	PROPN
dpc-5570	181	3	mean	mean	PROPN
dpc-5570	181	4	pga	pga	PROPN
dpc-5570	181	5	values	value	NOUN
dpc-5570	181	6	at	at	ADP
dpc-5570	181	7	t0	t0	PROPN
dpc-5570	181	8	and	and	CCONJ
dpc-5570	181	9	t28	t28	NUM
dpc-5570	181	10	(	(	PUNCT
dpc-5570	181	11	6.5	6.5	NUM
dpc-5570	181	12	and	and	CCONJ
dpc-5570	181	13	1.75	1.75	NUM
dpc-5570	181	14	,	,	PUNCT
dpc-5570	181	15	respectively	respectively	ADV
dpc-5570	181	16	)	)	PUNCT
dpc-5570	181	17	t	t	NOUN
dpc-5570	181	18	-	-	PUNCT
dpc-5570	181	19	test	test	NOUN
dpc-5570	181	20	,	,	PUNCT
dpc-5570	181	21	pp<0.001	pp<0.001	NOUN
dpc-5570	181	22	.	.	PUNCT
dpc-5570	182	1	original	original	ADJ
dpc-5570	182	2	article	article	NOUN
dpc-5570	182	3	|	|	ADV
dpc-5570	182	4	dermatol	dermatol	ADJ
dpc-5570	182	5	pract	pract	NOUN
dpc-5570	182	6	concept	concept	NOUN
dpc-5570	182	7	.	.	PUNCT
dpc-5570	183	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	183	2	7	7	NUM
dpc-5570	183	3	psoriatic	psoriatic	ADJ
dpc-5570	183	4	arthritis	arthritis	NOUN
dpc-5570	183	5	of	of	ADP
dpc-5570	183	6	more	more	ADJ
dpc-5570	183	7	than	than	ADP
dpc-5570	183	8	one	one	NUM
dpc-5570	183	9	year	year	NOUN
dpc-5570	183	10	’s	’s	PART
dpc-5570	183	11	duration	duration	NOUN
dpc-5570	183	12	.	.	PUNCT
dpc-5570	184	1	these	these	DET
dpc-5570	184	2	treatment	treatment	NOUN
dpc-5570	184	3	decisions	decision	NOUN
dpc-5570	184	4	are	be	AUX
dpc-5570	184	5	based	base	VERB
dpc-5570	184	6	on	on	ADP
dpc-5570	184	7	the	the	DET
dpc-5570	184	8	existing	exist	VERB
dpc-5570	184	9	literature	literature	NOUN
dpc-5570	184	10	,	,	PUNCT
dpc-5570	184	11	which	which	PRON
dpc-5570	184	12	indicates	indicate	VERB
dpc-5570	184	13	superior	superior	ADJ
dpc-5570	184	14	efficacy	efficacy	NOUN
dpc-5570	184	15	of	of	ADP
dpc-5570	184	16	these	these	DET
dpc-5570	184	17	biologics	biologic	NOUN
dpc-5570	184	18	classes	class	NOUN
dpc-5570	184	19	compared	compare	VERB
dpc-5570	184	20	to	to	ADP
dpc-5570	184	21	anti	anti	ADJ
dpc-5570	184	22	-	-	ADJ
dpc-5570	184	23	il-23	il-23	ADJ
dpc-5570	184	24	agents	agent	NOUN
dpc-5570	184	25	such	such	ADJ
dpc-5570	184	26	as	as	ADP
dpc-5570	184	27	tildrakizumab	tildrakizumab	NOUN
dpc-5570	184	28	[	[	X
dpc-5570	184	29	34	34	NUM
dpc-5570	184	30	]	]	PUNCT
dpc-5570	184	31	.	.	PUNCT
dpc-5570	185	1	psoriasis	psoriasis	NOUN
dpc-5570	185	2	and	and	CCONJ
dpc-5570	185	3	psa	psa	NOUN
dpc-5570	185	4	are	be	AUX
dpc-5570	185	5	diseases	disease	NOUN
dpc-5570	185	6	deeply	deeply	ADV
dpc-5570	185	7	linked	link	VERB
dpc-5570	185	8	to	to	ADP
dpc-5570	185	9	metabolic	metabolic	NOUN
dpc-5570	185	10	comorbidities	comorbiditie	NOUN
dpc-5570	185	11	,	,	PUNCT
dpc-5570	185	12	all	all	PRON
dpc-5570	185	13	having	have	VERB
dpc-5570	185	14	a	a	DET
dpc-5570	185	15	substrate	substrate	NOUN
dpc-5570	185	16	of	of	ADP
dpc-5570	185	17	chronic	chronic	ADJ
dpc-5570	185	18	systemic	systemic	ADJ
dpc-5570	185	19	inflammation	inflammation	NOUN
dpc-5570	185	20	that	that	PRON
dpc-5570	185	21	may	may	AUX
dpc-5570	185	22	play	play	VERB
dpc-5570	185	23	a	a	DET
dpc-5570	185	24	self	self	NOUN
dpc-5570	185	25	-	-	PUNCT
dpc-5570	185	26	maintaining	maintain	VERB
dpc-5570	185	27	role	role	NOUN
dpc-5570	185	28	[	[	X
dpc-5570	185	29	35	35	NUM
dpc-5570	185	30	]	]	PUNCT
dpc-5570	185	31	.	.	PUNCT
dpc-5570	186	1	as	as	ADP
dpc-5570	186	2	of	of	ADP
dpc-5570	186	3	march	march	PROPN
dpc-5570	186	4	2025	2025	NUM
dpc-5570	186	5	,	,	PUNCT
dpc-5570	186	6	a	a	DET
dpc-5570	186	7	dermatologist	dermatologist	NOUN
dpc-5570	186	8	in	in	ADP
dpc-5570	186	9	europe	europe	PROPN
dpc-5570	186	10	can	can	AUX
dpc-5570	186	11	choose	choose	VERB
dpc-5570	186	12	the	the	DET
dpc-5570	186	13	systemic	systemic	ADJ
dpc-5570	186	14	drug	drug	NOUN
dpc-5570	186	15	for	for	ADP
dpc-5570	186	16	each	each	DET
dpc-5570	186	17	psoriasis	psoriasis	NOUN
dpc-5570	186	18	patient	patient	ADJ
dpc-5570	186	19	from	from	ADP
dpc-5570	186	20	a	a	DET
dpc-5570	186	21	pool	pool	NOUN
dpc-5570	186	22	of	of	ADP
dpc-5570	186	23	18	18	NUM
dpc-5570	186	24	different	different	ADJ
dpc-5570	186	25	therapies	therapy	NOUN
dpc-5570	186	26	,	,	PUNCT
dpc-5570	186	27	in	in	ADP
dpc-5570	186	28	addition	addition	NOUN
dpc-5570	186	29	to	to	ADP
dpc-5570	186	30	biosimilars	biosimilars	PROPN
dpc-5570	186	31	[	[	X
dpc-5570	186	32	36	36	NUM
dpc-5570	186	33	]	]	PUNCT
dpc-5570	186	34	.	.	PUNCT
dpc-5570	187	1	among	among	ADP
dpc-5570	187	2	the	the	DET
dpc-5570	187	3	approved	approve	VERB
dpc-5570	187	4	biological	biological	ADJ
dpc-5570	187	5	drugs	drug	NOUN
dpc-5570	187	6	for	for	ADP
dpc-5570	187	7	psa	psa	NOUN
dpc-5570	187	8	,	,	PUNCT
dpc-5570	187	9	the	the	DET
dpc-5570	187	10	ones	one	NOUN
dpc-5570	187	11	directed	direct	VERB
dpc-5570	187	12	against	against	ADP
dpc-5570	187	13	tnfα	tnfα	NOUN
dpc-5570	187	14	show	show	VERB
dpc-5570	187	15	the	the	DET
dpc-5570	187	16	weakest	weak	ADJ
dpc-5570	187	17	safety	safety	NOUN
dpc-5570	187	18	profile	profile	NOUN
dpc-5570	187	19	,	,	PUNCT
dpc-5570	187	20	having	having	AUX
dpc-5570	187	21	demonstrated	demonstrate	VERB
dpc-5570	187	22	a	a	DET
dpc-5570	187	23	lower	low	ADJ
dpc-5570	187	24	efficacy	efficacy	NOUN
dpc-5570	187	25	in	in	ADP
dpc-5570	187	26	obese	obese	ADJ
dpc-5570	187	27	patients	patient	NOUN
dpc-5570	187	28	than	than	ADP
dpc-5570	187	29	in	in	ADP
dpc-5570	187	30	normal	normal	ADJ
dpc-5570	187	31	-	-	PUNCT
dpc-5570	187	32	weight	weight	NOUN
dpc-5570	187	33	patients	patient	NOUN
dpc-5570	187	34	and	and	CCONJ
dpc-5570	187	35	an	an	DET
dpc-5570	187	36	association	association	NOUN
dpc-5570	187	37	with	with	ADP
dpc-5570	187	38	weight	weight	NOUN
dpc-5570	187	39	gain	gain	NOUN
dpc-5570	187	40	in	in	ADP
dpc-5570	187	41	treated	treat	VERB
dpc-5570	187	42	patients	patient	NOUN
dpc-5570	187	43	[	[	X
dpc-5570	187	44	37	37	NUM
dpc-5570	187	45	]	]	PUNCT
dpc-5570	187	46	.	.	PUNCT
dpc-5570	188	1	inhibitors	inhibitor	NOUN
dpc-5570	188	2	of	of	ADP
dpc-5570	188	3	il-17	il-17	X
dpc-5570	188	4	,	,	PUNCT
dpc-5570	188	5	while	while	SCONJ
dpc-5570	188	6	not	not	PART
dpc-5570	188	7	associated	associate	VERB
dpc-5570	188	8	with	with	ADP
dpc-5570	188	9	weight	weight	NOUN
dpc-5570	188	10	gain	gain	NOUN
dpc-5570	188	11	in	in	ADP
dpc-5570	188	12	treated	treat	VERB
dpc-5570	188	13	patients	patient	NOUN
dpc-5570	188	14	,	,	PUNCT
dpc-5570	188	15	have	have	VERB
dpc-5570	188	16	a	a	DET
dpc-5570	188	17	weaker	weak	ADJ
dpc-5570	188	18	response	response	NOUN
dpc-5570	188	19	in	in	ADP
dpc-5570	188	20	obese	obese	ADJ
dpc-5570	188	21	patients	patient	NOUN
dpc-5570	188	22	than	than	ADP
dpc-5570	188	23	in	in	ADP
dpc-5570	188	24	normal	normal	ADJ
dpc-5570	188	25	-	-	PUNCT
dpc-5570	188	26	weight	weight	NOUN
dpc-5570	188	27	patients	patient	NOUN
dpc-5570	188	28	and	and	CCONJ
dpc-5570	188	29	are	be	AUX
dpc-5570	188	30	also	also	ADV
dpc-5570	188	31	associated	associate	VERB
dpc-5570	188	32	with	with	ADP
dpc-5570	188	33	an	an	DET
dpc-5570	188	34	increased	increase	VERB
dpc-5570	188	35	risk	risk	NOUN
dpc-5570	188	36	of	of	ADP
dpc-5570	188	37	candidiasis	candidiasis	NOUN
dpc-5570	188	38	,	,	PUNCT
dpc-5570	188	39	exacerbated	exacerbate	VERB
dpc-5570	188	40	in	in	ADP
dpc-5570	188	41	patients	patient	NOUN
dpc-5570	188	42	with	with	ADP
dpc-5570	188	43	diabetes	diabetes	NOUN
dpc-5570	188	44	mellitus	mellitus	NOUN
dpc-5570	188	45	[	[	X
dpc-5570	188	46	37,38	37,38	NUM
dpc-5570	188	47	]	]	PUNCT
dpc-5570	188	48	.	.	PUNCT
dpc-5570	189	1	anti	anti	ADJ
dpc-5570	189	2	-	-	ADJ
dpc-5570	189	3	il-23	il-23	ADJ
dpc-5570	189	4	antibodies	antibody	NOUN
dpc-5570	189	5	do	do	AUX
dpc-5570	189	6	not	not	PART
dpc-5570	189	7	seem	seem	VERB
dpc-5570	189	8	to	to	PART
dpc-5570	189	9	affect	affect	VERB
dpc-5570	189	10	glycolipid	glycolipid	ADJ
dpc-5570	189	11	metabolism	metabolism	NOUN
dpc-5570	189	12	or	or	CCONJ
dpc-5570	189	13	exhibit	exhibit	VERB
dpc-5570	189	14	a	a	DET
dpc-5570	189	15	different	different	ADJ
dpc-5570	189	16	clinical	clinical	ADJ
dpc-5570	189	17	response	response	NOUN
dpc-5570	189	18	in	in	ADP
dpc-5570	189	19	obese	obese	ADJ
dpc-5570	189	20	patients	patient	NOUN
dpc-5570	189	21	[	[	X
dpc-5570	189	22	37	37	NUM
dpc-5570	189	23	]	]	PUNCT
dpc-5570	189	24	.	.	PUNCT
dpc-5570	190	1	recently	recently	ADV
dpc-5570	190	2	,	,	PUNCT
dpc-5570	190	3	tildrakizumab	tildrakizumab	NOUN
dpc-5570	190	4	has	have	AUX
dpc-5570	190	5	become	become	VERB
dpc-5570	190	6	available	available	ADJ
dpc-5570	190	7	also	also	ADV
dpc-5570	190	8	in	in	ADP
dpc-5570	190	9	a	a	DET
dpc-5570	190	10	dosage	dosage	NOUN
dpc-5570	190	11	of	of	ADP
dpc-5570	190	12	200	200	NUM
dpc-5570	190	13	mg	mg	NOUN
dpc-5570	190	14	,	,	PUNCT
dpc-5570	190	15	which	which	PRON
dpc-5570	190	16	is	be	AUX
dpc-5570	190	17	useful	useful	ADJ
dpc-5570	190	18	in	in	ADP
dpc-5570	190	19	patients	patient	NOUN
dpc-5570	190	20	weighing	weigh	VERB
dpc-5570	190	21	over	over	ADP
dpc-5570	190	22	100	100	NUM
dpc-5570	190	23	kg	kg	NOUN
dpc-5570	190	24	and/or	and/or	CCONJ
dpc-5570	190	25	with	with	ADP
dpc-5570	190	26	a	a	DET
dpc-5570	190	27	high	high	ADJ
dpc-5570	190	28	disease	disease	NOUN
dpc-5570	190	29	burden	burden	NOUN
dpc-5570	190	30	,	,	PUNCT
dpc-5570	190	31	maintaining	maintain	VERB
dpc-5570	190	32	the	the	DET
dpc-5570	190	33	same	same	ADJ
dpc-5570	190	34	safety	safety	NOUN
dpc-5570	190	35	profile	profile	NOUN
dpc-5570	190	36	compared	compare	VERB
dpc-5570	190	37	to	to	ADP
dpc-5570	190	38	the	the	DET
dpc-5570	190	39	standard	standard	NOUN
dpc-5570	190	40	dose	dose	NOUN
dpc-5570	190	41	of	of	ADP
dpc-5570	190	42	100	100	NUM
dpc-5570	190	43	mg	mg	NOUN
dpc-5570	190	44	[	[	X
dpc-5570	190	45	39,40	39,40	NUM
dpc-5570	190	46	]	]	PUNCT
dpc-5570	190	47	.	.	PUNCT
dpc-5570	191	1	in	in	ADP
dpc-5570	191	2	light	light	NOUN
dpc-5570	191	3	of	of	ADP
dpc-5570	191	4	the	the	DET
dpc-5570	191	5	rct	rct	PROPN
dpc-5570	191	6	tildrakizumab	tildrakizumab	PROPN
dpc-5570	191	7	data	data	VERB
dpc-5570	191	8	[	[	X
dpc-5570	191	9	23	23	NUM
dpc-5570	191	10	]	]	PUNCT
dpc-5570	191	11	and	and	CCONJ
dpc-5570	191	12	based	base	VERB
dpc-5570	191	13	on	on	ADP
dpc-5570	191	14	our	our	PRON
dpc-5570	191	15	real	real	ADJ
dpc-5570	191	16	-	-	PUNCT
dpc-5570	191	17	life	life	NOUN
dpc-5570	191	18	clinical	clinical	ADJ
dpc-5570	191	19	experience	experience	NOUN
dpc-5570	191	20	[	[	X
dpc-5570	191	21	21	21	NUM
dpc-5570	191	22	]	]	PUNCT
dpc-5570	191	23	,	,	PUNCT
dpc-5570	191	24	we	we	PRON
dpc-5570	191	25	consider	consider	VERB
dpc-5570	191	26	tildrakizumab	tildrakizumab	NOUN
dpc-5570	191	27	to	to	PART
dpc-5570	191	28	be	be	AUX
dpc-5570	191	29	an	an	DET
dpc-5570	191	30	effective	effective	ADJ
dpc-5570	191	31	therapeutic	therapeutic	ADJ
dpc-5570	191	32	option	option	NOUN
dpc-5570	191	33	for	for	ADP
dpc-5570	191	34	psoriasis	psoriasis	NOUN
dpc-5570	191	35	patients	patient	NOUN
dpc-5570	191	36	with	with	ADP
dpc-5570	191	37	metabolic	metabolic	NOUN
dpc-5570	191	38	comorbidities	comorbiditie	NOUN
dpc-5570	191	39	and	and	CCONJ
dpc-5570	191	40	signs	sign	NOUN
dpc-5570	191	41	and	and	CCONJ
dpc-5570	191	42	symptoms	symptom	NOUN
dpc-5570	191	43	of	of	ADP
dpc-5570	191	44	early	early	ADJ
dpc-5570	191	45	psa	psa	NOUN
dpc-5570	191	46	who	who	PRON
dpc-5570	191	47	are	be	AUX
dpc-5570	191	48	candidates	candidate	NOUN
dpc-5570	191	49	for	for	ADP
dpc-5570	191	50	biologics	biologic	NOUN
dpc-5570	191	51	to	to	PART
dpc-5570	191	52	intercept	intercept	VERB
dpc-5570	191	53	long	long	ADJ
dpc-5570	191	54	-	-	PUNCT
dpc-5570	191	55	term	term	NOUN
dpc-5570	191	56	complications	complication	NOUN
dpc-5570	191	57	such	such	ADJ
dpc-5570	191	58	as	as	ADP
dpc-5570	191	59	bone	bone	NOUN
dpc-5570	191	60	erosions	erosion	NOUN
dpc-5570	191	61	and	and	CCONJ
dpc-5570	191	62	joint	joint	ADJ
dpc-5570	191	63	deformities	deformity	NOUN
dpc-5570	191	64	[	[	X
dpc-5570	191	65	32	32	NUM
dpc-5570	191	66	]	]	PUNCT
dpc-5570	191	67	.	.	PUNCT
dpc-5570	192	1	conclusions	conclusion	NOUN
dpc-5570	192	2	awareness	awareness	NOUN
dpc-5570	192	3	of	of	ADP
dpc-5570	192	4	the	the	DET
dpc-5570	192	5	efficacy	efficacy	NOUN
dpc-5570	192	6	of	of	ADP
dpc-5570	192	7	tildrakizumab	tildrakizumab	NOUN
dpc-5570	192	8	in	in	ADP
dpc-5570	192	9	psa	psa	NOUN
dpc-5570	192	10	could	could	AUX
dpc-5570	192	11	allow	allow	VERB
dpc-5570	192	12	clinicians	clinician	NOUN
dpc-5570	192	13	to	to	PART
dpc-5570	192	14	promptly	promptly	ADV
dpc-5570	192	15	intervene	intervene	VERB
dpc-5570	192	16	in	in	ADP
dpc-5570	192	17	patients	patient	NOUN
dpc-5570	192	18	suffering	suffer	VERB
dpc-5570	192	19	from	from	ADP
dpc-5570	192	20	severe	severe	ADJ
dpc-5570	192	21	skin	skin	NOUN
dpc-5570	192	22	psoriasis	psoriasis	NOUN
dpc-5570	192	23	and	and	CCONJ
dpc-5570	192	24	metabolic	metabolic	NOUN
dpc-5570	192	25	comorbidities	comorbiditie	NOUN
dpc-5570	192	26	by	by	ADP
dpc-5570	192	27	acting	act	VERB
dpc-5570	192	28	early	early	ADV
dpc-5570	192	29	on	on	ADP
dpc-5570	192	30	co	co	ADJ
dpc-5570	192	31	-	-	ADJ
dpc-5570	192	32	occurring	occurring	ADJ
dpc-5570	192	33	arthritic	arthritic	ADJ
dpc-5570	192	34	symptoms	symptom	NOUN
dpc-5570	192	35	[	[	X
dpc-5570	192	36	30	30	NUM
dpc-5570	192	37	]	]	PUNCT
dpc-5570	192	38	.	.	PUNCT
dpc-5570	193	1	further	further	ADJ
dpc-5570	193	2	real	real	ADJ
dpc-5570	193	3	-	-	PUNCT
dpc-5570	193	4	life	life	NOUN
dpc-5570	193	5	studies	study	NOUN
dpc-5570	193	6	are	be	AUX
dpc-5570	193	7	warranted	warrant	VERB
dpc-5570	193	8	to	to	PART
dpc-5570	193	9	confirm	confirm	VERB
dpc-5570	193	10	the	the	DET
dpc-5570	193	11	role	role	NOUN
dpc-5570	193	12	of	of	ADP
dpc-5570	193	13	tildrakizumab	tildrakizumab	NOUN
dpc-5570	193	14	in	in	ADP
dpc-5570	193	15	psa	psa	NOUN
dpc-5570	193	16	,	,	PUNCT
dpc-5570	193	17	but	but	CCONJ
dpc-5570	193	18	our	our	PRON
dpc-5570	193	19	results	result	NOUN
dpc-5570	193	20	could	could	AUX
dpc-5570	193	21	be	be	AUX
dpc-5570	193	22	considered	consider	VERB
dpc-5570	193	23	a	a	DET
dpc-5570	193	24	clue	clue	NOUN
dpc-5570	193	25	of	of	ADP
dpc-5570	193	26	the	the	DET
dpc-5570	193	27	biological	biological	ADJ
dpc-5570	193	28	likelihood	likelihood	NOUN
dpc-5570	193	29	linked	link	VERB
dpc-5570	193	30	to	to	ADP
dpc-5570	193	31	the	the	DET
dpc-5570	193	32	treatment	treatment	NOUN
dpc-5570	193	33	of	of	ADP
dpc-5570	193	34	psa	psa	NOUN
dpc-5570	193	35	with	with	ADP
dpc-5570	193	36	an	an	DET
dpc-5570	193	37	il-23	il-23	NOUN
dpc-5570	193	38	inhibitor	inhibitor	NOUN
dpc-5570	193	39	.	.	PUNCT
dpc-5570	194	1	our	our	PRON
dpc-5570	194	2	patients	patient	NOUN
dpc-5570	194	3	achieved	achieve	VERB
dpc-5570	194	4	complete	complete	ADJ
dpc-5570	194	5	remission	remission	NOUN
dpc-5570	194	6	,	,	PUNCT
dpc-5570	194	7	or	or	CCONJ
dpc-5570	194	8	at	at	ADP
dpc-5570	194	9	least	least	ADJ
dpc-5570	194	10	a	a	DET
dpc-5570	194	11	dramatic	dramatic	ADJ
dpc-5570	194	12	improvement	improvement	NOUN
dpc-5570	194	13	in	in	ADP
dpc-5570	194	14	psa	psa	NOUN
dpc-5570	194	15	symptoms	symptom	NOUN
dpc-5570	194	16	after	after	ADP
dpc-5570	194	17	28	28	NUM
dpc-5570	194	18	weeks	week	NOUN
dpc-5570	194	19	of	of	ADP
dpc-5570	194	20	treatment	treatment	NOUN
dpc-5570	194	21	,	,	PUNCT
dpc-5570	194	22	together	together	ADV
dpc-5570	194	23	with	with	ADP
dpc-5570	194	24	an	an	DET
dpc-5570	194	25	almost	almost	ADV
dpc-5570	194	26	complete	complete	ADJ
dpc-5570	194	27	resolution	resolution	NOUN
dpc-5570	194	28	of	of	ADP
dpc-5570	194	29	the	the	DET
dpc-5570	194	30	skin	skin	NOUN
dpc-5570	194	31	and	and	CCONJ
dpc-5570	194	32	nail	nail	NOUN
dpc-5570	194	33	lesions	lesion	NOUN
dpc-5570	194	34	confirmed	confirm	VERB
dpc-5570	194	35	by	by	ADP
dpc-5570	194	36	dlqi	dlqi	PROPN
dpc-5570	194	37	.	.	PUNCT
dpc-5570	195	1	informed	informed	ADJ
dpc-5570	195	2	consent	consent	NOUN
dpc-5570	195	3	statement	statement	NOUN
dpc-5570	195	4	:	:	PUNCT
dpc-5570	195	5	informed	inform	VERB
dpc-5570	195	6	consent	consent	NOUN
dpc-5570	195	7	was	be	AUX
dpc-5570	195	8	obtained	obtain	VERB
dpc-5570	195	9	from	from	ADP
dpc-5570	195	10	all	all	DET
dpc-5570	195	11	subjects	subject	NOUN
dpc-5570	195	12	involved	involve	VERB
dpc-5570	195	13	in	in	ADP
dpc-5570	195	14	the	the	DET
dpc-5570	195	15	study	study	NOUN
dpc-5570	195	16	.	.	PUNCT
dpc-5570	196	1	by	by	ADP
dpc-5570	196	2	more	more	ADJ
dpc-5570	196	3	than	than	ADP
dpc-5570	196	4	80	80	NUM
dpc-5570	196	5	%	%	NOUN
dpc-5570	196	6	,	,	PUNCT
dpc-5570	196	7	confirming	confirm	VERB
dpc-5570	196	8	that	that	SCONJ
dpc-5570	196	9	tildrakizumab	tildrakizumab	NOUN
dpc-5570	196	10	can	can	AUX
dpc-5570	196	11	lead	lead	VERB
dpc-5570	196	12	to	to	ADP
dpc-5570	196	13	a	a	DET
dpc-5570	196	14	substantial	substantial	ADJ
dpc-5570	196	15	reduction	reduction	NOUN
dpc-5570	196	16	in	in	ADP
dpc-5570	196	17	disease	disease	NOUN
dpc-5570	196	18	severity	severity	NOUN
dpc-5570	196	19	,	,	PUNCT
dpc-5570	196	20	which	which	PRON
dpc-5570	196	21	was	be	AUX
dpc-5570	196	22	paralleled	parallel	VERB
dpc-5570	196	23	by	by	ADP
dpc-5570	196	24	a	a	DET
dpc-5570	196	25	marked	mark	VERB
dpc-5570	196	26	improvement	improvement	NOUN
dpc-5570	196	27	in	in	ADP
dpc-5570	196	28	quality	quality	NOUN
dpc-5570	196	29	of	of	ADP
dpc-5570	196	30	life	life	NOUN
dpc-5570	196	31	,	,	PUNCT
dpc-5570	196	32	as	as	SCONJ
dpc-5570	196	33	measured	measure	VERB
dpc-5570	196	34	by	by	ADP
dpc-5570	196	35	the	the	DET
dpc-5570	196	36	dlqi	dlqi	NOUN
dpc-5570	196	37	.	.	PUNCT
dpc-5570	197	1	nail	nail	NOUN
dpc-5570	197	2	involvement	involvement	NOUN
dpc-5570	197	3	has	have	AUX
dpc-5570	197	4	been	be	AUX
dpc-5570	197	5	reported	report	VERB
dpc-5570	197	6	in	in	ADP
dpc-5570	197	7	up	up	ADP
dpc-5570	197	8	to	to	PART
dpc-5570	197	9	62.5	62.5	NUM
dpc-5570	197	10	%	%	NOUN
dpc-5570	197	11	of	of	ADP
dpc-5570	197	12	psoriatic	psoriatic	ADJ
dpc-5570	197	13	patients	patient	NOUN
dpc-5570	197	14	,	,	PUNCT
dpc-5570	197	15	a	a	DET
dpc-5570	197	16	finding	finding	NOUN
dpc-5570	197	17	confirmed	confirm	VERB
dpc-5570	197	18	in	in	ADP
dpc-5570	197	19	our	our	PRON
dpc-5570	197	20	cohort	cohort	NOUN
dpc-5570	197	21	[	[	X
dpc-5570	197	22	16	16	NUM
dpc-5570	197	23	]	]	PUNCT
dpc-5570	197	24	.	.	PUNCT
dpc-5570	198	1	the	the	DET
dpc-5570	198	2	observed	observe	VERB
dpc-5570	198	3	improvement	improvement	NOUN
dpc-5570	198	4	in	in	ADP
dpc-5570	198	5	napsi	napsi	NOUN
dpc-5570	198	6	was	be	AUX
dpc-5570	198	7	remarkable	remarkable	ADJ
dpc-5570	198	8	(	(	PUNCT
dpc-5570	198	9	approximately	approximately	ADV
dpc-5570	198	10	78	78	NUM
dpc-5570	198	11	%	%	NOUN
dpc-5570	198	12	)	)	PUNCT
dpc-5570	198	13	,	,	PUNCT
dpc-5570	198	14	with	with	ADP
dpc-5570	198	15	one	one	NUM
dpc-5570	198	16	patient	patient	NOUN
dpc-5570	198	17	achieving	achieve	VERB
dpc-5570	198	18	complete	complete	ADJ
dpc-5570	198	19	remission	remission	NOUN
dpc-5570	198	20	of	of	ADP
dpc-5570	198	21	nail	nail	NOUN
dpc-5570	198	22	psoriasis	psoriasis	NOUN
dpc-5570	198	23	after	after	ADP
dpc-5570	198	24	28	28	NUM
dpc-5570	198	25	weeks	week	NOUN
dpc-5570	198	26	.	.	PUNCT
dpc-5570	199	1	the	the	DET
dpc-5570	199	2	pathogenesis	pathogenesis	NOUN
dpc-5570	199	3	of	of	ADP
dpc-5570	199	4	nail	nail	NOUN
dpc-5570	199	5	psoriasis	psoriasis	NOUN
dpc-5570	199	6	is	be	AUX
dpc-5570	199	7	more	more	ADV
dpc-5570	199	8	closely	closely	ADV
dpc-5570	199	9	associated	associate	VERB
dpc-5570	199	10	with	with	ADP
dpc-5570	199	11	psoriatic	psoriatic	ADJ
dpc-5570	199	12	arthritis	arthritis	NOUN
dpc-5570	199	13	than	than	ADP
dpc-5570	199	14	with	with	ADP
dpc-5570	199	15	cutaneous	cutaneous	ADJ
dpc-5570	199	16	psoriasis	psoriasis	NOUN
dpc-5570	199	17	,	,	PUNCT
dpc-5570	199	18	and	and	CCONJ
dpc-5570	199	19	its	its	PRON
dpc-5570	199	20	clinical	clinical	ADJ
dpc-5570	199	21	improvement	improvement	NOUN
dpc-5570	199	22	may	may	AUX
dpc-5570	199	23	reflect	reflect	VERB
dpc-5570	199	24	better	well	ADJ
dpc-5570	199	25	control	control	NOUN
dpc-5570	199	26	of	of	ADP
dpc-5570	199	27	joint	joint	ADJ
dpc-5570	199	28	involvement	involvement	NOUN
dpc-5570	200	1	[	[	X
dpc-5570	200	2	16	16	NUM
dpc-5570	200	3	]	]	PUNCT
dpc-5570	200	4	.	.	PUNCT
dpc-5570	201	1	patient	patient	PROPN
dpc-5570	201	2	pga	pga	PROPN
dpc-5570	201	3	assessed	assess	VERB
dpc-5570	201	4	by	by	ADP
dpc-5570	201	5	means	mean	NOUN
dpc-5570	201	6	of	of	ADP
dpc-5570	201	7	vas	vas	X
dpc-5570	201	8	is	be	AUX
dpc-5570	201	9	a	a	DET
dpc-5570	201	10	reliable	reliable	ADJ
dpc-5570	201	11	tool	tool	NOUN
dpc-5570	201	12	related	relate	VERB
dpc-5570	201	13	to	to	ADP
dpc-5570	201	14	both	both	CCONJ
dpc-5570	201	15	arthritic	arthritic	ADJ
dpc-5570	201	16	and	and	CCONJ
dpc-5570	201	17	cutaneous	cutaneous	ADJ
dpc-5570	201	18	disease	disease	NOUN
dpc-5570	201	19	activity	activity	NOUN
dpc-5570	201	20	[	[	X
dpc-5570	201	21	33	33	NUM
dpc-5570	201	22	]	]	PUNCT
dpc-5570	201	23	.	.	PUNCT
dpc-5570	202	1	thus	thus	ADV
dpc-5570	202	2	,	,	PUNCT
dpc-5570	202	3	we	we	PRON
dpc-5570	202	4	decided	decide	VERB
dpc-5570	202	5	to	to	PART
dpc-5570	202	6	evaluate	evaluate	VERB
dpc-5570	202	7	it	it	PRON
dpc-5570	202	8	in	in	ADP
dpc-5570	202	9	order	order	NOUN
dpc-5570	202	10	to	to	PART
dpc-5570	202	11	more	more	ADV
dpc-5570	202	12	accurately	accurately	ADV
dpc-5570	202	13	highlight	highlight	VERB
dpc-5570	202	14	the	the	DET
dpc-5570	202	15	overall	overall	ADJ
dpc-5570	202	16	trend	trend	NOUN
dpc-5570	202	17	of	of	ADP
dpc-5570	202	18	the	the	DET
dpc-5570	202	19	psoriatic	psoriatic	ADJ
dpc-5570	202	20	pathology	pathology	NOUN
dpc-5570	202	21	over	over	ADP
dpc-5570	202	22	time	time	NOUN
dpc-5570	202	23	in	in	ADP
dpc-5570	202	24	each	each	DET
dpc-5570	202	25	patient	patient	NOUN
dpc-5570	202	26	.	.	PUNCT
dpc-5570	203	1	as	as	SCONJ
dpc-5570	203	2	reported	report	VERB
dpc-5570	203	3	in	in	ADP
dpc-5570	203	4	the	the	DET
dpc-5570	203	5	results	result	NOUN
dpc-5570	203	6	,	,	PUNCT
dpc-5570	203	7	tildrakizumab	tildrakizumab	NOUN
dpc-5570	203	8	was	be	AUX
dpc-5570	203	9	able	able	ADJ
dpc-5570	203	10	to	to	PART
dpc-5570	203	11	strongly	strongly	ADV
dpc-5570	203	12	reduce	reduce	VERB
dpc-5570	203	13	the	the	DET
dpc-5570	203	14	burden	burden	NOUN
dpc-5570	203	15	of	of	ADP
dpc-5570	203	16	both	both	CCONJ
dpc-5570	203	17	joint	joint	ADJ
dpc-5570	203	18	and	and	CCONJ
dpc-5570	203	19	skin	skin	NOUN
dpc-5570	203	20	pathology	pathology	NOUN
dpc-5570	203	21	,	,	PUNCT
dpc-5570	203	22	as	as	SCONJ
dpc-5570	203	23	reported	report	VERB
dpc-5570	203	24	by	by	ADP
dpc-5570	203	25	the	the	DET
dpc-5570	203	26	patients	patient	NOUN
dpc-5570	203	27	,	,	PUNCT
dpc-5570	203	28	during	during	ADP
dpc-5570	203	29	the	the	DET
dpc-5570	203	30	28	28	NUM
dpc-5570	203	31	weeks	week	NOUN
dpc-5570	203	32	of	of	ADP
dpc-5570	203	33	treatment	treatment	NOUN
dpc-5570	203	34	.	.	PUNCT
dpc-5570	204	1	the	the	DET
dpc-5570	204	2	composite	composite	ADJ
dpc-5570	204	3	dapsa	dapsa	NOUN
dpc-5570	204	4	score	score	NOUN
dpc-5570	204	5	is	be	AUX
dpc-5570	204	6	a	a	DET
dpc-5570	204	7	good	good	ADJ
dpc-5570	204	8	tool	tool	NOUN
dpc-5570	204	9	to	to	PART
dpc-5570	204	10	assess	assess	VERB
dpc-5570	204	11	overall	overall	ADJ
dpc-5570	204	12	arthritis	arthritis	NOUN
dpc-5570	204	13	disease	disease	NOUN
dpc-5570	204	14	activity	activity	NOUN
dpc-5570	204	15	as	as	SCONJ
dpc-5570	204	16	it	it	PRON
dpc-5570	204	17	reflects	reflect	VERB
dpc-5570	204	18	multiple	multiple	ADJ
dpc-5570	204	19	aspects	aspect	NOUN
dpc-5570	204	20	of	of	ADP
dpc-5570	204	21	affected	affected	ADJ
dpc-5570	204	22	patients	patient	NOUN
dpc-5570	204	23	.	.	PUNCT
dpc-5570	205	1	our	our	PRON
dpc-5570	205	2	patients	patient	NOUN
dpc-5570	205	3	obtained	obtain	VERB
dpc-5570	205	4	a	a	DET
dpc-5570	205	5	statistically	statistically	ADV
dpc-5570	205	6	significant	significant	ADJ
dpc-5570	205	7	reduction	reduction	NOUN
dpc-5570	205	8	in	in	ADP
dpc-5570	205	9	their	their	PRON
dpc-5570	205	10	dapsa	dapsa	ADJ
dpc-5570	205	11	mean	mean	NOUN
dpc-5570	205	12	score	score	NOUN
dpc-5570	205	13	,	,	PUNCT
dpc-5570	205	14	thus	thus	ADV
dpc-5570	205	15	reflecting	reflect	VERB
dpc-5570	205	16	a	a	DET
dpc-5570	205	17	better	well	ADJ
dpc-5570	205	18	disease	disease	NOUN
dpc-5570	205	19	course	course	NOUN
dpc-5570	205	20	of	of	ADP
dpc-5570	205	21	psa	psa	NOUN
dpc-5570	205	22	.	.	PUNCT
dpc-5570	206	1	it	it	PRON
dpc-5570	206	2	is	be	AUX
dpc-5570	206	3	important	important	ADJ
dpc-5570	206	4	to	to	PART
dpc-5570	206	5	point	point	VERB
dpc-5570	206	6	out	out	ADP
dpc-5570	206	7	that	that	PRON
dpc-5570	206	8	mean	mean	VERB
dpc-5570	206	9	baseline	baseline	NOUN
dpc-5570	206	10	score	score	NOUN
dpc-5570	206	11	of	of	ADP
dpc-5570	206	12	dapsa	dapsa	NOUN
dpc-5570	206	13	reflected	reflect	VERB
dpc-5570	206	14	just	just	ADV
dpc-5570	206	15	a	a	DET
dpc-5570	206	16	mild	mild	ADJ
dpc-5570	206	17	or	or	CCONJ
dpc-5570	206	18	moderate	moderate	ADJ
dpc-5570	206	19	activity	activity	NOUN
dpc-5570	206	20	of	of	ADP
dpc-5570	206	21	psa	psa	NOUN
dpc-5570	206	22	.	.	PUNCT
dpc-5570	206	23	anti	anti	ADJ
dpc-5570	206	24	-	-	ADJ
dpc-5570	206	25	tnf	tnf	ADJ
dpc-5570	206	26	-	-	PUNCT
dpc-5570	206	27	α	α	NOUN
dpc-5570	206	28	or	or	CCONJ
dpc-5570	206	29	anti	anti	ADJ
dpc-5570	206	30	-	-	ADJ
dpc-5570	206	31	il-17	il-17	ADJ
dpc-5570	206	32	antibodies	antibody	NOUN
dpc-5570	206	33	are	be	AUX
dpc-5570	206	34	generally	generally	ADV
dpc-5570	206	35	prescribed	prescribe	VERB
dpc-5570	206	36	to	to	ADP
dpc-5570	206	37	patients	patient	NOUN
dpc-5570	206	38	with	with	ADP
dpc-5570	206	39	axial	axial	ADJ
dpc-5570	206	40	involvement	involvement	NOUN
dpc-5570	206	41	of	of	ADP
dpc-5570	206	42	psoriatic	psoriatic	ADJ
dpc-5570	206	43	arthritis	arthritis	NOUN
dpc-5570	206	44	.	.	PUNCT
dpc-5570	207	1	accordingly	accordingly	ADV
dpc-5570	207	2	,	,	PUNCT
dpc-5570	207	3	no	no	DET
dpc-5570	207	4	patient	patient	NOUN
dpc-5570	207	5	with	with	ADP
dpc-5570	207	6	axial	axial	ADJ
dpc-5570	207	7	disease	disease	NOUN
dpc-5570	207	8	was	be	AUX
dpc-5570	207	9	treated	treat	VERB
dpc-5570	207	10	with	with	ADP
dpc-5570	207	11	tildrakizumab	tildrakizumab	NOUN
dpc-5570	207	12	or	or	CCONJ
dpc-5570	207	13	included	include	VERB
dpc-5570	207	14	in	in	ADP
dpc-5570	207	15	this	this	DET
dpc-5570	207	16	study	study	NOUN
dpc-5570	207	17	.	.	PUNCT
dpc-5570	208	1	in	in	ADP
dpc-5570	208	2	our	our	PRON
dpc-5570	208	3	clinical	clinical	ADJ
dpc-5570	208	4	practice	practice	NOUN
dpc-5570	208	5	,	,	PUNCT
dpc-5570	208	6	our	our	PRON
dpc-5570	208	7	choice	choice	NOUN
dpc-5570	208	8	of	of	ADP
dpc-5570	208	9	therapeutic	therapeutic	ADJ
dpc-5570	208	10	option	option	NOUN
dpc-5570	208	11	considers	consider	VERB
dpc-5570	208	12	firstly	firstly	ADV
dpc-5570	208	13	anti	anti	ADJ
dpc-5570	208	14	-	-	ADJ
dpc-5570	208	15	il-17	il-17	ADJ
dpc-5570	208	16	or	or	CCONJ
dpc-5570	208	17	anti	anti	ADJ
dpc-5570	208	18	-	-	ADJ
dpc-5570	208	19	tnf	tnf	ADJ
dpc-5570	208	20	-	-	PUNCT
dpc-5570	208	21	α	α	NOUN
dpc-5570	208	22	drugs	drug	NOUN
dpc-5570	208	23	in	in	ADP
dpc-5570	208	24	patients	patient	NOUN
dpc-5570	208	25	with	with	ADP
dpc-5570	208	26	a	a	DET
dpc-5570	208	27	history	history	NOUN
dpc-5570	208	28	of	of	ADP
dpc-5570	208	29	m	m	PROPN
dpc-5570	208	30	ea	ea	PROPN
dpc-5570	208	31	n	n	NUM
dpc-5570	208	32	va	va	NOUN
dpc-5570	208	33	lu	lu	PROPN
dpc-5570	208	34	es	es	VERB
dpc-5570	208	35	0	0	NUM
dpc-5570	208	36	5	5	NUM
dpc-5570	208	37	10	10	NUM
dpc-5570	208	38	15	15	NUM
dpc-5570	208	39	20	20	NUM
dpc-5570	208	40	25	25	NUM
dpc-5570	208	41	t0	t0	NUM
dpc-5570	208	42	t28	t28	NUM
dpc-5570	209	1	d	d	PROPN
dpc-5570	209	2	ap	ap	PROPN
dpc-5570	209	3	sa	sa	PROPN
dpc-5570	210	1	(	(	PUNCT
dpc-5570	210	2	m	m	VERB
dpc-5570	210	3	ae	ae	PROPN
dpc-5570	210	4	n	n	PROPN
dpc-5570	210	5	v	v	PROPN
dpc-5570	210	6	al	al	PROPN
dpc-5570	210	7	ue	ue	PROPN
dpc-5570	210	8	s	s	PROPN
dpc-5570	210	9	)	)	PUNCT
dpc-5570	210	10	figure	figure	NOUN
dpc-5570	210	11	3	3	NUM
dpc-5570	210	12	.	.	PUNCT
dpc-5570	210	13	bar	bar	NOUN
dpc-5570	210	14	graphs	graph	NOUN
dpc-5570	210	15	showed	show	VERB
dpc-5570	210	16	statistically	statistically	ADV
dpc-5570	210	17	significant	significant	ADJ
dpc-5570	210	18	differences	difference	NOUN
dpc-5570	210	19	recorded	record	VERB
dpc-5570	210	20	between	between	ADP
dpc-5570	210	21	t0	t0	PROPN
dpc-5570	210	22	and	and	CCONJ
dpc-5570	210	23	t28	t28	VERB
dpc-5570	210	24	for	for	ADP
dpc-5570	210	25	dapsa	dapsa	ADJ
dpc-5570	210	26	score	score	NOUN
dpc-5570	210	27	(	(	PUNCT
dpc-5570	210	28	20.75	20.75	NUM
dpc-5570	210	29	and	and	CCONJ
dpc-5570	210	30	3.75	3.75	NUM
dpc-5570	210	31	,	,	PUNCT
dpc-5570	210	32	respectively	respectively	ADV
dpc-5570	210	33	)	)	PUNCT
dpc-5570	210	34	.	.	PUNCT
dpc-5570	211	1	t	t	X
dpc-5570	211	2	-	-	PUNCT
dpc-5570	211	3	test	test	NOUN
dpc-5570	211	4	;	;	PUNCT
dpc-5570	211	5	p<0.000023	p<0.000023	NUM
dpc-5570	211	6	.	.	NOUN
dpc-5570	212	1	8	8	NUM
dpc-5570	212	2	original	original	ADJ
dpc-5570	212	3	article	article	NOUN
dpc-5570	212	4	|	|	ADV
dpc-5570	212	5	dermatol	dermatol	ADJ
dpc-5570	212	6	pract	pract	NOUN
dpc-5570	212	7	concept	concept	NOUN
dpc-5570	212	8	.	.	PUNCT
dpc-5570	213	1	2025;15(4):5570	2025;15(4):5570	NUM
dpc-5570	213	2	21	21	NUM
dpc-5570	213	3	.	.	PUNCT
dpc-5570	214	1	campione	campione	PROPN
dpc-5570	214	2	e	e	PROPN
dpc-5570	214	3	,	,	PUNCT
dpc-5570	214	4	lambiase	lambiase	PROPN
dpc-5570	214	5	s	s	PROPN
dpc-5570	214	6	,	,	PUNCT
dpc-5570	214	7	gaeta	gaeta	PROPN
dpc-5570	214	8	shumak	shumak	PROPN
dpc-5570	214	9	r	r	PROPN
dpc-5570	214	10	,	,	PUNCT
dpc-5570	214	11	et	et	PROPN
dpc-5570	214	12	al	al	PROPN
dpc-5570	214	13	.	.	PROPN
dpc-5570	214	14	pharmaceuticals	pharmaceuticals	PROPN
dpc-5570	214	15	(	(	PUNCT
dpc-5570	214	16	basel	basel	PROPN
dpc-5570	214	17	)	)	PUNCT
dpc-5570	214	18	.	.	PUNCT
dpc-5570	215	1	2023;16:526	2023;16:526	X
dpc-5570	215	2	.	.	PUNCT
dpc-5570	215	3	doi:10.3390	doi:10.3390	PROPN
dpc-5570	215	4	/	/	SYM
dpc-5570	215	5	ph16040526	ph16040526	PROPN
dpc-5570	215	6	.	.	PUNCT
dpc-5570	216	1	pmid:37039171	pmid:37039171	VERB
dpc-5570	216	2	22	22	NUM
dpc-5570	216	3	.	.	PUNCT
dpc-5570	217	1	blauvelt	blauvelt	VERB
dpc-5570	217	2	a	a	DET
dpc-5570	217	3	,	,	PUNCT
dpc-5570	217	4	chiricozzi	chiricozzi	NOUN
dpc-5570	217	5	a	a	NOUN
dpc-5570	217	6	,	,	PUNCT
dpc-5570	217	7	ehst	ehst	NOUN
dpc-5570	217	8	bd	bd	PROPN
dpc-5570	217	9	,	,	PUNCT
dpc-5570	217	10	lebwohl	lebwohl	VERB
dpc-5570	217	11	mg	mg	PROPN
dpc-5570	217	12	.	.	PUNCT
dpc-5570	218	1	adv	adv	INTJ
dpc-5570	218	2	ther	ther	ADV
dpc-5570	218	3	.	.	PUNCT
dpc-5570	219	1	2023;40:3410–3433	2023;40:3410–3433	NUM
dpc-5570	219	2	.	.	PUNCT
dpc-5570	219	3	doi:10.1007	doi:10.1007	PROPN
dpc-5570	219	4	/	/	SYM
dpc-5570	219	5	s12325	s12325	PROPN
dpc-5570	219	6	-	-	PUNCT
dpc-5570	219	7	023	023	NUM
dpc-5570	219	8	-	-	PUNCT
dpc-5570	219	9	02568	02568	NUM
dpc-5570	219	10	-	-	PUNCT
dpc-5570	219	11	0	0	NUM
dpc-5570	219	12	.	.	PUNCT
dpc-5570	220	1	pmid:36926097	pmid:36926097	ADP
dpc-5570	220	2	23	23	NUM
dpc-5570	220	3	.	.	PUNCT
dpc-5570	221	1	menter	menter	PROPN
dpc-5570	221	2	ma	ma	PROPN
dpc-5570	221	3	,	,	PUNCT
dpc-5570	221	4	mehta	mehta	PROPN
dpc-5570	221	5	n	n	CCONJ
dpc-5570	221	6	,	,	PUNCT
dpc-5570	221	7	lebwohl	lebwohl	PROPN
dpc-5570	221	8	m	m	PROPN
dpc-5570	221	9	,	,	PUNCT
dpc-5570	221	10	et	et	PROPN
dpc-5570	221	11	al	al	PROPN
dpc-5570	221	12	.	.	PUNCT
dpc-5570	222	1	j	j	PROPN
dpc-5570	222	2	drugs	drugs	PROPN
dpc-5570	222	3	dermatol	dermatol	NOUN
dpc-5570	222	4	.	.	PUNCT
dpc-5570	223	1	2020;19:703–708	2020;19:703–708	X
dpc-5570	223	2	.	.	PUNCT
dpc-5570	224	1	doi:10.36849	doi:10.36849	PROPN
dpc-5570	224	2	/	/	SYM
dpc-5570	224	3	jdd.2020.5337	jdd.2020.5337	PROPN
dpc-5570	224	4	.	.	PUNCT
dpc-5570	225	1	pmid	pmid	NOUN
dpc-5570	225	2	:	:	PUNCT
dpc-5570	225	3	32522035	32522035	NUM
dpc-5570	225	4	24	24	NUM
dpc-5570	225	5	.	.	PUNCT
dpc-5570	226	1	gisondi	gisondi	PROPN
dpc-5570	226	2	p	p	NOUN
dpc-5570	226	3	,	,	PUNCT
dpc-5570	226	4	fargnoli	fargnoli	PROPN
dpc-5570	226	5	mc	mc	PROPN
dpc-5570	226	6	,	,	PUNCT
dpc-5570	226	7	amerio	amerio	ADP
dpc-5570	226	8	p	p	X
dpc-5570	226	9	,	,	PUNCT
dpc-5570	226	10	et	et	PROPN
dpc-5570	226	11	al	al	PROPN
dpc-5570	226	12	.	.	PROPN
dpc-5570	226	13	ital	ital	PROPN
dpc-5570	226	14	j	j	PROPN
dpc-5570	226	15	dermatol	dermatol	NOUN
dpc-5570	226	16	venereol	venereol	ADV
dpc-5570	226	17	.	.	PUNCT
dpc-5570	227	1	2022;157	2022;157	NOUN
dpc-5570	227	2	.	.	PUNCT
dpc-5570	228	1	doi:10.23736	doi:10.23736	PROPN
dpc-5570	228	2	/	/	SYM
dpc-5570	228	3	s2784	s2784	PROPN
dpc-5570	228	4	-	-	PUNCT
dpc-5570	228	5	8671.21.07132	8671.21.07132	NUM
dpc-5570	228	6	-	-	SYM
dpc-5570	228	7	2	2	NUM
dpc-5570	228	8	.	.	PUNCT
dpc-5570	228	9	pmid	pmid	NOUN
dpc-5570	228	10	:	:	PUNCT
dpc-5570	228	11	n	n	CCONJ
dpc-5570	228	12	/	/	SYM
dpc-5570	228	13	a	a	DET
dpc-5570	228	14	25	25	NUM
dpc-5570	228	15	.	.	PUNCT
dpc-5570	229	1	campione	campione	PROPN
dpc-5570	229	2	e	e	PROPN
dpc-5570	229	3	,	,	PUNCT
dpc-5570	229	4	zarabian	zarabian	PROPN
dpc-5570	229	5	n	n	CCONJ
dpc-5570	229	6	,	,	PUNCT
dpc-5570	229	7	cosio	cosio	PROPN
dpc-5570	229	8	t	t	PROPN
dpc-5570	229	9	,	,	PUNCT
dpc-5570	229	10	et	et	PROPN
dpc-5570	229	11	al	al	PROPN
dpc-5570	229	12	.	.	PROPN
dpc-5570	229	13	pharmaceuticals	pharmaceuticals	PROPN
dpc-5570	229	14	(	(	PUNCT
dpc-5570	229	15	basel	basel	PROPN
dpc-5570	229	16	)	)	PUNCT
dpc-5570	229	17	.	.	PUNCT
dpc-5570	230	1	2024;17:989	2024;17:989	X
dpc-5570	230	2	.	.	PUNCT
dpc-5570	231	1	doi:10.3390	doi:10.3390	PROPN
dpc-5570	231	2	/	/	SYM
dpc-5570	231	3	ph17080989	ph17080989	PROPN
dpc-5570	231	4	.	.	PUNCT
dpc-5570	232	1	pmid:37487912	pmid:37487912	PROPN
dpc-5570	232	2	26	26	NUM
dpc-5570	232	3	.	.	PUNCT
dpc-5570	233	1	wervers	werver	NOUN
dpc-5570	233	2	k	k	PROPN
dpc-5570	233	3	,	,	PUNCT
dpc-5570	233	4	vis	vis	X
dpc-5570	233	5	m	m	PROPN
dpc-5570	233	6	,	,	PUNCT
dpc-5570	233	7	tchetveriko	tchetveriko	NOUN
dpc-5570	233	8	i	i	PRON
dpc-5570	233	9	,	,	PUNCT
dpc-5570	233	10	et	et	PROPN
dpc-5570	233	11	al	al	PROPN
dpc-5570	233	12	.	.	PUNCT
dpc-5570	234	1	arthritis	arthritis	NOUN
dpc-5570	234	2	care	care	NOUN
dpc-5570	234	3	res	re	NOUN
dpc-5570	234	4	(	(	PUNCT
dpc-5570	234	5	hoboken	hoboken	PROPN
dpc-5570	234	6	)	)	PUNCT
dpc-5570	234	7	.	.	PUNCT
dpc-5570	235	1	2018;70:1764–1770	2018;70:1764–1770	NOUN
dpc-5570	235	2	.	.	PUNCT
dpc-5570	235	3	doi:10.1002	doi:10.1002	NOUN
dpc-5570	235	4	/	/	SYM
dpc-5570	235	5	acr.23571	acr.23571	PROPN
dpc-5570	235	6	.	.	PUNCT
dpc-5570	236	1	pmid	pmid	NOUN
dpc-5570	236	2	:	:	PUNCT
dpc-5570	236	3	29703795	29703795	NUM
dpc-5570	236	4	27	27	NUM
dpc-5570	236	5	.	.	PUNCT
dpc-5570	237	1	mease	mease	PROPN
dpc-5570	238	1	pj	pj	PROPN
dpc-5570	238	2	.	.	PUNCT
dpc-5570	238	3	arthritis	arthritis	PROPN
dpc-5570	238	4	care	care	NOUN
dpc-5570	238	5	res	re	NOUN
dpc-5570	238	6	(	(	PUNCT
dpc-5570	238	7	hoboken	hoboken	PROPN
dpc-5570	238	8	)	)	PUNCT
dpc-5570	238	9	.	.	PUNCT
dpc-5570	239	1	2011;63(suppl	2011;63(suppl	PROPN
dpc-5570	239	2	11):s64	11):s64	NUM
dpc-5570	239	3	–	–	PUNCT
dpc-5570	239	4	s85	s85	PROPN
dpc-5570	239	5	.	.	PUNCT
dpc-5570	239	6	doi:10.1002	doi:10.1002	PROPN
dpc-5570	239	7	/	/	SYM
dpc-5570	239	8	acr.20577	acr.20577	PROPN
dpc-5570	239	9	.	.	PUNCT
dpc-5570	240	1	pmid:21903950	pmid:21903950	PROPN
dpc-5570	240	2	28	28	NUM
dpc-5570	240	3	.	.	PUNCT
dpc-5570	241	1	taylor	taylor	PROPN
dpc-5570	241	2	w	w	PROPN
dpc-5570	241	3	,	,	PUNCT
dpc-5570	241	4	gladman	gladman	NOUN
dpc-5570	241	5	d	d	NOUN
dpc-5570	241	6	,	,	PUNCT
dpc-5570	241	7	helliwell	helliwell	NOUN
dpc-5570	241	8	p	p	NOUN
dpc-5570	241	9	,	,	PUNCT
dpc-5570	241	10	marchesoni	marchesoni	NOUN
dpc-5570	241	11	a	a	NOUN
dpc-5570	241	12	,	,	PUNCT
dpc-5570	241	13	mease	mease	ADJ
dpc-5570	241	14	p	p	NOUN
dpc-5570	241	15	,	,	PUNCT
dpc-5570	241	16	mielants	mielant	NOUN
dpc-5570	241	17	h	h	NOUN
dpc-5570	241	18	;	;	PUNCT
dpc-5570	241	19	caspar	caspar	PROPN
dpc-5570	241	20	study	study	PROPN
dpc-5570	241	21	group	group	NOUN
dpc-5570	241	22	.	.	PUNCT
dpc-5570	242	1	arthritis	arthritis	NOUN
dpc-5570	242	2	rheum	rheum	NOUN
dpc-5570	242	3	.	.	PUNCT
dpc-5570	243	1	2006;54:2665–2673	2006;54:2665–2673	PROPN
dpc-5570	243	2	.	.	PUNCT
dpc-5570	244	1	doi:10.1002	doi:10.1002	NOUN
dpc-5570	244	2	/	/	SYM
dpc-5570	244	3	art.21972	art.21972	PROPN
dpc-5570	244	4	.	.	PUNCT
dpc-5570	245	1	pmid:16940859	pmid:16940859	PROPN
dpc-5570	245	2	29	29	NUM
dpc-5570	245	3	.	.	PUNCT
dpc-5570	246	1	umezawa	umezawa	PROPN
dpc-5570	246	2	y.	y.	PROPN
dpc-5570	246	3	j	j	PROPN
dpc-5570	246	4	dermatol	dermatol	NOUN
dpc-5570	246	5	.	.	PUNCT
dpc-5570	247	1	2021;48:741–749	2021;48:741–749	NUM
dpc-5570	247	2	.	.	PUNCT
dpc-5570	248	1	doi:10.1111/13468138.15954	doi:10.1111/13468138.15954	PROPN
dpc-5570	248	2	.	.	PUNCT
dpc-5570	249	1	pmid:33716440	pmid:33716440	NOUN
dpc-5570	249	2	30	30	NUM
dpc-5570	249	3	.	.	PUNCT
dpc-5570	250	1	chao	chao	PROPN
dpc-5570	250	2	r	r	PROPN
dpc-5570	250	3	,	,	PUNCT
dpc-5570	250	4	kavanaugh	kavanaugh	PROPN
dpc-5570	250	5	a.	a.	PROPN
dpc-5570	250	6	curr	curr	PROPN
dpc-5570	250	7	rheumatol	rheumatol	PROPN
dpc-5570	250	8	rep	rep	PROPN
dpc-5570	250	9	.	.	PROPN
dpc-5570	250	10	2019;21:75	2019;21:75	NUM
dpc-5570	250	11	.	.	PUNCT
dpc-5570	250	12	doi:10.1007	doi:10.1007	VERB
dpc-5570	250	13	/	/	SYM
dpc-5570	250	14	s11926	s11926	NOUN
dpc-5570	250	15	-	-	PUNCT
dpc-5570	250	16	019	019	NUM
dpc-5570	250	17	-	-	PUNCT
dpc-5570	250	18	0866	0866	NUM
dpc-5570	250	19	-	-	PUNCT
dpc-5570	250	20	1	1	NUM
dpc-5570	250	21	.	.	NOUN
dpc-5570	250	22	pmid:31635214	pmid:31635214	PRON
dpc-5570	250	23	31	31	NUM
dpc-5570	250	24	.	.	PUNCT
dpc-5570	251	1	ishchenko	ishchenko	PROPN
dpc-5570	251	2	a	a	PRON
dpc-5570	251	3	,	,	PUNCT
dpc-5570	251	4	pazmino	pazmino	NOUN
dpc-5570	251	5	s	s	PART
dpc-5570	251	6	,	,	PUNCT
dpc-5570	251	7	neerinckx	neerinckx	PROPN
dpc-5570	251	8	b	b	NUM
dpc-5570	251	9	,	,	PUNCT
dpc-5570	251	10	lories	lory	NOUN
dpc-5570	251	11	r	r	NOUN
dpc-5570	251	12	,	,	PUNCT
dpc-5570	251	13	de	de	X
dpc-5570	251	14	vlam	vlam	PROPN
dpc-5570	251	15	k.	k.	PROPN
dpc-5570	251	16	arthritis	arthritis	PROPN
dpc-5570	251	17	care	care	NOUN
dpc-5570	251	18	res	re	NOUN
dpc-5570	251	19	(	(	PUNCT
dpc-5570	251	20	hoboken	hoboken	PROPN
dpc-5570	251	21	)	)	PUNCT
dpc-5570	251	22	.	.	PUNCT
dpc-5570	252	1	2023	2023	NUM
dpc-5570	252	2	.	.	PUNCT
dpc-5570	253	1	doi:10.1002	doi:10.1002	NOUN
dpc-5570	253	2	/	/	SYM
dpc-5570	253	3	acr.25230	acr.25230	PROPN
dpc-5570	253	4	.	.	PUNCT
dpc-5570	253	5	pmid:36793107	pmid:36793107	VERB
dpc-5570	253	6	32	32	NUM
dpc-5570	253	7	.	.	PUNCT
dpc-5570	254	1	fitzgerald	fitzgerald	PROPN
dpc-5570	254	2	o	o	PROPN
dpc-5570	254	3	,	,	PUNCT
dpc-5570	254	4	ogdie	ogdie	VERB
dpc-5570	254	5	a	a	PRON
dpc-5570	254	6	,	,	PUNCT
dpc-5570	254	7	chandran	chandran	PROPN
dpc-5570	254	8	v	v	PROPN
dpc-5570	254	9	,	,	PUNCT
dpc-5570	254	10	et	et	PROPN
dpc-5570	254	11	al	al	PROPN
dpc-5570	254	12	.	.	PUNCT
dpc-5570	255	1	nat	nat	PROPN
dpc-5570	255	2	rev	rev	VERB
dpc-5570	255	3	dis	dis	PROPN
dpc-5570	255	4	primers	primer	NOUN
dpc-5570	255	5	.	.	PUNCT
dpc-5570	256	1	2021;7:59	2021;7:59	PROPN
dpc-5570	256	2	.	.	PUNCT
dpc-5570	257	1	doi:10.1038	doi:10.1038	PROPN
dpc-5570	257	2	/	/	SYM
dpc-5570	257	3	s41572	s41572	NOUN
dpc-5570	257	4	-	-	PUNCT
dpc-5570	257	5	021	021	NUM
dpc-5570	257	6	-	-	PUNCT
dpc-5570	257	7	00293	00293	NUM
dpc-5570	257	8	-	-	PUNCT
dpc-5570	257	9	y.	y.	NOUN
dpc-5570	257	10	pmid	pmid	PROPN
dpc-5570	257	11	:	:	PUNCT
dpc-5570	257	12	33930422	33930422	NUM
dpc-5570	257	13	33	33	NUM
dpc-5570	257	14	.	.	PUNCT
dpc-5570	258	1	cauli	cauli	PROPN
dpc-5570	258	2	a	a	PROPN
dpc-5570	258	3	,	,	PUNCT
dpc-5570	258	4	gladman	gladman	NOUN
dpc-5570	258	5	dd	dd	PROPN
dpc-5570	258	6	,	,	PUNCT
dpc-5570	258	7	mathieu	mathieu	PROPN
dpc-5570	258	8	a	a	PROPN
dpc-5570	258	9	,	,	PUNCT
dpc-5570	258	10	et	et	PROPN
dpc-5570	258	11	al	al	PROPN
dpc-5570	258	12	.	.	PUNCT
dpc-5570	259	1	j	j	PROPN
dpc-5570	259	2	rheumatol	rheumatol	NOUN
dpc-5570	259	3	.	.	PUNCT
dpc-5570	260	1	2018;45:1256–1262	2018;45:1256–1262	NOUN
dpc-5570	260	2	.	.	PUNCT
dpc-5570	261	1	doi:10.3899	doi:10.3899	NOUN
dpc-5570	261	2	/	/	SYM
dpc-5570	261	3	jrheum.171183	jrheum.171183	PROPN
dpc-5570	261	4	.	.	PUNCT
dpc-5570	262	1	pmid	pmid	PROPN
dpc-5570	262	2	:	:	PUNCT
dpc-5570	262	3	29587325	29587325	NUM
dpc-5570	262	4	34	34	NUM
dpc-5570	262	5	.	.	PUNCT
dpc-5570	263	1	duffin	duffin	PROPN
dpc-5570	263	2	kc	kc	PROPN
dpc-5570	263	3	,	,	PUNCT
dpc-5570	263	4	mazzuoccolo	mazzuoccolo	PROPN
dpc-5570	263	5	ld	ld	PROPN
dpc-5570	263	6	,	,	PUNCT
dpc-5570	263	7	cura	cura	PROPN
dpc-5570	263	8	mj	mj	PROPN
dpc-5570	263	9	,	,	PUNCT
dpc-5570	263	10	et	et	PROPN
dpc-5570	263	11	al	al	PROPN
dpc-5570	263	12	.	.	PUNCT
dpc-5570	264	1	j	j	PROPN
dpc-5570	264	2	rheumatol	rheumatol	NOUN
dpc-5570	264	3	.	.	PUNCT
dpc-5570	265	1	2023;50:131–143	2023;50:131–143	ADJ
dpc-5570	265	2	.	.	PUNCT
dpc-5570	266	1	doi:10.3899	doi:10.3899	NOUN
dpc-5570	266	2	/	/	SYM
dpc-5570	267	1	jrheum.220316	jrheum.220316	PROPN
dpc-5570	267	2	.	.	PUNCT
dpc-5570	268	1	pmid	pmid	PROPN
dpc-5570	268	2	:	:	PUNCT
dpc-5570	268	3	36514963	36514963	NUM
dpc-5570	268	4	35	35	NUM
dpc-5570	268	5	.	.	PUNCT
dpc-5570	269	1	aljohani	aljohani	PROPN
dpc-5570	269	2	r.	r.	PROPN
dpc-5570	269	3	open	open	PROPN
dpc-5570	269	4	access	access	PROPN
dpc-5570	269	5	rheumatol	rheumatol	NOUN
dpc-5570	269	6	res	re	NOUN
dpc-5570	269	7	rev	rev	PROPN
dpc-5570	269	8	.	.	PROPN
dpc-5570	269	9	2022;14:7–16	2022;14:7–16	PROPN
dpc-5570	269	10	.	.	PUNCT
dpc-5570	270	1	doi:10.2147	doi:10.2147	NOUN
dpc-5570	270	2	/	/	SYM
dpc-5570	270	3	oarrr.s347797	oarrr.s347797	NOUN
dpc-5570	270	4	.	.	PUNCT
dpc-5570	271	1	pmid	pmid	NOUN
dpc-5570	271	2	:	:	PUNCT
dpc-5570	271	3	n	n	CCONJ
dpc-5570	271	4	/	/	SYM
dpc-5570	271	5	a	a	DET
dpc-5570	271	6	36	36	NUM
dpc-5570	271	7	.	.	PUNCT
dpc-5570	272	1	nast	nast	PROPN
dpc-5570	272	2	a	a	PRON
dpc-5570	272	3	,	,	PUNCT
dpc-5570	272	4	spuls	spuls	PROPN
dpc-5570	272	5	pi	pi	NOUN
dpc-5570	272	6	,	,	PUNCT
dpc-5570	272	7	dressler	dressler	PROPN
dpc-5570	272	8	c	c	PROPN
dpc-5570	272	9	,	,	PUNCT
dpc-5570	272	10	et	et	PROPN
dpc-5570	272	11	al	al	PROPN
dpc-5570	272	12	.	.	PROPN
dpc-5570	273	1	euroguiderm	euroguiderm	PROPN
dpc-5570	273	2	guideline	guideline	NOUN
dpc-5570	273	3	for	for	ADP
dpc-5570	273	4	the	the	DET
dpc-5570	273	5	systemic	systemic	ADJ
dpc-5570	273	6	treatment	treatment	NOUN
dpc-5570	273	7	of	of	ADP
dpc-5570	273	8	psoriasis	psoriasis	NOUN
dpc-5570	273	9	vulgaris	vulgaris	NOUN
dpc-5570	273	10	.	.	PUNCT
dpc-5570	274	1	september	september	PROPN
dpc-5570	274	2	2023	2023	NUM
dpc-5570	274	3	,	,	PUNCT
dpc-5570	274	4	revised	revise	VERB
dpc-5570	274	5	march	march	PROPN
dpc-5570	274	6	2024	2024	NUM
dpc-5570	274	7	.	.	PUNCT
dpc-5570	275	1	pmid	pmid	NOUN
dpc-5570	275	2	:	:	PUNCT
dpc-5570	275	3	n	n	CCONJ
dpc-5570	275	4	/	/	SYM
dpc-5570	275	5	a.	a.	NOUN
dpc-5570	275	6	doi	doi	PROPN
dpc-5570	275	7	:	:	PUNCT
dpc-5570	275	8	n	n	CCONJ
dpc-5570	275	9	/	/	SYM
dpc-5570	275	10	a	a	DET
dpc-5570	275	11	37	37	NUM
dpc-5570	275	12	.	.	PUNCT
dpc-5570	276	1	bellinato	bellinato	PROPN
dpc-5570	276	2	f	f	PROPN
dpc-5570	276	3	,	,	PUNCT
dpc-5570	276	4	maurelli	maurelli	PROPN
dpc-5570	276	5	m	m	PROPN
dpc-5570	276	6	,	,	PUNCT
dpc-5570	276	7	geat	geat	PROPN
dpc-5570	276	8	d	d	NOUN
dpc-5570	276	9	,	,	PUNCT
dpc-5570	276	10	girolomoni	girolomoni	VERB
dpc-5570	276	11	g	g	NOUN
dpc-5570	276	12	,	,	PUNCT
dpc-5570	276	13	gisondi	gisondi	ADJ
dpc-5570	276	14	p.	p.	PROPN
dpc-5570	276	15	am	be	AUX
dpc-5570	276	16	j	j	PROPN
dpc-5570	276	17	clin	clin	PROPN
dpc-5570	276	18	dermatol	dermatol	NOUN
dpc-5570	276	19	.	.	PUNCT
dpc-5570	277	1	2024;25:527–540	2024;25:527–540	NUM
dpc-5570	277	2	.	.	PUNCT
dpc-5570	278	1	doi:10.1007	doi:10.1007	PROPN
dpc-5570	278	2	/	/	SYM
dpc-5570	278	3	s40257	s40257	NOUN
dpc-5570	278	4	-	-	PUNCT
dpc-5570	278	5	024	024	NUM
dpc-5570	278	6	-00857	-00857	NOUN
dpc-5570	278	7	-	-	PUNCT
dpc-5570	278	8	0	0	NUM
dpc-5570	278	9	.	.	NOUN
dpc-5570	278	10	pmid:37643328	pmid:37643328	PROPN
dpc-5570	278	11	38	38	NUM
dpc-5570	278	12	.	.	PUNCT
dpc-5570	279	1	yamanaka	yamanaka	PROPN
dpc-5570	279	2	-	-	PUNCT
dpc-5570	279	3	takaichi	takaichi	PROPN
dpc-5570	279	4	m	m	PROPN
dpc-5570	279	5	,	,	PUNCT
dpc-5570	279	6	ghanian	ghanian	PROPN
dpc-5570	279	7	s	s	PROPN
dpc-5570	279	8	,	,	PUNCT
dpc-5570	279	9	katzka	katzka	PROPN
dpc-5570	279	10	da	da	PROPN
dpc-5570	279	11	,	,	PUNCT
dpc-5570	279	12	torgerson	torgerson	PROPN
dpc-5570	279	13	rr	rr	PROPN
dpc-5570	279	14	,	,	PUNCT
dpc-5570	279	15	alavi	alavi	PROPN
dpc-5570	279	16	a.	a.	PROPN
dpc-5570	279	17	am	am	PROPN
dpc-5570	279	18	j	j	PROPN
dpc-5570	279	19	clin	clin	PROPN
dpc-5570	279	20	dermatol	dermatol	NOUN
dpc-5570	279	21	.	.	PUNCT
dpc-5570	280	1	2022;23:469–480	2022;23:469–480	PROPN
dpc-5570	280	2	.	.	PUNCT
dpc-5570	280	3	doi:10.1007	doi:10.1007	PROPN
dpc-5570	280	4	/s40257	/s40257	PROPN
dpc-5570	280	5	-	-	PUNCT
dpc-5570	280	6	022	022	NUM
dpc-5570	280	7	-	-	PUNCT
dpc-5570	280	8	00686	00686	NUM
dpc-5570	280	9	-	-	PUNCT
dpc-5570	280	10	z.	z.	NOUN
dpc-5570	280	11	pmid:35703936	pmid:35703936	PROPN
dpc-5570	280	12	39	39	NUM
dpc-5570	280	13	.	.	PUNCT
dpc-5570	281	1	european	european	ADJ
dpc-5570	281	2	medicines	medicine	NOUN
dpc-5570	281	3	agency	agency	NOUN
dpc-5570	281	4	.	.	PUNCT
dpc-5570	282	1	ilumetri	ilumetri	ADJ
dpc-5570	282	2	:	:	PUNCT
dpc-5570	282	3	epar	epar	NOUN
dpc-5570	282	4	product	product	NOUN
dpc-5570	282	5	information	information	NOUN
dpc-5570	282	6	.	.	PUNCT
dpc-5570	283	1	https://www.ema.europa.eu/en/medicines/human/epar/	https://www.ema.europa.eu/en/medicines/human/epar/	PROPN
dpc-5570	283	2	ilumetri	ilumetri	ADJ
dpc-5570	283	3	40	40	NUM
dpc-5570	283	4	.	.	PUNCT
dpc-5570	284	1	reich	reich	PROPN
dpc-5570	284	2	k	k	PROPN
dpc-5570	284	3	,	,	PUNCT
dpc-5570	284	4	papp	papp	PROPN
dpc-5570	284	5	ka	ka	PROPN
dpc-5570	284	6	,	,	PUNCT
dpc-5570	284	7	blauvelt	blauvelt	VERB
dpc-5570	284	8	a	a	PRON
dpc-5570	284	9	,	,	PUNCT
dpc-5570	284	10	et	et	PROPN
dpc-5570	284	11	al	al	PROPN
dpc-5570	284	12	.	.	PUNCT
dpc-5570	284	13	lancet	lancet	PROPN
dpc-5570	284	14	.	.	PUNCT
dpc-5570	285	1	2017;390:276–288	2017;390:276–288	NUM
dpc-5570	285	2	.	.	PUNCT
dpc-5570	286	1	doi:10.1016	doi:10.1016	PROPN
dpc-5570	286	2	/	/	SYM
dpc-5570	286	3	s0140	s0140	PROPN
dpc-5570	286	4	-	-	PUNCT
dpc-5570	286	5	6736(17)31279	6736(17)31279	NUM
dpc-5570	286	6	-	-	SYM
dpc-5570	286	7	5	5	NUM
dpc-5570	286	8	.	.	PUNCT
dpc-5570	286	9	pmid:28689501	pmid:28689501	VERB
dpc-5570	286	10	references	reference	NOUN
dpc-5570	286	11	1	1	NUM
dpc-5570	286	12	.	.	PUNCT
dpc-5570	287	1	zhou	zhou	PROPN
dpc-5570	287	2	x	x	PROPN
dpc-5570	287	3	,	,	PUNCT
dpc-5570	287	4	chen	chen	PROPN
dpc-5570	287	5	y	y	PROPN
dpc-5570	287	6	,	,	PUNCT
dpc-5570	287	7	cui	cui	PROPN
dpc-5570	287	8	l	l	PROPN
dpc-5570	287	9	,	,	PUNCT
dpc-5570	287	10	shi	shi	PROPN
dpc-5570	287	11	y	y	PROPN
dpc-5570	287	12	,	,	PUNCT
dpc-5570	287	13	guo	guo	PROPN
dpc-5570	287	14	c.	c.	PROPN
dpc-5570	287	15	cell	cell	PROPN
dpc-5570	287	16	death	death	NOUN
dpc-5570	288	1	dis	dis	PROPN
dpc-5570	288	2	.	.	PUNCT
dpc-5570	289	1	2022;13:81	2022;13:81	NOUN
dpc-5570	289	2	.	.	PUNCT
dpc-5570	290	1	doi:10.1038	doi:10.1038	NOUN
dpc-5570	290	2	/	/	SYM
dpc-5570	290	3	s41419	s41419	PROPN
dpc-5570	290	4	-	-	NOUN
dpc-5570	290	5	022	022	NUM
dpc-5570	290	6	-	-	PUNCT
dpc-5570	290	7	04523	04523	NUM
dpc-5570	290	8	-	-	SYM
dpc-5570	290	9	3	3	NUM
dpc-5570	290	10	.	.	PUNCT
dpc-5570	290	11	pmid:35075118	pmid:35075118	PROPN
dpc-5570	290	12	2	2	NUM
dpc-5570	290	13	.	.	PUNCT
dpc-5570	291	1	hawkes	hawkes	PROPN
dpc-5570	291	2	je	je	PROPN
dpc-5570	291	3	,	,	PUNCT
dpc-5570	291	4	yan	yan	PROPN
dpc-5570	291	5	by	by	ADP
dpc-5570	291	6	,	,	PUNCT
dpc-5570	291	7	chan	chan	PROPN
dpc-5570	291	8	tc	tc	PROPN
dpc-5570	291	9	,	,	PUNCT
dpc-5570	291	10	krueger	krueger	PROPN
dpc-5570	291	11	jg	jg	PROPN
dpc-5570	291	12	.	.	PUNCT
dpc-5570	292	1	j	j	PROPN
dpc-5570	292	2	immunol	immunol	NOUN
dpc-5570	292	3	.	.	PUNCT
dpc-5570	293	1	2018;201:1605–1613	2018;201:1605–1613	NUM
dpc-5570	293	2	.	.	PUNCT
dpc-5570	294	1	doi:10.4049	doi:10.4049	PROPN
dpc-5570	294	2	/	/	SYM
dpc-5570	294	3	jimmunol.1800013	jimmunol.1800013	PROPN
dpc-5570	294	4	.	.	PUNCT
dpc-5570	294	5	pmid	pmid	PROPN
dpc-5570	294	6	:	:	PUNCT
dpc-5570	294	7	30181299	30181299	NUM
dpc-5570	294	8	3	3	NUM
dpc-5570	294	9	.	.	PUNCT
dpc-5570	295	1	martin	martin	PROPN
dpc-5570	295	2	da	da	PROPN
dpc-5570	295	3	,	,	PUNCT
dpc-5570	295	4	towne	towne	PROPN
dpc-5570	295	5	je	je	PROPN
dpc-5570	295	6	,	,	PUNCT
dpc-5570	295	7	kricorian	kricorian	PROPN
dpc-5570	295	8	g	g	PROPN
dpc-5570	295	9	,	,	PUNCT
dpc-5570	295	10	et	et	PROPN
dpc-5570	295	11	al	al	PROPN
dpc-5570	295	12	.	.	PUNCT
dpc-5570	296	1	j	j	PROPN
dpc-5570	296	2	invest	invest	VERB
dpc-5570	296	3	dermatol	dermatol	NOUN
dpc-5570	296	4	.	.	PUNCT
dpc-5570	297	1	2013;133:17–26	2013;133:17–26	NUM
dpc-5570	297	2	.	.	PUNCT
dpc-5570	297	3	doi:10.1038	doi:10.1038	PROPN
dpc-5570	297	4	/	/	SYM
dpc-5570	297	5	jid.2012.194	jid.2012.194	PROPN
dpc-5570	297	6	.	.	PUNCT
dpc-5570	297	7	pmid:22673731	pmid:22673731	VERB
dpc-5570	298	1	4	4	NUM
dpc-5570	298	2	.	.	X
dpc-5570	299	1	chan	chan	PROPN
dpc-5570	299	2	tc	tc	PROPN
dpc-5570	299	3	,	,	PUNCT
dpc-5570	299	4	hawkes	hawkes	PROPN
dpc-5570	299	5	je	je	PROPN
dpc-5570	299	6	,	,	PUNCT
dpc-5570	299	7	krueger	krueger	PROPN
dpc-5570	299	8	jg	jg	PROPN
dpc-5570	299	9	.	.	PUNCT
dpc-5570	300	1	ther	ther	PROPN
dpc-5570	300	2	adv	adv	PROPN
dpc-5570	300	3	chronic	chronic	ADJ
dpc-5570	300	4	dis	dis	PROPN
dpc-5570	300	5	.	.	PUNCT
dpc-5570	301	1	2018;9:111–119	2018;9:111–119	X
dpc-5570	301	2	.	.	PUNCT
dpc-5570	301	3	doi:10.1177/2040622318759282	doi:10.1177/2040622318759282	PROPN
dpc-5570	301	4	.	.	PUNCT
dpc-5570	302	1	pmid:29796240	pmid:29796240	NOUN
dpc-5570	302	2	5	5	NUM
dpc-5570	302	3	.	.	PUNCT
dpc-5570	303	1	yago	yago	PROPN
dpc-5570	303	2	t	t	PROPN
dpc-5570	303	3	,	,	PUNCT
dpc-5570	303	4	nanke	nanke	PROPN
dpc-5570	303	5	y	y	PROPN
dpc-5570	303	6	,	,	PUNCT
dpc-5570	303	7	kawamoto	kawamoto	NOUN
dpc-5570	303	8	m	m	PROPN
dpc-5570	303	9	,	,	PUNCT
dpc-5570	303	10	kobashigawa	kobashigawa	PROPN
dpc-5570	303	11	t	t	PROPN
dpc-5570	303	12	,	,	PUNCT
dpc-5570	303	13	yamanaka	yamanaka	PROPN
dpc-5570	303	14	h	h	PROPN
dpc-5570	303	15	,	,	PUNCT
dpc-5570	303	16	kotake	kotake	PROPN
dpc-5570	303	17	s.	s.	PROPN
dpc-5570	303	18	j	j	PROPN
dpc-5570	303	19	clin	clin	PROPN
dpc-5570	303	20	med	med	PROPN
dpc-5570	303	21	.	.	PUNCT
dpc-5570	303	22	2017;6:81	2017;6:81	PROPN
dpc-5570	303	23	.	.	PUNCT
dpc-5570	304	1	doi:10.3390	doi:10.3390	PROPN
dpc-5570	304	2	/	/	SYM
dpc-5570	304	3	jcm6090081	jcm6090081	PROPN
dpc-5570	304	4	.	.	PUNCT
dpc-5570	305	1	pmid:28850053	pmid:28850053	PROPN
dpc-5570	305	2	6	6	NUM
dpc-5570	305	3	.	.	PUNCT
dpc-5570	305	4	boutet	boutet	PROPN
dpc-5570	305	5	ma	ma	PROPN
dpc-5570	305	6	,	,	PUNCT
dpc-5570	305	7	nerviani	nerviani	ADP
dpc-5570	305	8	a	a	DET
dpc-5570	305	9	,	,	PUNCT
dpc-5570	305	10	gallo	gallo	PROPN
dpc-5570	305	11	afflitto	afflitto	PROPN
dpc-5570	305	12	g	g	PROPN
dpc-5570	305	13	,	,	PUNCT
dpc-5570	305	14	pitzalis	pitzali	VERB
dpc-5570	305	15	c.	c.	PROPN
dpc-5570	305	16	int	int	PROPN
dpc-5570	305	17	j	j	PROPN
dpc-5570	305	18	mol	mol	ADP
dpc-5570	305	19	sci	sci	PROPN
dpc-5570	305	20	.	.	PUNCT
dpc-5570	306	1	2018;19:530	2018;19:530	X
dpc-5570	306	2	.	.	PUNCT
dpc-5570	307	1	doi:10.3390	doi:10.3390	PROPN
dpc-5570	307	2	/	/	SYM
dpc-5570	307	3	ijms19020530	ijms19020530	PROPN
dpc-5570	307	4	.	.	PUNCT
dpc-5570	308	1	pmid:29425183	pmid:29425183	PROPN
dpc-5570	308	2	7	7	NUM
dpc-5570	308	3	.	.	PUNCT
dpc-5570	309	1	vecellio	vecellio	PROPN
dpc-5570	309	2	m	m	PROPN
dpc-5570	309	3	,	,	PUNCT
dpc-5570	309	4	hake	hake	PROPN
dpc-5570	309	5	vx	vx	PROPN
dpc-5570	309	6	,	,	PUNCT
dpc-5570	309	7	davidson	davidson	PROPN
dpc-5570	309	8	c	c	PROPN
dpc-5570	309	9	,	,	PUNCT
dpc-5570	309	10	carena	carena	PROPN
dpc-5570	309	11	mc	mc	PROPN
dpc-5570	309	12	,	,	PUNCT
dpc-5570	309	13	wordsworth	wordsworth	PROPN
dpc-5570	309	14	bp	bp	PROPN
dpc-5570	309	15	,	,	PUNCT
dpc-5570	309	16	selmi	selmi	PROPN
dpc-5570	309	17	c.	c.	PROPN
dpc-5570	309	18	front	front	PROPN
dpc-5570	309	19	immunol	immunol	NOUN
dpc-5570	309	20	.	.	PUNCT
dpc-5570	310	1	2021;11:596086	2021;11:596086	NUM
dpc-5570	310	2	.	.	PUNCT
dpc-5570	310	3	doi:10.3389	doi:10.3389	PROPN
dpc-5570	310	4	/fimmu.2020.596086	/fimmu.2020.596086	PROPN
dpc-5570	310	5	.	.	PUNCT
dpc-5570	310	6	pmid:33574815	pmid:33574815	VERB
dpc-5570	310	7	8	8	NUM
dpc-5570	310	8	.	.	PUNCT
dpc-5570	311	1	gao	gao	PROPN
dpc-5570	311	2	q	q	PROPN
dpc-5570	311	3	,	,	PUNCT
dpc-5570	311	4	zhao	zhao	PROPN
dpc-5570	311	5	yx	yx	PROPN
dpc-5570	311	6	,	,	PUNCT
dpc-5570	311	7	wang	wang	PROPN
dpc-5570	311	8	xj	xj	PROPN
dpc-5570	311	9	,	,	PUNCT
dpc-5570	311	10	shi	shi	PROPN
dpc-5570	311	11	j	j	PROPN
dpc-5570	311	12	,	,	PUNCT
dpc-5570	311	13	wang	wang	PROPN
dpc-5570	311	14	hm	hm	PROPN
dpc-5570	311	15	.	.	PUNCT
dpc-5570	312	1	eur	eur	PROPN
dpc-5570	313	1	rev	rev	PROPN
dpc-5570	313	2	med	med	PROPN
dpc-5570	313	3	pharmacol	pharmacol	PROPN
dpc-5570	313	4	sci	sci	PROPN
dpc-5570	313	5	.	.	PUNCT
dpc-5570	314	1	2021;25:2958–2970	2021;25:2958–2970	PROPN
dpc-5570	314	2	.	.	PUNCT
dpc-5570	315	1	doi:10.26355	doi:10.26355	PROPN
dpc-5570	315	2	/	/	SYM
dpc-5570	315	3	eurrev	eurrev	X
dpc-5570	315	4	_	_	PROPN
dpc-5570	315	5	202104_25549	202104_25549	X
dpc-5570	315	6	.	.	PUNCT
dpc-5570	315	7	pmid:33877659	pmid:33877659	PROPN
dpc-5570	315	8	9	9	NUM
dpc-5570	315	9	.	.	PUNCT
dpc-5570	316	1	malara	malara	PROPN
dpc-5570	316	2	g	g	PROPN
dpc-5570	316	3	,	,	PUNCT
dpc-5570	316	4	trifirò	trifirò	ADV
dpc-5570	316	5	c	c	NOUN
dpc-5570	316	6	,	,	PUNCT
dpc-5570	316	7	bartolotta	bartolotta	NOUN
dpc-5570	316	8	a	a	X
dpc-5570	316	9	,	,	PUNCT
dpc-5570	316	10	et	et	PROPN
dpc-5570	316	11	al	al	PROPN
dpc-5570	316	12	.	.	PROPN
dpc-5570	317	1	eur	eur	PROPN
dpc-5570	317	2	rev	rev	PROPN
dpc-5570	317	3	med	med	PROPN
dpc-5570	317	4	pharmacol	pharmacol	PROPN
dpc-5570	317	5	sci	sci	PROPN
dpc-5570	317	6	.	.	PUNCT
dpc-5570	318	1	2021;25:406–412	2021;25:406–412	NUM
dpc-5570	318	2	.	.	PUNCT
dpc-5570	319	1	doi:10.26355	doi:10.26355	PROPN
dpc-5570	319	2	/	/	SYM
dpc-5570	319	3	eurrev_202101_24408	eurrev_202101_24408	PROPN
dpc-5570	319	4	.	.	PUNCT
dpc-5570	320	1	pmid	pmid	NOUN
dpc-5570	320	2	:	:	PUNCT
dpc-5570	320	3	n	n	CCONJ
dpc-5570	320	4	/	/	SYM
dpc-5570	320	5	a	a	DET
dpc-5570	320	6	10	10	NUM
dpc-5570	320	7	.	.	PUNCT
dpc-5570	321	1	boehncke	boehncke	NOUN
dpc-5570	321	2	wh	wh	PROPN
dpc-5570	321	3	,	,	PUNCT
dpc-5570	321	4	brembilla	brembilla	PROPN
dpc-5570	321	5	nc	nc	PROPN
dpc-5570	321	6	,	,	PUNCT
dpc-5570	321	7	nissen	nissen	PROPN
dpc-5570	321	8	mj	mj	PROPN
dpc-5570	321	9	.	.	PUNCT
dpc-5570	321	10	expert	expert	PROPN
dpc-5570	321	11	rev	rev	VERB
dpc-5570	321	12	clin	clin	PROPN
dpc-5570	321	13	immunol	immunol	PROPN
dpc-5570	321	14	.	.	PUNCT
dpc-5570	322	1	2021;17:5–13	2021;17:5–13	NUM
dpc-5570	322	2	.	.	PUNCT
dpc-5570	323	1	doi:10.1080/1744666x.2020.1857733	doi:10.1080/1744666x.2020.1857733	NOUN
dpc-5570	323	2	.	.	PUNCT
dpc-5570	324	1	pmid:33063834	pmid:33063834	NUM
dpc-5570	324	2	11	11	NUM
dpc-5570	324	3	.	.	PUNCT
dpc-5570	324	4	steel	steel	PROPN
dpc-5570	324	5	kja	kja	PROPN
dpc-5570	324	6	,	,	PUNCT
dpc-5570	324	7	srenathan	srenathan	PROPN
dpc-5570	324	8	u	u	PROPN
dpc-5570	324	9	,	,	PUNCT
dpc-5570	324	10	ridley	ridley	PROPN
dpc-5570	324	11	m	m	PROPN
dpc-5570	324	12	,	,	PUNCT
dpc-5570	324	13	et	et	PROPN
dpc-5570	324	14	al	al	PROPN
dpc-5570	324	15	.	.	PUNCT
dpc-5570	325	1	arthritis	arthritis	NOUN
dpc-5570	325	2	rheumatol	rheumatol	NOUN
dpc-5570	325	3	.	.	PUNCT
dpc-5570	326	1	2020;72:435–447	2020;72:435–447	NOUN
dpc-5570	326	2	.	.	PUNCT
dpc-5570	326	3	doi:10.1002	doi:10.1002	NOUN
dpc-5570	326	4	/	/	SYM
dpc-5570	326	5	art.41156	art.41156	PROPN
dpc-5570	326	6	.	.	PUNCT
dpc-5570	326	7	pmid:31830072	pmid:31830072	NOUN
dpc-5570	326	8	12	12	NUM
dpc-5570	326	9	.	.	PUNCT
dpc-5570	327	1	van	van	PROPN
dpc-5570	327	2	baarsen	baarsen	PROPN
dpc-5570	327	3	lg	lg	PROPN
dpc-5570	327	4	,	,	PUNCT
dpc-5570	327	5	lebre	lebre	PROPN
dpc-5570	327	6	mc	mc	PROPN
dpc-5570	327	7	,	,	PUNCT
dpc-5570	327	8	van	van	PROPN
dpc-5570	327	9	der	der	NOUN
dpc-5570	327	10	coelen	coelen	PROPN
dpc-5570	327	11	d	d	PROPN
dpc-5570	327	12	,	,	PUNCT
dpc-5570	327	13	et	et	PROPN
dpc-5570	327	14	al	al	PROPN
dpc-5570	327	15	.	.	PUNCT
dpc-5570	328	1	arthritis	arthritis	NOUN
dpc-5570	328	2	res	re	NOUN
dpc-5570	328	3	ther	ther	ADV
dpc-5570	328	4	.	.	PUNCT
dpc-5570	329	1	2014;16:426	2014;16:426	X
dpc-5570	329	2	.	.	PUNCT
dpc-5570	329	3	doi:10.1186	doi:10.1186	PROPN
dpc-5570	329	4	/	/	SYM
dpc-5570	329	5	s13075	s13075	VERB
dpc-5570	329	6	-	-	PUNCT
dpc-5570	329	7	014	014	NUM
dpc-5570	329	8	-	-	PUNCT
dpc-5570	329	9	0426	0426	NUM
dpc-5570	329	10	-	-	PUNCT
dpc-5570	329	11	z.	z.	PROPN
dpc-5570	329	12	pmid:25492383	pmid:25492383	NUM
dpc-5570	329	13	13	13	NUM
dpc-5570	329	14	.	.	PUNCT
dpc-5570	330	1	mcgonagle	mcgonagle	PROPN
dpc-5570	330	2	d	d	PROPN
dpc-5570	330	3	,	,	PUNCT
dpc-5570	330	4	benjamin	benjamin	PROPN
dpc-5570	330	5	m	m	PROPN
dpc-5570	330	6	,	,	PUNCT
dpc-5570	330	7	tan	tan	PROPN
dpc-5570	330	8	al	al	PROPN
dpc-5570	330	9	.	.	PUNCT
dpc-5570	331	1	curr	curr	PROPN
dpc-5570	331	2	opin	opin	PROPN
dpc-5570	331	3	rheumatol	rheumatol	NOUN
dpc-5570	331	4	.	.	PUNCT
dpc-5570	332	1	2009;21:340–347	2009;21:340–347	ADJ
dpc-5570	332	2	.	.	PUNCT
dpc-5570	333	1	doi:10.1097	doi:10.1097	PROPN
dpc-5570	333	2	/	/	SYM
dpc-5570	333	3	bor.0b013e32832c6ab9	bor.0b013e32832c6ab9	PROPN
dpc-5570	333	4	.	.	PUNCT
dpc-5570	334	1	pmid:19412148	pmid:19412148	NOUN
dpc-5570	334	2	14	14	NUM
dpc-5570	334	3	.	.	PUNCT
dpc-5570	335	1	mease	mease	PROPN
dpc-5570	335	2	p	p	NOUN
dpc-5570	335	3	,	,	PUNCT
dpc-5570	335	4	husni	husni	VERB
dpc-5570	335	5	me	i	PRON
dpc-5570	335	6	,	,	PUNCT
dpc-5570	335	7	chakravarty	chakravarty	NOUN
dpc-5570	335	8	sd	sd	PROPN
dpc-5570	335	9	,	,	PUNCT
dpc-5570	335	10	et	et	PROPN
dpc-5570	335	11	al	al	PROPN
dpc-5570	335	12	.	.	PUNCT
dpc-5570	336	1	acr	acr	PROPN
dpc-5570	336	2	open	open	ADJ
dpc-5570	336	3	rheumatol	rheumatol	NOUN
dpc-5570	336	4	.	.	PUNCT
dpc-5570	337	1	2020;2:640–647	2020;2:640–647	NUM
dpc-5570	337	2	.	.	PUNCT
dpc-5570	337	3	doi:10.1002	doi:10.1002	NOUN
dpc-5570	337	4	/	/	SYM
dpc-5570	337	5	acr2.11180	acr2.11180	PROPN
dpc-5570	337	6	.	.	PUNCT
dpc-5570	338	1	pmid	pmid	NOUN
dpc-5570	338	2	:	:	PUNCT
dpc-5570	338	3	33480523	33480523	NUM
dpc-5570	338	4	15	15	NUM
dpc-5570	338	5	.	.	PUNCT
dpc-5570	339	1	sobolewski	sobolewski	PROPN
dpc-5570	339	2	p	p	X
dpc-5570	339	3	,	,	PUNCT
dpc-5570	339	4	walecka	walecka	NOUN
dpc-5570	339	5	i	i	PRON
dpc-5570	339	6	,	,	PUNCT
dpc-5570	339	7	dopytalska	dopytalska	PROPN
dpc-5570	339	8	k.	k.	PROPN
dpc-5570	339	9	reumatologia	reumatologia	PROPN
dpc-5570	339	10	.	.	PUNCT
dpc-5570	340	1	2017;55(3):131–135	2017;55(3):131–135	NUM
dpc-5570	340	2	.	.	X
dpc-5570	340	3	doi:10.5114	doi:10.5114	PROPN
dpc-5570	340	4	/	/	SYM
dpc-5570	340	5	reum.2017.68912	reum.2017.68912	PROPN
dpc-5570	340	6	.	.	PUNCT
dpc-5570	341	1	pmid	pmid	NOUN
dpc-5570	341	2	:	:	PUNCT
dpc-5570	341	3	n	n	CCONJ
dpc-5570	341	4	/	/	SYM
dpc-5570	341	5	a	a	DET
dpc-5570	341	6	16	16	NUM
dpc-5570	341	7	.	.	PUNCT
dpc-5570	342	1	ventura	ventura	PROPN
dpc-5570	342	2	a	a	PROPN
dpc-5570	342	3	,	,	PUNCT
dpc-5570	342	4	mazzeo	mazzeo	NOUN
dpc-5570	342	5	m	m	PROPN
dpc-5570	342	6	,	,	PUNCT
dpc-5570	342	7	gaziano	gaziano	PROPN
dpc-5570	342	8	r	r	PROPN
dpc-5570	342	9	,	,	PUNCT
dpc-5570	342	10	et	et	PROPN
dpc-5570	342	11	al	al	PROPN
dpc-5570	342	12	.	.	PROPN
dpc-5570	342	13	drug	drug	PROPN
dpc-5570	342	14	des	des	PROPN
dpc-5570	342	15	devel	devel	NOUN
dpc-5570	342	16	ther	ther	ADV
dpc-5570	342	17	.	.	PUNCT
dpc-5570	343	1	2017;11:2527–2535	2017;11:2527–2535	ADJ
dpc-5570	343	2	.	.	PUNCT
dpc-5570	343	3	doi:10.2147	doi:10.2147	NOUN
dpc-5570	343	4	/	/	SYM
dpc-5570	343	5	dddt.s136986	dddt.s136986	NOUN
dpc-5570	343	6	.	.	PUNCT
dpc-5570	344	1	pmid	pmid	NOUN
dpc-5570	344	2	:	:	PUNCT
dpc-5570	344	3	28781911	28781911	NUM
dpc-5570	344	4	17	17	NUM
dpc-5570	344	5	.	.	PUNCT
dpc-5570	345	1	fragoulis	fragoulis	PROPN
dpc-5570	345	2	ge	ge	PROPN
dpc-5570	345	3	,	,	PUNCT
dpc-5570	345	4	siebert	siebert	PROPN
dpc-5570	345	5	s.	s.	PROPN
dpc-5570	345	6	musculoskeletal	musculoskeletal	PROPN
dpc-5570	345	7	care	care	NOUN
dpc-5570	345	8	.	.	PUNCT
dpc-5570	346	1	2022;20	2022;20	NUM
dpc-5570	346	2	:	:	PUNCT
dpc-5570	346	3	(	(	PUNCT
dpc-5570	346	4	article	article	NOUN
dpc-5570	346	5	)	)	PUNCT
dpc-5570	346	6	.	.	PUNCT
dpc-5570	347	1	doi:10.1002	doi:10.1002	NOUN
dpc-5570	347	2	/	/	SYM
dpc-5570	347	3	msc.1694	msc.1694	X
dpc-5570	347	4	.	.	NOUN
dpc-5570	347	5	pmid:34879411	pmid:34879411	PROPN
dpc-5570	347	6	18	18	NUM
dpc-5570	347	7	.	.	PUNCT
dpc-5570	348	1	mease	mease	PROPN
dpc-5570	348	2	pj	pj	PROPN
dpc-5570	348	3	,	,	PUNCT
dpc-5570	348	4	chohan	chohan	PROPN
dpc-5570	348	5	s	s	PROPN
dpc-5570	348	6	,	,	PUNCT
dpc-5570	348	7	fructuoso	fructuoso	NOUN
dpc-5570	348	8	fjg	fjg	NOUN
dpc-5570	348	9	,	,	PUNCT
dpc-5570	348	10	et	et	PROPN
dpc-5570	348	11	al	al	PROPN
dpc-5570	348	12	.	.	PUNCT
dpc-5570	349	1	ann	ann	PROPN
dpc-5570	349	2	rheum	rheum	PROPN
dpc-5570	349	3	dis	dis	PROPN
dpc-5570	349	4	.	.	PUNCT
dpc-5570	350	1	2021;80:1147–1157	2021;80:1147–1157	NUM
dpc-5570	350	2	.	.	PUNCT
dpc-5570	351	1	doi:10.1136	doi:10.1136	NOUN
dpc-5570	351	2	/	/	SYM
dpc-5570	351	3	annrheumdis-2020	annrheumdis-2020	NOUN
dpc-5570	351	4	-	-	PUNCT
dpc-5570	351	5	219014	219014	NUM
dpc-5570	351	6	.	.	PUNCT
dpc-5570	352	1	pmid:34271384	pmid:34271384	PROPN
dpc-5570	352	2	19	19	NUM
dpc-5570	352	3	.	.	PUNCT
dpc-5570	353	1	palmer	palmer	PROPN
dpc-5570	353	2	v	v	PROPN
dpc-5570	353	3	,	,	PUNCT
dpc-5570	353	4	cornier	corny	ADJ
dpc-5570	353	5	m	m	NOUN
dpc-5570	353	6	,	,	PUNCT
dpc-5570	353	7	waring	ware	VERB
dpc-5570	353	8	a	a	DET
dpc-5570	353	9	,	,	PUNCT
dpc-5570	353	10	valdebran	valdebran	ADJ
dpc-5570	353	11	m.	m.	NOUN
dpc-5570	353	12	int	int	PROPN
dpc-5570	353	13	j	j	PROPN
dpc-5570	353	14	dermatol	dermatol	NOUN
dpc-5570	353	15	.	.	PUNCT
dpc-5570	354	1	2023;62:1437–1446	2023;62:1437–1446	X
dpc-5570	354	2	.	.	PUNCT
dpc-5570	354	3	doi:10.1111	doi:10.1111	PROPN
dpc-5570	354	4	/	/	SYM
dpc-5570	354	5	ijd.16873	ijd.16873	PROPN
dpc-5570	354	6	.	.	PUNCT
dpc-5570	354	7	pmid:36245010	pmid:36245010	PROPN
dpc-5570	354	8	20	20	NUM
dpc-5570	354	9	.	.	PUNCT
dpc-5570	355	1	cintoni	cintoni	PROPN
dpc-5570	355	2	m	m	PROPN
dpc-5570	355	3	,	,	PUNCT
dpc-5570	355	4	palombaro	palombaro	ADJ
dpc-5570	355	5	m	m	PROPN
dpc-5570	355	6	,	,	PUNCT
dpc-5570	355	7	maramao	maramao	PROPN
dpc-5570	355	8	fs	fs	PROPN
dpc-5570	355	9	,	,	PUNCT
dpc-5570	355	10	et	et	PROPN
dpc-5570	355	11	al	al	PROPN
dpc-5570	355	12	.	.	PUNCT
dpc-5570	355	13	nutrients	nutrients	PROPN
dpc-5570	355	14	.	.	PUNCT
dpc-5570	356	1	2023;15:3876	2023;15:3876	NUM
dpc-5570	356	2	.	.	PUNCT
dpc-5570	356	3	doi:10.3390	doi:10.3390	PROPN
dpc-5570	356	4	/	/	SYM
dpc-5570	356	5	nu15183876	nu15183876	NOUN
dpc-5570	356	6	.	.	PUNCT
dpc-5570	357	1	pmid:37616585	pmid:37616585	NOUN